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The continuous formation of new blood cells is driven by hematopoietic stem cells (HSCs), 
which reside in specialized niches in the bone marrow [1]. In these niches the HSCs are 
nurtured and nourished. Fundamental to the biology of HSCs is their ability to self-renew 
via asymmetrical cell division, in which a new HSC and a Hematopoietic Progenitor Cell 
(HPC) are generated. This self-renewal ensures that the HSC pool is protected from 
exhaustion [2]. Although, all HSCs divide via asymmetrical cell division, the frequency of 
these cell divisions varies amongst the HSCs. In this respect, the most primitive HSCs 
divide only rarely, whereas other HSCs divide more frequently [3]. 
The formation of mature and functional blood cells by the HSCs occurs via several 
consecutive cell divisions and maturation stages. The initial asymmetrical cell division is 
followed by several symmetrical cell divisions, during which two identical daughter cells 
are generated. These newly formed cells are more differentiated than their parental cells 
and become increasingly committed to either the myeloid or the lymphoid lineage. In 
the myeloid lineage of hematopoiesis erythrocytes, platelets and certain white blood cell 
types, such as monocytes and granulocytes are formed. In the lymphoid lineage, T cells, 
B cells and NK cells are generated. 
It may be obvious that this intricate process of hematopoiesis is highly regulated to ensure 
the proper generation of sufficient blood cells. Therefore, aberrations in this process 
can severely hamper normal hematopoiesis and even result in the onset of leukemia. 
In the case of leukemia, these aberrations are often the result of inherited or acquired 
genetic alterations [4;5]. The aberrant hematopoiesis in leukemia typically results in an 
enormous overproduction of a certain blood cell type or in an impairment of immature 
cells to differentiate into their mature and functional status.
The acute leukemia’s are characterized by the rapid increase of large numbers of immature 
blood cells. This enormous production of immature blood cells impairs the production of 
normal cells. Furthermore, due to overcrowding of the bone marrow these immature 
blood cells can enter the circulation and spread throughout the body. Typical for chronic 
leukemia’s is the accumulation of more mature blood cells and the longer progression time 
as compared with the acute leukemia’s. Since acute and chronic leukemia’s can affect 
cells belonging the myeloid or the lymphoid lineage, four main categories of leukemia 
can be defined: Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute 
Lymphocytic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL). In addition, 
leukemia’s can be further classified based upon the cell type involved e.g. B cell Chronic 
Lymphocytic Leukemia (B-CLL) or T cell Acute Lymphocytic Leukemia (T-ALL). 
Therapeutic strategies for leukemia mainly comprise of intensive radiotherapy and 
chemotherapeutics. Unfortunately, these therapeutics have severe and sometimes life-
threatening side effects as the result of toxicity towards normal cells. Furthermore, all 
too often, therapy-resistant relapses after seemingly successful therapy occur. Together, 
this indicates that effective and leukemia-targeted therapies, with reduced toxicity are 
urgently warranted. This leukemia-targeted therapy can be achieved using antibody-based 
therapeutic strategies. By this means a tumoricidal agent can be delivered selectively to 
the leukemia cells. In this respect, the targeted delivery of apoptosis inducing agents 
seems a particular promising approach for the elimination of leukemia cells. This targeted 
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apoptosis induction in leukemia cells is in fact the main focus of this thesis and the 
studies described herein. 
APOPTOSIS
To ensure normal homeostasis, diseased cells are removed continuously from the human 
body by apoptosis induction. Apoptosis is highly regulated process which forces targeted 
cells to commit suicide. Furthermore, to prevent collateral damage of the apoptotic cells 
towards healthy surrounding cells, the cells are carefully removed. The diseased cells 
that are removed by apoptosis typically include aged cells at the end of their life-cycle 
as well as (pre-)cancerous and virus infected cells. The initiation of apoptosis in targeted 
cells can occur via specialized immune cells such as NK and activated T-cells, which 
are designed to recognize diseased cells. Thereto, the NK and activated T-cells express 
pro-apoptotic proteins on their cell surface which enables them to initiate the apoptotic 
cascade in the targeted cells [6]. The subsequent execution of apoptosis is the final result 
of the activity of an intricate network of pro-apoptotic proteins in the targeted cells. 
Key players in the apoptotic cascade are the cysteine-aspartic acid proteases (caspases) 
and members of the Bcl2 family of proteins [7]. The pro-apoptotic caspases can be 
divided, based upon their position in the cascade, in the initiator caspases and the 
effector caspases. As their name implies the initiator caspases are at the apex of the 
apoptotic signaling cascade and mainly serve to relay and amplify the apoptotic signal. 
The effector caspases are more downstream in the cascade and they are able to cleave 
numerous proteins, finally resulting in DNA fragmentation and apoptotic cell death. The 
Bcl2 family of proteins consists of pro-apoptotic molecules such as Bax, Bad and Bid as 
well as anti-apoptotic molecules such as Bcl2 and Bcl-xL [8;9]. The balance between the 
activation status of pro-apoptotic and anti-apoptotic proteins determines the fate of the 
cell. When pro-apoptotic proteins dominate the cell will go into apoptosis, however when 
the anti-apoptotic proteins dominate the cell will survive. In cancer cells this balance is 
often deregulated and dominated by anti-apoptotic proteins which results in a disturbed 
apoptosis and enhanced cell survival. Therefore, tipping the balance in favor of the pro-
apoptotic proteins specifically in cancer cells is of particular interest for therapeutic 
strategies. 
There are two main apoptotic pathways which are referred to as the intrinsic and 
the extrinsic apoptotic pathway. The intrinsic apoptotic pathway is regulated by the 
mitochondria and is activated upon intracellular stress, which triggers the mitochondria 
to release pro-apoptotic proteins [10]. In this respect, DNA damage induced by 
chemotherapeutics can activate the intrinsic apoptotic pathway. The extrinsic apoptotic 
pathway is initiated by binding of so-called death ligands to their cognate death receptors 
[11]. Since these death receptors convey a potent apoptotic signal and are relatively easy 
accessible, the targeted activation of these death receptors has generated enormous 
enthusiasm for novel cancer therapies [12;13]. 
APOPTOSIS INDUCTION By THE DEATH LIGANDS TRAIL AND FASL 
Two prominent death ligands are the tumor necrosis factor (TNF) family members, TNF 
Related Apoptosis Inducing Ligand (TRAIL) and Fibroblast associated cell surface Ligand 
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(FasL). Like the other TNF family members, TRAIL and FasL are self-assembling trimeric 
proteins. Both, TRAIL and FasL are expressed on the cell surface of NK- and activated 
T-cells. Activation of the corresponding death receptors by TRAIL and FasL, results in the 
intracellular formation of the Death Inducing Signaling Complex (DISC). This assembly of 
the DISC results in the sequential activation of the initiator caspase-8 or -10 and effector 
caspases, ultimately followed by apoptotic cell death. In addition, in some cell types, the 
death-receptor pathway relies on a mitochondrial amplification loop that is activated by 
caspase-8-mediated cleavage of pro-apoptotic Bid to a truncated form. Next, truncated 
Bid (tBid) mediates the release of pro-apoptotic cytochrome C and caspase-9 from the 
mitochondria [14], thereby connecting the extrinsic to the intrinsic apoptotic pathway. 
Although TRAIL and FasL are expressed on the cell surface of NK- and T-cells, they can 
be proteolytically cleaved off, yielding soluble forms of TRAIL (sTRAIL) and FasL (sFasL). 
Intriguingly, sTRAIL potently induces apoptosis in variety of malignant cells, whereas 
normal cells appear to be resistant to sTRAIL mediated apoptosis [15-17]. The mode of 
action of this apparent tumor-selectivity of sTRAIL-induced apoptosis is still enigmatic. 
Nevertheless, this tumor-restricted activity has sparked the potential use of TRAIL for 
the treatment of human malignancies, including leukemia. In contrast, the application 
of sFasL for the treatment of cancer was originally deemed impossible due to severe 
hepatotoxicity observed in sFasL treated mice [18;19]. However, it became apparent 
that this toxicity was due to high molecular weight aggregates present in the used sFasL 
preparations. Additional studies demonstrated that homotrimeric sFasL is in fact not toxic 
at all [20;21]. This observation renewed the potential of sFasL for the effective and safe 
treatment of cancer. 
Despite, that the use of homotrimeric sTRAIL and sFasL preparations for the treatment of 
leukemia seems very promising, several limitations may hamper their use. A fundamental 
problem is the widespread expression of the various cognate death receptors throughout 
the human body. This unfavorable surplus of potential binding sites will impede the 
leukemia-selective accretion of sTRAIL and sFasL. In addition, the apoptotic activity of 
sTRAIL and sFasL is less pronounced than the activity of their corresponding membrane-
bound forms [20;22]. 
TARGETED DELIVERy OF TRAIL AND FASL TO LEUKEMIA CELLS
To overcome the limitations associated with sTRAIL and sFasL we developed a method 
for the targeted delivery sTRAIL and sFasL to leukemia cells. To this end we genetically 
fused a single chain fragment of the variable region (scFv) antibody fragment with either 
sTRAIL or sFasL. The scFv’s have the same specificity as the parental antibodies, however 
they are much smaller [23]. In our studies we have used several scFv’s which specifically 
recognize leukemia-associated antigens such as CD7, CD20, CD33 and CLL-1. Thus, these 
fusion proteins are designed to selectively deliver sTRAIL or sFasL to the cell surface of 
target antigen-positive leukemia cells. By using this fusion protein format the limitation 
associated with the wide spread expression of the death receptors on normal cells can 
be circumvented. In addition, the high affinity binding of the scFv to the target antigen is 
characterized by fast on/slow off binding kinetics. Therefore, the fusion proteins accrete 
at the cell surface of target antigen-positive cells. Importantly, this cell surface accreted 
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sTRAIL and sFasL resemble their membrane bound form, resulting in a strongly enhanced 
apoptotic activity [24;25]. 
To accelerate the potential clinical application we expressed the fusion proteins in the 
eukaryotic Chinese Hamster Ovary (CHO) cells, an industry-favored production cell line 
[26]. Production of the fusion proteins in the CHO cells benefits from the stringent quality 
control mechanism and post-translational modifications typical for eukaryotic cells. This 
CHO-based production platform resulted in the production of stable and homotrimeric 
fusion proteins, in the absence of detectable high-molecular-weight protein aggregates. 
An obvious potential limitation to antibody-based approaches is the escape of target 
antigen-negative tumor cells from therapy. In this respect, a heterogeneous expression 
of selected target antigens has been demonstrated in leukemia. As a result, target 
antigen-negative leukemia cells may exist, which consequently can escape from antibody-
based therapeutic approaches [27;28]. Furthermore, target antigen-negative leukemia 
cells can arise during or after therapy due to therapy-induced down-regulation. In this 
respect, in chapters 2, 4, 6 and 8 we demonstrated the so-called bystander effect, which 
is an essential part of the concept of targeted apoptosis induction by scFv:sTRAIL and 
scFv:sFasL fusion proteins. The bystander effect is based on the principle that targeted 
tumor cells are not only eliminated, but are also exploited to convey a therapeutic effect 
towards neighboring tumor cells which can be devoid of the target antigen.
CD7 AS A TARGET ANTIGEN ON MALIGNANT T-CELLS
CD7 is an antigen which is highly expressed on T cell Acute Lymphocytic Leukemia 
(T-ALL) [29] . Although, the function of CD7 is not yet fully understood it is known 
that is normally expressed on T and myeloid cells in early hematopoietic-cell ontogeny, 
thymocytes, natural killer (NK) cells, and to a distinct subset of peripheral-blood T cells. 
Due to the high expression on T-ALL, CD7 has been used for antibody-based therapeutic 
strategies in both preclinical studies and clinical trials [30;31]. In chapter 2, we report 
on scFv:sFasL fusion protein designed to induce apoptosis in CD7+ leukemia’s. Thereto, 
we produced a homotrimeric fusion protein designated scFvCD7:sFasL. In our study we 
assessed the CD7-restricted apoptosis induction of this fusion protein towards CD7+ 
leukemic T-cells lines and patient-derived CD7+ leukemia cells. 
CD20 AS A TARGET ANTIGEN ON MALIGNANT B-CELLS
Malignant B-cells typically express high levels of normal B-cell surface antigens, such 
as CD20. This elevated expression of CD20 on malignant B cells has resulted in the 
development of the CD20-targeted monoclonal antibody Rituximab. The anti-leukemia 
effect of Rituximab is the result of antibody dependent cellular cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC) upon binding to CD20[32]. In addition, part 
of the tumoricidal activity of Rituximab is the result of the direct activation of apoptosis 
via cross-linking of cell surface-expressed CD20 on malignant B cells [33]. However, the 
exact mechanism by which Rituximab induces apoptosis via the cross-linking of CD20 is 




Although, Rituximab has improved the therapy outcome for patients its application is often 
not curative [34]. Thus, the development of alternative Rituximab-based approaches 
with enhanced tumoricidal activity is warranted, especially towards Rituximab-resistant 
malignant B cells that currently escape from therapy. Therefore, in chapter 4 we generated 
scFvRit:sFasL, a fusion protein in which the specificity and apoptosis-inducing activity of 
Rituximab is retained and combined with the potent apoptosis inducing activity of FasL.
CD33 AS A TARGET ANTIGEN ON ACUTE MyELOID LEUKEMIA (AML) CELLS
In the next chapters we have turned our focus to the targeted elimination of AML cells. The 
prognosis for AML patients is dismal with a 5-year survival rate of 20- 30% [35;36]. Like 
T-ALL and B-CLL cells, AML cells express several lineage-specific antigens that may be 
exploited for antibody-based therapy. The best characterized of the AML target antigens 
is CD33. The expression of CD33 on AML cells has resulted in the clinical development 
of Gemtuzumab Ozogamicin (GO), a CD33-targeted immunotoxin. GO comprises an anti-
CD33 antibody chemically coupled to a highly cytotoxic calicheamicin derivative via a 
hydrolysable linker. After CD33-selective binding of GO, the CD33-GO-complex internalizes 
and ends up lysosomes. In the acidic milieu of the lysosomes the calicheamicin moiety is 
hydrolytically released from the antibody moiety. Subsequently, free calicheamicin can 
translocate to the nucleus and intercalate with the DNA, causing site-specific double-strand 
breaks resulting in apoptotic cell death [37;38]. Although, GO has a generally acceptable 
safety profile, its application is associated with serious and dose-limiting toxicity in some 
patients, including hepatotoxicity and severe myelosuppression [35;39-41]. Therefore, 
the rational design of combinatorial approaches of GO with other therapeutics in order to 
achieve optimal tumoricidal activity with reduced toxicity is warranted. In chapter 5, we 
demonstrate that a promising candidate for such a combinatorial approach is valproic acid 
(VPA). For over 20 years VPA is being used safely for the treatment of seizures. Recently 
however, it was shown that VPA acts as a histone deacetylase inhibitor (HDACi) with 
promising anti-AML activity [42;43]. Treatment of cells with an HDACi results in a hyper-
acetylated state of their histones, which translates in a more open chromatin structure. 
Consequently, the DNA becomes more accessible to intercalating agents. Therefore, we 
hypothesized that treatment of AML cells with VPA should augment calicheamicin binding 
capacity and potentiate the apoptotic activity of GO. 
Furthermore, to utilize CD33 for the targeted delivery of sTRAIL we have generated 
a novel fusion protein designated scFvCD33:sTRAIL, which is described in chapter 6. 
In this study we compared the in vitro activity of scFvCD33:sTRAIL with the activity 
of GO towards CD33+ AML cells. Furthermore, we compared the toxicity profile of 
scFvCD33:sTRAIL and GO 
TARGETING LEUKEMIA STEM CELLS (LSCS) 
To a varying degree most leukemia types initially respond well to therapy with partial 
or even complete remissions. However, after a period of minimal residual disease many 
patients succumb to refractory relapses of the disease. Recent insights indicate that the 
development of these relapses may be due to the selective continued survival of a small, 
but distinct population of therapy-resistant tumor-initiating cells, commonly referred 
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to as Leukemia Stem Cells (LSCs) [44;45]. These LSCs are thought to originate either 
from normal hematopoietic stem cells (HSCs) or from more differentiated progenitor 
cells that have acquired malignant features [46]. In the latter case, the progenitor cells 
have de-differentiated and re-acquired stem cell-like characteristics via as yet undefined 
pathways. Both LSCs and HSCs possess self-renewal capacity but are relative quiescent 
compared to more mature progenitor’s cells. However, LSCs typically have a much 
stronger capacity for cellular expansion than normal HSCs, probably due to an increase 
in symmetric self-renewal activity of LSCs [44;47]. Although LSCs are typically resistant 
to conventional therapy, several possibilities for the targeted elimination of these LSCs 
seem feasible. In chapter 7, we review several promising possibilities for the elimination 
of LSCs and provide perspectives and recommendations for future therapeutic strategies. 
Since the expression of death receptors appears to be upregulated on LSCs as compared 
with HSCs, one of those promising possibilities appears to be the targeted delivery of 
sTRAIL and sFasL to the LSCs [48;49]. 
Unfortunately, not all AML patients are eligible for CD33-targeted therapy and therefore 
the exploitation of additional AML cell surface antigens is warranted. In this respect, 
C-type Lectin Like Molecule-1 (CLL-1) appears to be attractive alternative target antigen 
to CD33. CLL-1 is expressed in >90% of the AML patients [50;51] in which expression 
appears to be retained under all conditions of treatment and disease [52]. In peripheral 
blood, both monocytes and granulocytes show moderate CLL-1 expression, while CLL-1 
is completely absent in any other tissue. Importantly, CLL-1 is also expressed on CD34+/
CD38- AML LSCs, whereas it is not expressed on normal hematopoietic stem cells [51-53]. 
The targeted elimination of CD34+/CD38- AML LSCs is of particular therapeutic interest, 
since they are thought to be responsible for the frequent therapy-resistant relapses in 
AML [47]. In chapter 8 the anti-AML LSCs activity of scFvCLL-1:sTRAIL and scFvCLL-
1:sFasL is reported. Together, the targeted delivery of sTRAIL and sFasL to leukemia cells 
including the LSCs might offer a step towards curative leukemia therapy.   
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Agonistic anti-Fas antibodies and multimeric recombinant Fas ligand (FasL) 
preparations show high tumoricidal activity against leukemic cells, but are 
unsuitable for clinical application due to unacceptable systemic toxicity. 
Consequently, new anti-leukemia strategies based on Fas activation have to 
meet the criterion of strictly localized action at the tumor-cell surface. recent 
insight into the FasL/Fas system has revealed that soluble homotrimeric FasL 
(sFasL) is in fact nontoxic to normal cells, but also lacks tumoricidal activity. We 
report on a novel fusion protein, designated scFvCD7:sFasL, that is designed to 
have leukemia-restricted activity. scFvCD7:sFasL consists of sFasL genetically 
linked to a high-affinity single-chain fragment of variable regions (scFv) antibody 
fragment specific for the T-cell leukemia-associated antigen CD7. Soluble 
homotrimeric scFvCD7:sFasL is inactive and acquires tumoricidal activity only 
after specific binding to tumor cell-surface-expressed CD7. Treatment of T-cell 
acute lymphoblastic leukemia (T-ALL) cell lines and patient-derived T-ALL, 
peripheral T-cell lymphoma (PTCL), and CD7-positive acute myeloid leukemia 
(AML) cells with homotrimeric scFvCD7:sFasL revealed potent CD7-restricted 
induction of apoptosis that was augmented by conventional drugs, farnesyl 
transferase inhibitor L-744832, and the proteasome inhibitor bortezomib 
(Velcade; Millenium, Cambridge, MA). Importantly, identical treatment did not 
affect normal human peripheral-blood lymphocytes (PBLs) and endothelial cells, 
with only moderate apoptosis in interleukin-2 (IL-2)/CD3-activated T cells. CD7-
restricted activation of Fas in T-cell leukemic cells by scFvCD7:sFasL revitalizes 
interest in the applicability of Fas signaling in leukemia therapy. 
INTRODUCTION
Despite advances in T-cell leukemia therapy, only a minority of patients achieves long 
term tumor-free survival with conventional chemotherapy at the cost of significant and 
often irreversible toxic side effects [1] Therefore, new therapeutic approaches with 
enhanced tumor selectivity and more favorable toxicity profiles are urgently needed. 
Several promising targeted approaches have been developed, including naked antibodies 
[2;3], immunotoxins [4;5] and various cancer-selective small inhibitory molecules [6;7]. 
Furthermore, certain members of the tumor necrosis factor (TNF) superfamily show 
promising proapoptotic activity toward various human leukemias and lymphomas. 
Fas ligand (FasL), a prominent member of the TNF superfamily, shows superior anti-
leukemia activity. FasL is present on lymphocytes and monocytes/macrophages as a 
type II transmembrane protein, (memFasL). Fas, the cognate receptor for FasL, belongs 
to the family of transmembrane proteins known as death receptors. Death receptors 
can detect the presence of specific extracellular death signals and rapidly trigger cellular 
destruction by apoptosis. Fas expression at the cell surface is observed in biopsies and 
cell lines derived from a variety of tumors. Moreover, the antitumoral effects of various 
chemotherapeutic drugs have been attributed partly to p53-mediated up-regulation of 
Fas and FasL[8-12] Fas signaling is also known to be a key element in the effector phase 
of a cytotoxic T lymphocyte (CTL) response against tumor cells. 
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Like other members of the TNF superfamily, the extracellular domain of FasL can be 
proteolytically cleaved into a soluble homotrimeric form (sFasL) [13-15]. 
Early attempts to exploit Fas agonists such as anti-Fas antibodies and multimeric 
recombinant FasL preparations for therapy revealed extremely potent tumoricidal effects 
toward isolated primary tumor cells and cell lines [15-19]. However, in vivo application 
of most Fas antagonists was associated with acute lethality in mice [20-22], thereby 
excluding therapeutic evaluation in humans. Nevertheless, the principal feasibility of 
therapeutic Fas activation in cancer therapy was clearly demonstrated in mice that lack 
a functional FasL/Fas system (lpr/gld mice) [23] and by treatment of xenografted tumors 
with human Fas-specific antibodies [24]. 
Recent studies have revealed that certain recombinant FasL preparations contain 
oligomeric, multimeric, and even aggregated sFasL forms and that these forms are 
responsible for the observed systemic toxicity [25]. In contrast, homotrimeric sFasL 
is not toxic to normal cells and may even antagonize the function of membrane-bound 
FasL [25-27]. Importantly, homotrimeric sFasL also lacks tumoricidal activity. However, 
selective delivery of sFasL to a predetermined tumor-associated target antigen can 
restore the full apoptotic potential of sFasL [28]. 
Recently, we demonstrated that the leukemia selectivity of homotrimeric TRAIL (TNF-
related apoptosis-inducing ligand), another TNF superfamily member, can be strongly 
enhanced by genetically fusing it to a CD7-selective antibody fragment [29]. Human 
CD7 is a lineage-specific antigen that is highly expressed in patients with acute T-cell 
leukemia and in approximately 10% of patients with acute myeloid leukemia [30-33]. The 
function of CD7 is not yet fully understood. In normal cells CD7 expression is limited to 
T and myeloid cells in early hematopoietic-cell ontogeny, thymocytes, natural killer (NK) 
cells, and to a distinct subset of peripheral-blood T cells [34-38]. Human CD7 has been 
used for the targeted delivery of several monoclonal antibody (mAb) toxin conjugates in 
both preclinical studies and clinical trials [4;5;39;40]. 
Here, we report on a novel homotrimeric sFasL fusion protein, designated scFvCD7:sFasL, 
with enhanced and leukemia-restricted activity toward T-cell acute lymphoblastic 
leukemia (T-ALL) cell lines and patient-derived T-ALL, peripheral T-cell lymphoma (PTCL), 
and CD7-positive acute myeloid lymphoma (AML) cancer cells. We provide evidence that 
homotrimeric scFvCD7:sFasL is bioactive only after specific binding to cell-surface-
expressed CD7 with no toxicity toward CD7-negative cells and only moderate activity 
toward interleukin-2 (IL-2)/CD3-activated CD7-positive T cells. 
MATERIAL AND METHODS
mAbs and scFv antibody fragment 
mAb TH69 is a murine immunoglobulin G1 (IgG1) with specificity for human CD7 [3] 
(kindly provided by Dr Martin Gramatzki, University Clinic Schleswig-Holstein, Kiel, 
Germany). Phagemid pCANTAB5E/scFv3A1F encoding anti-CD7 antibody fragment 3A1F 
[41] was kindly provided by Dr Chris Pennell (Department of Laboratory Medicine and 
Pathology, University of Minnesota). mAb TH69 and scFv3A1F compete for binding to the 
extracellular domain of human CD7. FasL-neutralizing mAb Alf2.1 was purchased from 
Sigma-Aldrich Chemie (Zwijndrecht, the Netherlands). Flag-tagged sFasL was purchased 
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from Alexis (10P’s BVBA; Breda, the Netherlands). Flag-tagged sFasL was secondarily   
cross-linked by preincubation with 5-fold excess of anti-Flag mAb M2 (Alexis). 
Chemotherapeutics 
The cytostatic drugs used are vincristine (stock; 1mg/mL in phosphate-buffered saline 
[PBS]), amsacrine (stock; 1 mM in PBS), and actinomycin D (stock; 2mg/mL in ethanol). 
Farnesyl transferase inhibitor L-744832 (Merck, Darmstadt, Germany) was dissolved at 
10mM in DMSO. The proteasome inhibitor bortezomib was dissolved at 10mM in dH2O. All 
final concentrations were prepared by serial dilutions in serum-free medium. 
Cell lines 
Human CD7-positive T-ALL cell lines Jurkat, CEM, and the CD7-negative human B-cell 
lymphoma cell lines Ramos and Raji were purchased from the American Type Culture 
Collection (ATCC; Manassas, VA). T-cell lines MOLT16 and HuT78 were a kind gift from Dr 
Martin Gramatzki. A CD7-positive transfectant of the Ramos cell line (Ramos.CD7) was 
generated previously [29]. All cell lines were cultured in RPMI (Cambrex, East Rutherford, 
NJ) supplemented with 10% fetal calf serum (FCS) at 37°C in a humidified 5% CO2 
atmosphere. 
Leukocytes, PBLs, activated T cells, and HUVECs 
Leukocytes were isolated from whole blood of healthy donors by standard Ammonium 
Chloride method [42]. Peripheral-blood lymphocytes (PBLs) were isolated from whole blood 
of healthy donors by standard density gradient centrifugation procedures (Lymphoprep; 
Axis-Shield PoC As, Oslo, Norway). Freshly isolated PBLs were resuspended at 2.0 x 106 
cells/ml in RPMI, supplemented with 10% human pooled serum. Activated T cells were 
generated by incubation of freshly isolated PBLs with anti-CD3 mAb WT32 (0.5µg/mL) 
for 72 hours, followed by IL-2 stimulation (100ng/mL) for 48 hours. Human umbilical vein 
endothelial cells (HUVECs) were isolated as previously described [43]. HUVECs were used 
before culture passage no. 4 and, for experiments, were pre-cultured in 6-well plates at 
60% confluency. 
Construction of scFvCD7:sFasL 
Previously, we constructed the eukaryotic expression plasmid pEE14scFv:sTRAIL for 
rapid construction, evaluation, and stable expression of scFv:sTRAIL fusion proteins in 
CHO-K1 cells [44]. Important features of this vector are the murine kappa light-chain 
leader peptide encoded upstream of 2 multiple cloning sites (MCSs) that are separated by 
a 26-residue in-frame linker sequence, and the glutamine synthetase selectable marker 
gene, which allows for amplified expression of the recombinant protein in the established 
industrial production cell line CHO-K1. The vector exploits the strong cytomegalovirus 
(CMV) promoter to drive recombinant protein expression, while the leader peptide directs 
secretion of the recombinant protein into the culture supernatant. In the first MCS, a 
745-bp DNA fragment encoding anti-CD7 scFv3A1F derived from Phagemid pCANTAB5E/
scFv3A1F was directionally inserted using the unique SfiI and NotI restriction enzyme 
sites. In the second MCS, soluble TRAIL (sTRAIL)-encoding cDNA was swapped for 
a polymerase chain reaction (PCR)-truncated 539-bp DNA fragment encoding the 
extracellular domain of human sFasL using restriction enzymes xhoI and HindIII and 
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standard DNA manipulation procedures. FasL cDNA truncation was performed by PCR 
using proofread DNA polymerase according to standard protocol using the following 
primers: T1, 5’-ATCCTCGAGTCTAGTGGGAGCGGATCTACCAGCCAGATGCACACA-3’ (xhoI 
site is underlined); and T2, 5’-CCCAAGCTTTGCTTCTCTTAGAGCTTATATAAG-3’ (HindIII 
site is underlined). 
Production of scFvCD7:sFasL 
ScFvCD7:sFasL was expressed in CHO-K1 cells using the glutamine synthetase selection/
amplification system essentially as described previously [44]. Briefly, CHO-K1 cells were 
transfected with pEE14scFvCD7: sFasL using FuGENE-6 reagent (Roche Diagnostics, 
Almere, the Netherlands). Stable transfectants with amplified expression were isolated 
and single-cell-sorted by high-speed cell sorter (Cytomation, Ft Collins, CO). Individual 
clones were assessed for stable and high secretion of scFvCD7: sFasL in the absence of 
MSx selection reagent by FasL enzyme-linked immunosorbent assay (ELISA) according 
to manufacturer’s recommendations (Axora, San Diego, CA). This procedure identified 
CHO-K1 production cell line 100B2, stably secreting scFvCD7:sFasL (1.34 µg/mL) into the 
medium. ScFvCD7:sFasL containing supernatant was harvested (10.000g for 10 minutes) 
and stored at -80°C. 
Solution behavior of scFvCD7:sFasL 
The solution behavior of scFvCD7:sFasL was analyzed by size-exclusion (SE) fast-
performance liquid chromatography (FPLC) with a calibrated HiLoad 16/60 Superdex 
200 Prep-grade column (Amersham Biosciences, Uppsala, Sweden); 5 mL supernatant 
derived from CHO-K1 cell line 100B2 was loaded onto the column, after which individual 
samples were collected at a 3-minute interval. Individual samples were analyzed for their 
capacity to induce apoptosis in CD7-positive FasL-sensitive MOLT16 cells. 
CD7-specific binding of scFvCD7:sFasL 
CD7-specific binding of scFvCD7:sFasL was analyzed by incubating 1.0 x 106 CEM cells 
with scFvCD7:sFasL (1.34µg/mL) in the presence or absence of CD7-blocking mAb TH69 
(5µg/mL). CD7-specific binding was analyzed by flow cytometry with PE-conjugated anti-
FasL mAb (Diaclone SAS, Besancon, France). Incubations were performed for 45 minutes 
at 0°C and were followed by 2 washes with serum-free medium. 
CD7-restricted induction of apoptosis by scFvCD7:sFasL 
Tumor cells were seeded at 0.25 x 106 cells/well in a 48-well plate and treated for 16 hours 
with the indicated concentrations of scFvCD7:sFasL in the presence or absence of mAb 
TH69 (5µg/mL) or mAb Alf2.1 (1µg/mL). Where indicated, cells were treated with cross-
linked sFasL (Flag-tagged sFasL) or with scFvCD7:sTRAIL [29]. Apoptosis was assessed by 
one of the assays described in “Assays used to assess apoptosis.” Percentage of specific 
apoptosis was calculated using the following formula: specific apoptosis = (experimental 
apoptosis - spontaneous apoptosis)/(100 - spontaneous apoptosis) x 100%. 
Assays used to assess apoptosis 
PS exposure to the outer cell membrane. Flow cytometric analysis of exposure of 
phosphatidylserine (PS) on the outer membrane was performed with an annexinV-FITC/
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PI kit (VPS Diagnostics, Hoeven, the Netherlands). Loss of mitochondrial membrane 
potential (Δψ). Δψ was analyzed with the cell-permeant green-fluorescent lipophilic 
dye DiOC6 (Molecular Probes, Eugene, OR). After treatment, cells were harvested by 
centrifugation (300g for 5 minutes), incubated for 20 minutes at 37°C with 0.1µM DiOC6 
in fresh medium, washed once with PBS, and analyzed by flow cytometry. Fluorescence 
microscopy of activated caspase-3. After treatment, cells were spotted on microscope 
slides and fixed in acetone. Active caspase-3 staining was performed with mAb 5A1 (Cell 
Signaling Technology, Beverly, MA) and secondary FITC-conjugated antibody (DAKO, 
Carpinteria, CA). DAPI was used to stain all nuclei. Specific staining was evaluated using 
a Quantimed 600S fluorescence microscope (Leica Camera, Solms, Germany) equipped 
with a Leica PL Fluotar 40x/0.70 objective lens. Imaging was performed with Lytofluor 
imaging medium; images were captured with a Leica DC350 Fx camera, and were 
acquired through Leica QWin 3 software. Detection of apoptotic DNA fragmentation. 
DNA fragmentation was analyzed using mAb F7-26 (Alexis) according to manufacturer’s 
recommendations. mAb F7-26 specifically detects DNA fragmented by apoptosis without 
reactivity for otherwise fragmented double-stranded DNA [45]. 
Differential quantification of apoptosis in target and bystander cells in mixed-culture 
experiments 
For mixed-culture experiments, CD7-positive target cells were labeled with the red 
fluorescent dye DiI (Molecular Probes). Briefly, cells (1.0 x 106 cells/mL) were incubated 
for 5 minutes at 37°C in serum-free medium containing 5µM DiI, followed by 3 washes 
with standard medium. DiI-labeled target and non-labeled bystander cells were mixed 
at indicated ratios with a final cell concentration of 0.5 x 106 cells/well in a 48-well plate. 
After treatment, differential fluorescent characteristics of target cells and bystander cells 
were used to separately evaluate apoptosis by PS exposure to the outer cell membrane 
or by Δψ. 
Additive induction of apoptosis by scFvCD7:sFasL, chemotherapeutics, and small inhibitory 
molecules 
Additive apoptotic effects of treatment of cells with scFvCD7:sFasL and various 
chemotherapeutics or small inhibitory molecules was determined using the cooperativity 
index (CI), in which the sum of apoptosis induced by single-agent treatment is divided by 
apoptosis induced by combination treatment. When CI was less than 1, treatment was 
considered synergistic; when CI equaled 1, treatment was considered additive; and when 
CI was greater than 1, treatment was considered antagonistic. 
CD7-restricted induction of apoptosis in patient-derived leukemic cells 
Blood cells derived from 4 individual patients with T-ALL (patient nos. 1 to 4), 1 patient 
with PTCL (patient no. 5), and 1 patient with CD7-positive AML (patient no. 6) were 
treated for 16 hours with scFvCD7:sFasL (150ng/mL) in the presence or absence of mAb 
TH69 where indicated. In addition, blood cells derived from patient no. 6 (AML) were co-
treated with either vincristine or amsacrine. Apoptosis was assessed by PS exposure to 
the outer cell membrane and staining for active caspase-3 as described. 
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Figure 1. Solution behavior and stability of scFvCD7:sFasL. (A) Culture medium derived from 
CHO-K1 production cells containing scFvCD7:sFasL was subjected to SE-FPLC using a calibrated 
HiLoad 16/60 FPLC column. The apoptotic activity of each individual fraction was assessed using the 
FasL-sensitive CD7-positive MOLT16 cells in the presence or absence of CD7-blocking mAb TH69. The 
horizontal bar in the graph indicates the fractions pooled for further testing. (B) scFvCD7:sFasL was 
stored for various lengths of time, up to 9 days, at 37°C in the presence of 15% serum. At serial time 
points the remaining apoptotic activity of the stored scFvCD7:sFasL was assessed by treatment of 
FasL-sensitive CD7-positive CEM cells for 16 hours. Apoptotic activity was assessed by Δψ.
CD7-restricted induction of apoptosis by homotrimeric scFvCD7:sFasL 
Incubation of CEM cells with homotrimeric scFvCD7:sFasL resulted in strong and specific 
binding to the cell surface (Figure 2A, solid line), which was inhibited by pre-incubation with 
mAb TH69 (Figure 2A, dotted line). Treatment of a series of CD7-positive leukemic T-cell 
lines with serially increasing concentrations of homotrimeric scFvCD7:sFasL (1-110ng/
RESULTS
Fractionation and stability of homotrimeric scFvCD7:sFasL 
Fractionation of crude supernatant containing scFvCD7:sFasL by SE-FPLC and 
subsequent assessment of the apoptotic activity of each separate fraction revealed 2 
peaks of apoptotic activity of 160 kDa and 700 kDa, respectively (Figure 1A). The peak 
corresponding to a molecular weight (MW) of approximately 160 kDa closely resembles 
that of the calculated MW of 147 kDa for homotrimeric scFvCD7:sFasL. Samples taken 
from this peak showed strong and CD7-restricted induction of apoptosis toward MOLT16 
cells, which was completely abrogated by pretreatment with CD7-blocking mAb TH69. 
Samples taken from the 700-kDa peak showed strong apoptosis induction toward both 
CD7-positive MOLT16 cells and CD7-negative Ramos cells, which in contrast to the 160 
kDa peak could not be inhibited by pretreatment with mAb TH69. Fractions from the 
700-kDa peak were discarded. Fractions from the 160 kDa peak containing homotrimeric 
scFvCD7:sFasL were pooled and used for further experimental procedures and analyses. 
Subsequently, we analyzed for secondary formation of scFvCD7:sFasL multimers or 
aggregates. Prolonged storage of up to 7 days at 37°C in medium containing 15% serum 
did not lead to any detectable secondary formation of multimers or aggregates (data not 
shown). Furthermore, samples of scFvCD7:sFasL stored for up to 9 days at 37°C in the 
presence of serum retained potent and CD7-restricted apoptotic activity toward FasL-
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mL) dose-dependently increased apoptosis in all CD7-positive T-cell lines tested (Figure 
2B; Jurkat, 82%; CEM, 90%; Hut78, 70%; and MOLT16, 98%). CD7-negative Raji cells 
were fully resistant to scFvCD7:sFasL (Figure 2B; 2.0%), but were sensitive to secondarily 
cross-linked sFasL (Figure 2B; 78%). Apoptosis by homotrimeric scFvCD7:sFasL was 
Figure 2. CD7-restricted binding and apoptosis induction by scFvCD7:sFasL. (A) CD7-
restricted binding of scFvCD7:sFasL was assessed using CD7-positive CEM cells. Cells were incubated 
with scFvCD7:sFasL (solid line) or with unconditioned medium (filled area). Specific binding was 
demonstrated by preincubating CEM cells with mAb TH69 followed by incubation with scFvCD7:sFasL 
(dashed line). Binding of scFvCD7:sFasL was determined by flow cytometry using PE-conjugated anti-
FasL mAb. (B) CD7-restricted induction of apoptosis by scFvCD7:sFasL was assessed using CD7-
positive cells (MOLT-16, CEM, Jurkat, and HUT-78) and CD7-negative Raji cells. All cell types were 
treated for 16 hours with increasing concentrations of scFvCD7:sFasL, after which apoptosis was 
assessed by Δψ. Additionally, Raji cells were treated with increasing concentrations of cross-linked 
sFasL (cr-sFasL). Indicated values are mean + SEM of 3 independent experiments. (C) Jurkat cells 
were treated for 16 hours with scFvCD7:sFasL (20ng/mL) in the presence or absence of MAb TH69 or 
FasL-neutralizing MAb Alf2.1. Apoptosis was assessed by staining for apoptotic DNA-fragmentation 
using mAb F7-26. Horizontal bars indicate the percentage of apoptosis. (D) To compare the specific 
apoptotic activity of scFvCD7:sFasL with that of the related TRAIL fusion protein scFvCD7: sTRAIL, 
Jurkat cells were treated with equimolar concentrations of scFvCD7:sFasL and scFvCD7:sTRAIL for 
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associated with apoptotic DNA-fragmentation and was inhibited by pre-treatment with 
mAb TH69 or co-incubation with FasL-neutralizing MAb Alf2.1 (Figure 2C). Interestingly, 
when Jurkat cells were treated with equimolar concentrations of scFvCD7:sFasL and 
the previously described scFvCD7:sTRAIL fusion protein [29], scFvCD7:sFasL displayed 
approximately 4-fold more potent apoptotic activity (Figure 2D; EC50  70 pM, EC50  275 
pM, respectively). Similar results were obtained using CEM cells (data not shown). 
Potent antitumor bystander apoptosis induction by homotrimeric scFvCD7:sFasL 
Cell-surface accretion of homotrimeric scFvCD7:sFasL on CD7-positive target cells can be 
exploited to cross-link Fas on neighboring tumor cells that are devoid of CD7 expression, 
a principle known as bystander effect [46]. The pro-apoptotic bystander effect of 
homotrimeric scFvCD7:sFasL was assessed using mixed-culture experiments in which 
Ramos.CD7+ target cells were mixed with CD7-negative Raji bystander cells (ratio 1:1). 
In Ramos.CD7 target cells, scFvCD7:sFasL potently induced apoptosis (Figure 3A). In 
addition, in Raji bystander cells, a bystander apoptotic effect of up to 34% was detected 
(Figure 3B). In both target and bystander cells, apoptosis was specifically inhibited in 
the presence of mAb TH69 or mAb Alf2.1 (Figure 3A-B). No bystander apoptosis was 
observed when parental CD7-negative Ramos cells were used in this experiment (data 
not shown). 
Figure 3. Potent induction of apoptosis in CD7-negative bystander tumor cells. Mixed cultures of 
Ramos.CD7 target cells and Raji bystander cells (ratio 1:1) were treated for 16 hours with scFvCD7:sFasL 
(100ng/mL) in the presence or absence of mAb TH69 or mAb Alf2.1. The differential fluorescent labeling of 
target and bystander cell populations was used to separately evaluate apoptosis induction by Δψ in Ramos.
CD7 target cells (A) and Raji bystander cells (B). Indicated values are mean + SEM of 3 independent 
experiments. Statistical analysis was performed using 2-tailed Student t test. *P<.05; **P<.01.
Absence of apoptotic activity of homotrimeric scFvCD7:sFasL toward PBLs and 
leukocytes 
A subpopulation of normal PBLs is CD7-positive and might sustain collateral damage 
during treatment. Therefore, we investigated the apoptotic activity of homotrimeric 
scFvCD7:sFasL toward normal PBLs. To this end, PBLs were treated with excess 
amounts of scFvCD7:sFasL (325ng/mL) for up to 7 days, which revealed no specific 
induction of apoptosis. In contrast, treatment with cross-linked sFasL (100ng/mL) did 














































































Figure 4. Treatment of normal human leukocytes, activated T cells, and HUVECs with 
scFvCD7:sFasL. (A) Resting PBLs were subjected to treatment with scFvCD7:sFasL (325ng/mL), or cross-
linked sFasL (100ng/mL) for up to 7 days, after which experimental apoptosis was assessed by annexin V/PI 
staining. Indicated values are representatives of 3 independent experiments. (B) Isolated PBLs were mixed 
at a ratio of 1:10 with DiI-labeled Jurkat cells. Mixed cultures were treated for 24 hours with scFvCD7:sFasL 
(100 ng/mL) or secondarily cross-linked sFasL (100ng/mL). Differential fluorescent labeling of Jurkat target 
cell and PBLs was used to separately evaluate apoptosis induction by annexinV staining. Indicated values 
are representatives of 3 independent experiments. (C) Activated T cells were subjected to treatment with 
scFvCD7:sFasL (325ng/mL) for up to 7 days, after which apoptosis was assessed by annexinV/PI staining. 
Indicated values are representatives of 3 independent experiments. (D) Resting HUVECs were treated 
for 24 hours with scFvCD7:sFasL (100ng/mL), secondarily cross-linked sFasL (100ng/mL), or actinomycin 
D (2µg/mL). Apoptosis was assessed by Δψ. (E) Resting HUVECs were mixed with fluorescently labeled 
Jurkat cells (ratio 1:1) and treated with scFvCD7:sFasL (100ng/mL) or actinomycin D (2µg/ml) for 24 hours. 
Differential fluorescent labeling of Jurkat target cells and HUVEC bystander cells was used to separately 
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possible “innocent” bystander apoptotic effect toward normal human leukocytes when 
homotrimeric scFvCD7:sFasL is present in a membrane-bound state at the cell surface of 
CD7-positive tumor cells (Jurkat). Treatment of mixed cultures of Jurkat cells and freshly 
isolated leukocytes (ratio 4:1) with homotrimeric scFvCD7:sFasL revealed no increase in 
apoptosis in leukocytes (Figure 4B; PBLs, 8%; Jurkat, 72%). Again, cross-linked sFasL did 
induce apoptosis in both Jurkat and PBLs (Figure 4B; PBLs, 23%; Jurkat, 70%). 
Moderate apoptotic activity of homotrimeric scFvCD7:sFasL toward activated T cells 
Treatment of anti-CD3/IL-2 activated T cells with excess amounts of homotrimeric 
scFvCD7:sFasL(325 ng/mL) induced apoptosis in approximately 45% of activated T 
cells at day 1 (Figure 4C). Up to day 7, scFvCD7:sFasL consistently induced apoptosis of 
approximately 15% in these cells. 
No apoptotic activity toward resting HUVECs 
To simulate the effect of scFvCD7:sFasL on human endothelial cells, HUVECs were treated 
with excess amounts of homotrimeric scFvCD7:sFasL. No apoptosis was detected after 24 
hours of treatment with homotrimeric scFvCD7:sFasL (Figure 4D; 2%), whereas treatment 
with cross-linked sFasL or actinomycin D significantly induced apoptosis (Figure 4D; 7% 
and 53%, respectively). 
Figure 5. Additive tumoricidal effect of scFvCD7:sFasL with several classes of antileukemia 
agents. Jurkat cells were treated for 16 hours with scFvCD7:sFasL (5ng/mL) alone or in combination with 
vincristin (0.1ng/mL) (A), farnesyl transferase inhibitor L-744832 (25µM) (B), and the proteasome inhibitor 
bortezomib (10nM) (C). Apoptosis induction was assessed by Δψ. The CI was calculated as described in 
“Materials and methods” and used to determine the cooperative effect of combination treatment.
When homotrimeric scFvCD7:sFasL is bound to the cell surface of circulating leukemic 
T cells, a possible innocent bystander effect toward endothelial cells might occur. We 
simulated this situation by treatment of mixed cultures of HUVECs and Jurkat cells (ratio 
1:1) with homotrimeric scFvCD7:sFasL. In these experiments, resting HUVECs proved to 
be fully resistant to the possible innocent bystander effect of homotrimeric scFvCD7:sFasL 





















































































































Additive tumoricidal effects of scFvCD7:sFasL with chemotherapeutics and small inhibitory 
molecules 
Sensitivity to FasL-induced apoptosis has previously been shown to be augmented by 
pre- or co-treatment with various chemotherapeutics and small inhibitory molecules. To 
establish whether scFvCD7:sFasL had similar properties, Jurkat cells were simultaneously 
treated with homotrimeric scFvCD7:sFasL and the microtubule inhibitor vincristine, the 
farnesyl transferase inhibitor L-744832, or the proteasome inhibitor bortezomib. Co-
treatment with homotrimeric scFvCD7:sFasL and vincristine resulted in an increase in 
apoptosis compared with single-agent treatment (Figure 5A; CI=0.9). Co-treatment with 
L-744832 or with bortezomib similarly increased apoptosis (Figure 5B-C, CI=0.7 and 0.85, 
respectively). Identical treatment of PBLs, activated T cells, or HUVECs did not result in a 
significant increase in apoptosis compared with the respective chemotherapeutic agents 
alone (Figure 6). 
Treatment in vitro of T-ALL, PTCL, and CD7-positive AML patient-derived leukemic blood 
samples 
Blood samples derived from 6 patients suffering from various forms of CD7-positive 
leukemia were treated in vitro with homotrimeric scFvCD7:sFasL. The samples included 
T-ALL (patient nos. 1-4), PTCL (patient no. 5), and CD7-positive AML (patient no. 6), all 
containing more than 90% leukemic cells (Figure 7A). In 3 of 4 T-ALL patient samples, 
treatment with homotrimeric scFvCD7: sFasL resulted in a marked increase in apoptosis 
induction (30%, 45%, and 46% for patient nos. 1, 3, and 4, respectively). Tumor cells 
from T-ALL patient no. 2 were refractory to treatment (5% apoptosis). Tumor cells 
derived from patient no. 5 (PTCL) showed a moderate response of 14%, while treatment 
of tumor cells derived from patient no. 6 (CD7-positive AML) resulted in a 23% increase in 
apoptosis. Co-incubation with mAb TH69 inhibited induction of apoptosis by homotrimeric 
scFvCD7:sFasL, as exemplified by the result from patient no. 6 (Figure 7B). Similar data 
were obtained for the other primary patient samples tested (data not shown). 
After treatment, cells from patient no. 4 were analyzed for the formation of active 
caspase-3. Specific staining indicated the activation of caspase-3 in more than 20% of 
the tumor cells, whereas untreated cells showed no formation of active caspase-3 (Figure 
7C). 
Additive apoptotic effect of treatment of primary leukemic cells with scFvCD7:sFasL and 
chemotherapeutic agents 
Blood samples derived from patient no. 6 (CD7-positive AML) were treated simultaneously 
with scFvCD7:sFasL and either vincristine (1ng/mL) or amsacrine (1µM) (Figure 7D). In 
both cases, combination treatment resulted in an additive induction of apoptosis (Figure 
7D; CI=1.0). 
DISCUSSION
Agonistic anti-Fas antibodies and multimeric recombinant FasL preparations show highly 
potent antileukemia activity. However, attempts to exploit these conventional Fas agonists 
for cancer therapy have met with unacceptable systemic toxicity, largely excluding Fas 
signaling as a therapeutic strategy for treatment of human malignancies.
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The toxicity observed for sFasL preparations appears to be directly related to the presence 
of multimeric and aggregated sFasL species that are frequently formed during or after 
overexpression in primitive host cells such as Escherichia coli. Moreover, it was shown 
that as few as 2 adjacent trimeric (hexameric) sFasL molecules are already sufficient for 
Fas signaling in Raji, Jurkat, and activated T cells, as was evidenced by the formation 
of a death-inducing signaling complex (DISC) and subsequent apoptosis induction [47]. 
We produced scFvCD7:sFasL in Chinese hamster ovary (CHO) cells, a currently favored 
industrial host-cell type for production of therapeutic recombinant proteins. We used a 
murine kappa light-chain leader peptide to direct produced scFvCD7: sFasL through the 
endoplasmic reticulum (ER) and Golgi complex, thus taking advantage of the associated 
stringent quality control mechanisms that facilitates secretion of correctly folded and 
non-aggregated scFvCD7:sFasL into the culture medium. Using SE chromatography we 
removed most, if not all, unwanted multimeric forms of scFvCD7:sFasL. Importantly, 
prolonged storage of homotrimeric scFvCD7:sFasL at 37°C in the presence of serum did 
not result in any detectable secondary aggregate formation, whereas apoptotic activity 
was retained. From this we conclude that scFvCD7:sFasL can be produced as soluble 
homogeneous homotrimers with no or only minimal secondary aggregate formation. 
Figure 6. Cotreatment of PBLs, activated T cells, or HUVECs with scFvCD7:sFasL and several 
classes of antileukemia agents. (A) PBLs, (B) activated T cells, and (C) HUVECs were treated with 
scFvCD7:sFasL (40ng/mL) combined with vincristine (0.5ng/mL), L-744832 (25µM), or bortezomib 










































































































































































































These features enable the specific targeting of biologically inactive homotrimeric 
scFvCD7sFasL to CD7-positive cells after which sFasL activation is induced by 
immobilization and multimerization on the target-cell surface. Treatment of a number 
of CD7-positive leukemic T-cell lines with scFvCD7:sFasL showed potent dose-dependent 
induction of apoptosis, which was specifically inhibited by pretreatment with mAb TH69 
or co-incubation with Fas-neutralizing mAb Alf2.1. Flow cytometric analysis identified that 
binding of scFvCD7:sFasL to Fas was barely detectable (data not shown). This observation 
can be explained by the fact that antibody-based proteins typically have fast-on and 
slow off-binding rates (for review see Hudson [48]), whereas binding of FasL to Fas 
(both trimers) is characterized by fast on/fast off rates [49] typical for cytokine/cytokine 
receptor interaction. Moreover, binding of homotrimeric scFvCD7:sFasL via the antibody 
domains substantially benefits from the associated avidity effect of the presence of 3 
scFv reading heads [50;51]. Although not investigated here, this enhanced avidity can 
be inferred from the fact that even molar excess of mAb TH69 cannot fully abrogate the 
apoptotic activity of scFvCD7:sFasL. From this we concluded that biologically inactive 
homotrimeric scFvCD7:sFasL acquires full bioactivity only upon binding to cell-surface-
expressed CD7, and that apoptosis is commenced by reciprocal cross-linking of Fas in an 
autocrine or paracrine manner. 
The paracrine activation of Fas by CD7-immobilized scFvCD7: sFasL opens up the possibility 
of apoptosis induction in neighboring FasL-sensitive leukemia cells that have lost CD7 
expression. Recently, we reported on an exceptionally strong antitumor bystander effect 
for an analogous scFv:sTRAIL fusion protein [46]. Similarly, the paracrine activation of 
Fas by CD7-immobilized scFvCD7:sFasL opens up the possibility of apoptosis induction in 
neighboring FasL-sensitive leukemia cells that have lost CD7 expression. 
In the present study, we found that scFvCD7:sFasL can induce a strong apoptotic effect 
toward bystander CD7-negative leukemic cells in mixed culture experiments with CD7-
positive leukemic cells (Figure 3). This bystander effect was specifically inhibited by mAb 
TH69 or mAb Alf2.1, indicating that the bystander effect predominantly depends on 
activation of scFvCD7:sFasL on the cell surface of CD7-positive tumor cells. The bystander 
activity of scFvCD7:sFasL might be an important feature in the treatment of CD7-positive 
T-cell leukemia, since it has been described that treatment with anti-CD7 mAb results in 
CD7 down-modulation on tumor cells [41]. 
Shedding, down-regulation, and target antigen modulation are likely to be responsible for 
a number of therapeutic failures observed in current antibody-based therapies. Recently, 
it has been reported that treatment with rituximab can result in loss of CD20 expression 
on lymphoma cells [52], leading to often fatal CD20-negative relapses. We speculate 
that treatment of non-Hodgkin lymphoma cells with a death-ligand fusion protein with 
specificity for CD20 may strongly benefit from the associated bystander effect. In 
contrast, only moderate bystander effects have been reported for immunotoxin-based 
strategies, most likely because these strategies usually depend on a number of necessary 
consecutive features, including internalization, intercellular gap junction communication, 
and enzymatic conversions [53;54]. 
Previously, Samel et al [28] provided proof of principle of targeted Fas signaling by fusing 
sFasL to a single-chain fragment of variable regions (scFv) specific for the fibroblast 
activation protein FAP, a tumor-associated stroma marker. The intravenous application of 
this novel Fas reagent in mice revealed no signs of systemic toxicity and prevented growth 
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of xenotransplanted FAP-positive, but not FAP-negative, tumor cells. Nevertheless, from 
these elegant experiments it cannot be concluded that in humans a similar favorable 
toxicity profile will be observed. 
In the current study, we explored the feasibility and safety of scFv-targeted Fas signaling 
in vitro by treating various CD7-positive human leukemia types in the absence or presence 
of normal human blood cells and endothelial cells (HUVECs). Treatment of PBLs with 
scFvCD7:sFasL did not induce apoptosis in any of the normal cell types present, including 
resting CD7-positive T cells and CD7-positive NK cells. This is a remarkable finding since 
Figure 7. Treatment of T-ALL, PTCL, and CD7-positive AML patient-derived blood samples in 
vitro. (A) Blood cells derived from 4 patients with T-ALL, 1 patient with PTCL, and 1 patient with CD7-
positive AML were subjected to treatment with scFvCD7:sFasL (150ng/mL) and analyzed for apoptosis 
induction using annexinV/PI staining. (B) Primary CD7-positive AML cells were subjected to treatment with 
scFvCD7:sFasL alone or in the presence of mAb TH69 for 16 hours, after which apoptosis was assessed by 
annexinV/PI staining. Statistical analysis was performed using 2-tailed Student t test. *P<.05. (C) Primary 
T-ALL cells were subjected to scFvCD7:sFasL (150ng/mL) and then assessed for the presence of active 
caspase-3 using fluorescent microscopy as described in “Fluorescence microscopy of activated caspase-3.” 
(D) Primary CD7-positive AML cells were subjected to single-agent treatment with scFvCD7:sFasL (100ng/
mL), vincristine (10ng/mL), amsacrine (1µM), or to combination treatment. Apoptosis was assessed by 


























































































































specific binding of scFvCD7:sFasL to CD7 on these cells results in the local activation of 
scFvCD7:sFasL that is subsequently able to perform autocrine or paracrine Fas signaling. 
Apparently, normal cell types are relatively resistant to this form of Fas signaling. In 
contrast, treatment of anti-CD3/IL-2-activated T cells with homotrimeric scFvCD7:sFasL 
induced apoptosis in approximately 45% of activated T cells at day 1 (Figure 4C). It is well 
established that fratricidal Fas/FasL interactions between activated T cells are paramount 
to the effective resolution of an immune response [55]. Although not studied here, we 
speculate that fusion proteins such as scFvCD7:sFasL, or those that target activation 
markers such as CD69, can be applied to treat T-cell-mediated autoimmunity. 
Upon intravenous application in patients with leukemia, many different cell types 
will simultaneously encounter either free or cell-bound scFvCD7:sFasL. Binding of 
homotrimeric scFvCD7:sFasL to the cell surface of abundantly circulating leukemic T cells 
might lead to a potentially harmful innocent bystander effect toward normal cells (eg, 
endothelial cells). We simulated this situation using mixed-culture experiments in which 
HUVECs were cocultured with CD7-positive Jurkat cells (ratio 1:1) in the presence of 
homotrimeric scFvCD7:sFasL. In this experiment HUVECs proved to be fully resistant to a 
possible innocent bystander effect scFvCD7:sFasL treatment (Figure 4E). 
Subsequently, we treated blood samples derived from 6 patients suffering from various 
forms of CD7-positive leukemias with homotrimeric scFvCD7:sFasL. Samples, all 
containing more than 90% leukemic cells, were derived from 4 patients with T-ALL, 1 
patient with PTCL, and 1 patient with CD7-positive AML, respectively. Three of 4 T-ALL 
patient samples showed a marked increase in apoptosis induction (3%, 45%, and 46% 
for patient nos. 1, 3, and 4, respectively). Tumor cells from T-ALL patient no. 2 (5% 
apoptosis) were refractory to treatment. Tumor cells derived from patient no. 5 (PTCL) 
showed a moderate response of 14%, while treatment of tumor cells derived from patient 
no. 6 (CD7-positive AML) resulted in a 23% increase in apoptosis. At first glance, the 
therapeutic effect of scFvCD7:sFasL toward these primary tumor cells might seem rather 
moderate. However, ex vivo primary tumor cells typically grow in a non-synchronized 
way at relatively low cell division rates. Previously, it was shown that leukemic cells 
are only sensitive to FasL-induced apoptosis in the G1 phase of the cell cycle [53;54]. 
Subsequently, the effect observed ex vivo may be an underestimation of the therapeutic 
effect of scFvCD7:sFasL when applied in vivo. In addition, a marked variability in response 
was observed between patient samples, which might be related to differences in CD7 
or Fas expression or, alternatively, differential expression of intracellular modulators of 
apoptosis such as the caspase-8 homolog cFLIP. 
Various chemotherapeutic agents are known to sensitize tumor cells to Fas-mediated 
apoptosis at distinct levels, including receptor-proximal, mitochondrial, and/or effector-
caspase level. We subjected blood samples derived from patient no. 6 (CD7-positive AML) to 
cotreatment with scFvCD7:sFasL and suboptimal concentrations of the chemotherapeutic 
agents vincristine and amsacrine that are already part of clinical practice. Cotreatment 
resulted in promising additive effects on apoptosis induction (Figure 7D). Importantly, 
identical treatment of normal PBLs, activated T cells, and resting/activated HUVECs did 
not result in significant increases in apoptosis compared with chemotherapy alone. In 
conclusion, we describe a novel and promising anti-T-cell leukemia agent that shows strong 
CD7-restricted tumoricidal activity toward various CD7-positive leukemia cell types that 
can be augmented with various chemotherapeutic agents and small inhibitory molecules 
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such as bortezomib. Toxicity toward normal cells appears to be restricted to a subset of 
activated T cells. Obviously, more research is needed to evaluate toxicity toward other 
cells and tissues with an emphasis on liver toxicity. New in vitro technologies, including 
those involving the use of human liver organ slices, appear to be appropriate for this 
purpose. Alternatively, scFvCD7:sFasL might be an excellent candidate for the purging 
of bone marrow from malignant CD7-positive cells. In each case further preclinical 
evaluation for scFvCD7:sFasL is warranted.
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Ab binding to CD20 has been shown to induce apoptosis in B cells. In this study, 
we demonstrate that rituximab sensitizes lymphoma B cells to Fas-induced 
apoptosis in a caspase-8-dependent manner. To elucidate the mechanism by 
which rituximab affects Fas-mediated cell death, we investigated rituximab-
induced signaling and apoptosis pathways. rituximab-induced apoptosis 
involved the death receptor pathway and proceeded in a caspase-8-dependent 
manner. ectopic overexpression of FLIP (the physiological inhibitor of the death 
receptor pathway) or application of zIETD-fmk (specific inhibitor of caspase-8, 
the initiator-caspase of the death receptor pathway) both specifically reduced 
rituximab-induced apoptosis in ramos B cells. Blocking the death receptor 
ligands Fas ligand or TrAIL, using neutralizing Abs, did not inhibit apoptosis, 
implying that a direct death receptor/ligand interaction is not involved in CD20-
mediated cell death. Instead, we hypothesized that rituximab-induced apoptosis 
involves membrane clustering of Fas molecules that leads to formation of the 
death-inducing signaling complex (DIsC) and downstream activation of the 
death receptor pathway. Indeed, Fas co-immune precipitation experiments 
showed that, upon CD20-cross-linking, Fas-associated death domain protein 
(FADD) and caspase-8 were recruited into the DIsC. Additionally, rituximab 
induced CD20 and Fas translocation to raft-like domains on the cell surface. 
Further analysis revealed that, upon stimulation with rituximab, Fas, caspase-8, 
and FADD were found in sucrose-gradient raft fractions together with CD20. 
In conclusion, in this study, we present evidence for the involvement of the 
death receptor pathway in rituximab-induced apoptosis of ramos B cells with 
concomitant sensitization of these cells to Fas-mediated apoptosis via Fas 
multimerization and recruitment of caspase-8 and FADD to the DIsC. 
INTRODUCTION
The efficient B cell depletion induced by the chimeric anti-CD20 Ab rituximab in vivo is 
due to simultaneous activation of multiple cell death-inducing mechanisms. It is well 
established that rituximab can activate both Ab-dependent cellular cytotoxicity and 
complement-dependent cytotoxicity [1;2]. In addition, cross-linking of rituximab, for 
example via FcR-positive cells, leads to the activation of an intracellular signaling cascade 
which results in B cell death by apoptosis [3;4]. Rituximab has been described to sensitize 
lymphoma cells to standard chemotherapeutic reagents used for treatment of non-
Hodgkin’s lymphoma and, very recently, to Fas receptor-induced apoptosis [5-7]. These 
observations are of significant clinical importance as exemplified by the implementation 
of combination therapies with rituximab, which have shown to prolong progression free 
and overall survival [8;9]. Despite its undisputed clinical relevance, the exact way by 
which rituximab exerts its apoptosis inducing activities is still not understood. 
Several signaling molecules and pathways have been described to be involved in rituximab-
induced apoptosis. Cross-linking of anti-CD20 Abs on B cells leads to translocation of 
CD20 to lipid microdomains know as rafts, followed by activation of members of the src 
family of tyrosine kinases, elevation in intracellular Ca2+, and phospholipase C  activation 
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[10;11]. In addition, CD20 cross-linking results in a rapid up-regulation of Bax, changes 
in RNA level of c-myc and Berg36, activation of MAPK family members p44 and 42, and 
increased AP-1 DNA binding activity [12]. p38 MAPK and STAT3 protein activity have been 
reported to be inhibited as a result of CD20 cross-linking by rituximab, subsequently 
down-regulating the antiapoptotic proteins Bcl-xL, Bcl-2, and inducing apoptosis protease 
activating factor 1 [13-15]. Other anti-apoptotic signaling pathways, including the ERK 
1/2 and the NF- κB pathway, have been reported to be inhibited by rituximab, resulting 
in the sensitization of various B cell lines to chemotherapy [5;16] and Fas receptor-
mediated apoptosis induction [7]. 
In vivo, in chronic lymphocyte leukemia patients, rituximab treatment results in activation 
of caspase-9 and -3, followed by the execution of apoptosis [4]. Although it is generally 
believed that the mitochondrial pathway, activated via caspase-9, is the main apoptotic 
cascade induced by rituximab, other routes, activated via caspase-7 and -8, have been 
reported as well [17;18]. 
To further delineate the significance of apoptosis inducing and apoptosis sensitizing 
signaling characteristics of rituximab, we studied the possible involvement of the death 
receptor pathway in rituximab-mediated apoptosis induction. We used the Burkitt 
lymphoma cell line Ramos and retrovirally transduced derivatives of this cell line, 
expressing high levels of FLIP and x-chromosome-linked inhibitor of apoptosis protein 
(xIAP) [4] as a model. This allowed us to differentiate between the involvement of the 
death-inducing signaling complex (DISC) and caspase-9 and -3 mediated apoptosis. 
Both the death receptor and the mitochondrial apoptosis pathway were triggered upon 
cross-linking of rituximab, resulting in the activation of caspase-9 as well as caspase-8. 
Rituximab-induced activation of caspase-8 was preceded by a death receptor/ligand-
independent clustering of Fas in membrane microdomains and by formation of the DISC. 
The lateral membrane re-organisation of Fas and the formation of a functional DISC 
by rituximab was instrumental to a significant part of rituximab-induced apoptosis and 
resulted in concomitant sensitization to apoptosis induction via the Fas receptor. In 
conclusion, in this study, we demonstrate a novel, initiating role for the death receptor 
pathway in the process of rituximab-mediated cell death, which provides a new, 
membrane-dependent mechanism to overcome Fas resistance and sensitize B cells to 
the death receptor-mediated apoptosis. 
MATERIAL AND METHODS 
Cells and culture media
The Burkitt lymphoma type, germinal center B cell line Ramos-RA1 (American Type 
Culture Collection), and retrovirally transduced derivatives of this cell line were cultured 
in RPMI 1640 culture medium (containing 25mM HEPES and L-glutamin) obtained 
from BioWhittaker supplemented with 10% heat-inactivated FCS from Bodinco, 1mM 
sodium pyruvate, 2mM L-glutamin, 0.5mM 2-ME, and 0.1mg/ml gentamicin sulfate all 
obtained from BioWhittaker and 0.02µg/ml Fungizone (Bristol-Meyers). All cell lines were 
maintained at 37°C in a humidified atmosphere containing 5% CO2.  
Abs and reagents       
Rituximab was provided by Roche. F(ab’)2 of goat anti-human-IgG (further denoted 
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as cross-linker or CL) used for cross-linking of rituximab, and the anti-BCR Ab (goat 
anti-human IgM) were obtained from Jackson ImmunoResearch Laboratories. Rabbit-
anti-human DNA fragmentation factor (DFF) and rabbit-anti-human active caspase-3 
Abs were obtained from BD Pharmingen. Anti-actin Abs were purchased from ICN 
Biochemicals, and hybridoma supernatant containing mouse-anti-human-caspase-8 Ab 
(clone C15; [19]) was provided by Dr. H. Walczak (Deutsches Krebsforschungszentrum, 
Heidelberg, Germany). Mouse-anti-human-caspase-9 and rabbit-anti-human Bid Abs 
were obtained from Cell Signaling Technology. Mouse-anti-human-Fas-associated death 
domain (FADD) Abs were purchased from BD Transduction Laboratories. HRP-conjugated 
secondary Abs for Western blotting were obtained from DakoCytomation or from Santa 
Cruz Biotechnology. Rabbit-anti-human poly(ADP-ribose) polymerase (PARP) Abs, rabbit-
anti-human Lyn Abs and the blocking anti-human-Fas ligand (FasL) Ab NOK-1 were also 
obtained from Santa Cruz Biotechnology. Soluble human recombinant SuperKillerTRAIL, 
the TRAIL-neutralizing Ab 2E5, the mouse-anti-human-CD95/Fas Ab APO1–3, the mouse-
anti-human-FLIP Ab NF6, and soluble human recombinant FasL APO-1L were purchased 
from Alexis. As a cross-linking enhancer of FasL APO-1L, the mouse-anti-FLAG M2 Ab was 
purchased from Sigma-Aldrich. The mouse IgM anti-human Fas Ab 7C11 was purchased 
from Immunotech. The caspase-inhibitors zVAD-FMK and zIETD-FMK were obtained 
from Calbiochem. Triton x-100, propidium iodide (PI), RNase A, puromycin, PMSF, 
sodium deoxycholate, trichloroacetic acid, and Tween 20 were obtained from Sigma-
Aldrich. Polyacrylamide and Bradford reagent were purchased from Bio-Rad. Skim milk 
was obtained from Difco (BD Biosciences). The restriction enzymes xhoI and NotI were 
purchased from Invitrogen Life Technologies. Protein-A Sepharose 4 Fast Flow beads 
were purchased from Pharmacia Biotech, and complete protease inhibitors mixture was 
obtained from Roche Diagnostics. 
Generation of retroviral particles encoding short form of cellular FLIP (cFLIPS (cFLIPS))
The human cFLIPS (GenBank accession no. U97075) gene was obtained using mRNA 
isolated from the testicular germ cell tumor cell line Tera, provided by Dr. S de Jong 
(Groningen University Medical Center, Groningen, The Netherlands). RNA was isolated 
using the StrataPrep Total RNA microprep kit (Stratagene). The Sensiscript Reverse 
Transcriptase kit (Qiagen) was used to generate cDNA. The forward primer used for 
amplification of cFLIPS was 5’-ATCTCGAGATGTCTGCTGAAGTCATCCAT-3’. The sequence 
of the backward primer was 5’-ATGCGGCCGCTCACATGGAACAATTTCCAAG-3’. In these 
primers xhoI and NotI restriction sites were introduced to enable shuttling into the 
retroviral vectors. PCR cycling was performed from 95 to 55 to 68°C and back, using 
eLONGase (Invitrogen Life Technologies). PCR-products were isolated from agarose 
gels using the QIAquick cel extraction kit (Qiagen), subcloned into the TOPO xL PCR-
cloning vector (Invitrogen Life Technologies) and sequence analyzed. Subsequently, 
the genes were shuttled into the retroviral vector LZRS-pBMN-IRES-eGFP, provided by 
Dr. H. Spits (Dutch Cancer Institute, Amsterdam, The Netherlands), which was derived 
from LZRS-lacZ(A) [20]. Amphotropic Phoenix packaging cells were transfected using 
Fugene (Roche Diagnostics) as described by the manufacturer. Transfected packaging 
cells were selected by culturing in the presence of 1µg/ml puromycin. Retroviral particle 
batches were obtained by isolating culture supernatant from large scale cultures (without 
puromycin) and stored at –80°C. 
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 Transduction of Ramos cells
Ramos cells were transduced by co-culturing 2 x 106 Ramos cells (in 2 ml) with 3 ml 
retroviral supernatant. The cultures were expanded and transduced cells were sorted 
on GFP-fluorescence by flow cytometry using the MoFlo (Modular Flow Cytometer; 
DakoCytomation). The xIAP overexpressing Ramos cell line was generated according to 
a similar protocol, as described previously [21]. Overexpression of cFLIPS and xIAP was 
confirmed by Western blot (results not shown). 
Induction of apoptosis by cross-linking rituximab on Ramos B cells
One day before each experiment, Ramos cells or cells from its retrovirally transduced 
derivatives were harvested and diluted to a concentration of 0.25 x 106 cells/ml. The 
Figure 1. Rituximab sensitizes Ramos B cells to Fas-mediated apoptosis. A, Ramos cells 
(1.0 x 106) were preincubated with 10µg/ml rituximab (RITX) for 30 min and subsequently incubated 
overnight (16h) with either medium control, 15µg/ml secondary cross-linking Ab (CL), or the anti-
Fas Ab 7C11 (Fas). CL alone and Fas alone were added as controls. To have an independent-positive 
control for both mitochondrial and death receptor-mediated apoptosis, Ramos cells were incubated 
with 5µg/ml anti-BCR Abs (IgM) and 500ng/ml soluble SuperKillerTRAIL (TRAIL). DNA fragmentation 
was determined by means of PI staining to measure the percentage of apoptotic cells. Experiments 
were performed in quadruplicate and the mean percentage of apoptosis is displayed along with 
the SEM. B, Ramos cells (1.0 x 106) were cultured for 16h with rituximab, Fas, or the combination 
as described before. Western blot lysates were prepared, and blotted and blots were stained for 
PARP cleavage (118 kDa and its 89 kDa cleavage product), procaspase-8 (55 kDa), Bid (26 kDa), 
procaspase-3 (32 kDa), and the housekeeping protein actin (36 kDa).
following day, cells were harvested and incubated for 30 min with 10µg/ml rituximab at 
a concentration of 5.0 x 106 cells/ml in culture medium at 37°C. Hereafter, the cells were 
washed to remove unbound rituximab and plated at a concentration of 1.0 x 106 cells/
ml in 24-well plates. Cross-linking was achieved by adding CL in a final concentration of 
15µg/ml. To inhibit caspase activity 20µM (final concentration) zVAD-FMK or zIETD-FMK 
was added in the experiments. 
Detection of DNA fragmentation
DNA fragmentation was analyzed as described previously [22;23]. In short, cells were 
washed in PBS containing 1% BSA and resuspended in a hypotonic buffer (0.1% sodium 





































of 50µg/ml. PI-fluorescence was detected at 625nm by flow cytometry (Epics Elite; 
Coulter Electronics). 
Preparation of cell lysates for Western blotting
Cells were lysed in lysis buffer (30mM Tris-HCl (pH 7.5), 150mM NaCl, 1% Nonidet P-40, 
10% glycerol, and 1mM PMSF, supplemented with complete protease inhibitors mixture) 
for 15 min at 4°C. After sonification on ice for 5s (Bandelin sonopuls), cell debris was 
pelleted by centrifugation at 10,000x g for 10 min at 4°C. The supernatant was collected, 
and protein concentrations of each sample were determined using Bradford reagent [24]. 



































































































Figure 2. Rituximab-mediated Fas sensitization is caspase-8 dependent. A, Ramos cells, the 
Ramos subline cells Ramos-XIAP, Ramos-FLIP, and the negative (empty vector) control derivative 
Ramos-LZRS (all 1.0 x 106) were incubated overnight with 10µg/ml rituximab, 2µg/ml Fas, or the 
combination of both. DNA fragmentation was determined to measure the percentage of apoptotic 
cells. Experiments were performed in quadruplicate and the mean percentage of apoptosis is displayed 
along with the SEM. B, Ramos cells (1.0 x 106) were incubated as described before with rituximab, 
Fas, or the combination of both. Caspase activation was inhibited with 20µM of the general caspase 
inhibitor zVAD-FMK or the caspase-8-specific inhibitor zIETD-FMK. The percentage of apoptotic cells 
was determined after 16h measuring DNA fragmentation, and the mean percentage is displayed 
together with the SEM. C and D, Ramos cells and the Ramos-FLIP cells were cultured with rituximab, 
Fas, or the combination for different time periods. After each period of incubation, apoptosis levels 
were defined in the samples by determining DNA fragmentation. One example of three separate 
experiments is displayed in both graphs
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volume of 2x sample buffer (50 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 5% 2–2-
ME, and 0.002% bromophenol blue) and heating the samples for 5 min at 95°C. SDS-
PAGE size-separated proteins were transferred onto Bio-Rad Trans-blot nitrocellulose 
membrane for immunodetection according the manufacturer’s protocol. 
Protein detection
Blots were blocked for at least 1h at room temperature in blocking buffer (PBS, 5% skim 
milk, and 0.1% Tween 20). Primary Abs were diluted in blocking buffer as recommended 
by the supplier, and blots were incubated for at least 1 h. Subsequently, the blots were 
washed in PBS containing 0.1% Tween 20 and secondary Ab (HRP conjugated, 1/2000 
diluted in blocking buffer) was added for 30 min. Finally, after washing, the conjugates 
were visualized using Lumi-LightPLUS Western blot substrate (Roche Diagnostics) and 
Kodak Biomax MR-1 film (Sigma-Aldrich). 
Immune precipitation of CD95/Fas
CD20 cross-linking was induced as described above, using 10µg/ml rituximab for the 30-
min pretreatment period and 15µg/ml CL for cross-linking on 10 x 106 Ramos cells per 
sample at a concentration of 1.0 x 106 cells/ml. Cells were harvested at various time points, 
washed using cold PBS and gently lysed in immunoprecipitation buffer (30mM Tris-HCl 
(pH 7.5), 150mM NaCl, 1% Nonidet P-40, 10% glycerol, and 1mM PMSF, supplemented 
with complete protease inhibitors mixture). Protein concentration was determined and 
aliquots of total lysates were used separately for Western blot analysis. The remaining 
samples were all adjusted to equal concentrations in 1ml precipitation buffer and Fas 
was immune precipitated for 1h using 2µg/ml anti-CD95/Fas Ab (APO 1–3). Precipitated 
Fas, together with co-precipitated proteins of the DISC, was extracted from the samples 
using protein A-Sepharose 4 Fast Flow beads. The beads plus the precipitate were mixed 
with an equal volume of 2x sample buffer, heated for 5 min at 95°C and spun down at 
70x g for 3 min at 4°C. Finally, the supernatant, including the precipitated proteins, was 
carefully separated from the beads, run on a SDS-polyacrylamide gel and transferred 
onto a Bio-Rad Trans-blot nitrocellulose membrane for immunodetection. 
Analysis by fluorescence microscopy
To perform fluorescent staining of CD20, rituximab was labeled with tetramethylrhodamine 
(TRITC) according to the manufacturer’s protocol (Molecular Probes). Ramos cells (1.0 x 
106 cells/ml) were cultured for 15 min in presence or absence of TRITC-labeled rituximab 
(10 µg/ml), washed using cold PBS and fixated with 3,5% paraformaldehyde (Merck) 
during 10 min on ice. Samples were subsequently incubated on ice with 2µg/ml anti-Fas 
Abs (7C11) and 5% goat anti-mouse Alexa Fluor 488-conjugated Abs (Molecular Probes), 
each for 20 min, after which two rounds of washing with cold PBS were performed. 
Untreated cells were directly fixed with paraformaldehyde and subsequently stained with 
both anti-Fas and rituximab-TRITC. After staining cells were analyzed using a Quantimet 
600S digital analysis system (Leica Microsystems). 
Isolation of lipid rafts by sucrose-gradient ultracentrifugation
Ramos cells 5.0 x 106 cells/ml were incubated with 10µg/ml rituximab for 15 min in culture 
medium at room temperature. After incubation, medium was removed by centrifugation 
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and the cells were dissolved in ice-cold Tris-buffer (20mM Tris-HCl (pH 7.4), 150mM NaCl, 
and 1mM EDTA) with 1% Triton x-100 and 1 µM aprotinin, leupeptin, and pepstatin A, all 
obtained from Sigma-Aldrich. The solution was vortexed and kept on ice for 30 min. The 
lysate was homogenized by passing it 20 times through a 21-gauge needle. To isolate lipid 
rafts, lysates were mixed with an equal volume of ice-cold 80% sucrose in Tris-buffer and 
overlaid with a 35% sucrose and a 5% sucrose layer in Tris-buffer. The gradients were 
centrifuged in a Beckman SW41 swing-out rotor at 40,000 rpm for 18h at 4°C, to allow 
equilibration. 
After centrifugation, 10 fractions were taken from top to bottom of the gradients. They 
were transferred to micro test tubes and vortexed. Protein content of the fractions was 
determined, and 10µg of protein was taken from each fraction and adjusted to 10µg/ml. 
Five microliters of sodium deoxycholate 25mg/ml was added to each tube, followed by 5 
min incubation on ice. Subsequently, 60µl of trichloroacetic acid 100% (w/v) was added 
and the samples were vortexed, incubated on ice for 10 min, and centrifuged for 15 min, 
4500x g at 4°C. Supernatant was removed and the precipitated proteins in the pellets 
were dissolved in 20µl sample buffer, neutralized for 10 min with ammonia vapor, and 
stored at –20°C. Western blotting and protein detection were performed as described.  
RESULTS
Rituximab sensitizes Ramos cells for Fas-mediated apoptosis
Rituximab sensitizes B cells to other apoptosis inducing drugs like cyclophosphamide, 
doxorubicin, vincristine, prednisone, paclitaxel, and cisplatin [9;18;25]. In addition, it 
was recently described that rituximab is able to revert Fas resistance [7;26]. We treated 
Ramos cells with combinations of rituximab, goat anti-human-IgG (CL), and anti-Fas Abs. 
As positive controls for the mitochondrial and the death receptor pathway, Ramos cells 
were treated with anti-BCR Abs (anti-IgM) or soluble TRAIL. Upon cross-linking, up to 
55% apoptosis was induced by rituximab. Without cross-linking, no apoptosis was induced 
by rituximab. Thus, although the death receptor pathway is functional, it appeared that 
Ramos cells are relatively resistant to Fas-induced apoptosis. Interestingly, in the absence 
of cross-linking secondary Abs, rituximab significantly increased apoptosis induction via 
Fas. Upon treatment with rituximab (without secondary cross-linking), Fas resistance 
was abrogated and up to 45% apoptosis was induced by anti-Fas Abs (Fig. 1A). In the 
presence of additionally applied secondary rituximab cross-linking Abs, apoptosis further 
increased to 62%, which is approximately similar to the level of apoptosis found after 
treatment with cross-linked rituximab without additionally applied anti-Fas Abs. Western 
blot analysis revealed that cell death via sensitization to Fas involved PARP cleavage, 
activation of caspase-8 by cleaving its 55 kDa proform, activation of caspase-3 and also 
cleavage of Bid (Fig. 1B). 
Fas sensitization by rituximab is dependent on caspase-8 activation
Rituximab is described to activate signaling cascades, including the mitochondrial 
apoptosis pathway, whereas Fas triggering classically induces the death receptor 
pathway. To explore the mechanism of rituximab-induced sensitization to Fas-mediated 
apoptosis, two Ramos-derived cell lines, overexpressing ectopic FLIP or xIAP (Ramos-
FLIP and Ramos-xIAP), were used. FLIP overexpression specifically blocks the activation 
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of the death receptor apoptosis pathway at the level of caspase-8 activation, whereas 
xIAP prevents apoptosis downstream from mitochondrial damage and death receptor 
apoptosis at the level of caspase-9 and -3. All cell lines were incubated overnight with 
rituximab, anti-Fas Abs and the combination thereof. As shown in Fig. 2A, Fas resistance 
could be overcome by rituximab-mediated sensitization in both the parental Ramos cell 
line and the empty vector control, Ramos-LZRS. 
However, apoptosis at the level of DNA fragmentation was almost completely blocked in 
both Ramos-FLIP and Ramos-xIAP. In accordance, inhibition of caspase activation, by 
a pancaspase inhibitor (zVAD-FMK) and by caspase-8 inhibition (zIETD-FMK), resulted 
in a complete inhibition of apoptosis induced by the combined treatment with rituximab 
and anti-Fas Abs, indicating that rituximab-mediated Fas sensitization is dependent on 
the activation of caspase-8 and its downstream effectors (Fig. 2B). In time, apoptosis 
induced by anti-Fas Abs alone or in combination with rituximab increased to the same 
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Figure 3. Rituximab-mediated apoptosis induction in time. A, Ramos cells (1.0 x 106) were 
incubated with 10µg/ml rituximab for 30 min and subsequently incubated for the described time 
periods with 15µg/ml CL (cross-linking Ab). Apoptosis was quantified by determination of DNA 
fragmentation by PI staining. The mean result of quadruplicate assays along with the SEM is displayed 
for each condition. B, Western blots were prepared from matching sample lysates and stained for the 
proforms of caspase-8 (55 kDa) and -9 (46 kDa), DFF (45 kDa), and PARP (118 and 89 kDa). Actin (36 
kDa) was included as a housekeeping protein to have a control for protein concentrations.
extend and with similar kinetics during the first 1–2h. Thereafter, Fas triggering sustained 
at a maximum level of 20% of apoptosis, whereas the combination of rituximab and anti-
Fas Abs induced a further increase in apoptosis levels up to 46%. In the Ramos-FLIP 
derivate, both the early and the late effects were inhibited regardless whether apoptosis 
was induced by anti-Fas Abs alone or in combination with rituximab (Fig. 2, C and D).
Rituximab induces caspase-mediated apoptosis
Although rituximab is not known to activate the death receptor pathway, rituximab-
mediated Fas sensitization appeared to depend completely on the activation of caspase-8. 
In addition, sensitization to Fas-induced apoptosis was observed in the absence of 
rituximab cross-linking, suggesting direct modulation of the Fas/death receptor complex 
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by rituximab. To further investigate the role of the death receptor pathway in CD20-
mediated apoptosis, we extensively studied the activation of caspases and the initiation 
of apoptosis by rituximab. Rituximab was cross-linked at the surface of Ramos B cells 
and initiator caspase cleavage was monitored. Anti-IgM and soluble TRAIL were used 
as positive controls for the mitochondrial and the death receptor pathway, respectively. 
Rituximab-mediated apoptosis was first detected between 8 and 12h of incubation and 
increased up to 40% after 24h (Fig. 3A). Subsequently, Western blot analysis was used to 
determine the kinetics of processing of caspase-8 and caspase-9 along with the proteolytic 
cleavage of DFF and PARP (Fig. 3B). The kinetics of DFF and PARP cleavage were similar to 
the kinetics found for DNA fragmentation. A concurrent processing of both caspase-8 and 
caspase-9 preceded DFF and PARP cleavage as well as DNA fragmentation. Degradation 
of both proforms of caspase-8 and -9 could be detected as early as 2h after starting 
rituximab cross-linking. 
The death receptor pathway plays an initiating role in rituximab-mediated apoptosis
The involvement of the death receptor pathway in rituximab- mediated apoptosis 
induction was studied in more detail using the Ramos-FLIP and Ramos-xIAP cell lines. 
As shown in Fig. 4A, overexpression of xIAP and, interestingly, also of FLIP, inhibited 
apoptosis induction at the level of DNA fragmentation by cross-linked rituximab. This 
strongly suggested a direct role for the death receptor pathway in rituximab-mediated 
apoptosis. In accordance with these results, addition of zIETD-FMK inhibited rituximab-
mediated apoptosis at the level of DNA fragmentation (Fig. 4B) and PARP cleavage 
(Fig. 4C). zVAD-FMK (pancaspase inhibitor) was applied as a control to confirm the 
involvement of caspases in general. The results presented in Fig. 4, A–C, demonstrated 
that rituximab-mediated apoptosis induction is caspase dependent and showed that the 
death receptor pathway is at least partially responsible for CD20-mediated cell death. 
It was shown by Shan et al. [3]  that apoptosis induction by fratricide, via interaction of 
membrane-bound FasL or soluble FasL with the Fas receptor, is not involved in CD20-
mediated cell death. To confirm this finding in our experimental setting and to investigate 
if the interaction between another well described ligand, TRAIL, and its death receptors, 
plays a role in rituximab-induced apoptosis, and FasL- and TRAIL-neutralizing Abs were 
added as described previously [27;28]. Both Abs were capable of completely neutralizing 
apoptosis induced by soluble FasL and TRAIL. However, neither blocking of FasL nor 
blocking of TRAIL decreased the percentage of apoptotic cells induced by cross-linking 
of rituximab (Fig. 4D), implying that rituximab-induced activation of the death receptor 
pathway is independent of death receptor/ligand interaction.
 
Rituximab initiates formation of the DISC
Spontaneous multimerization of CD95/Fas occurs in germinal center B cells and has been 
shown to play a role in clonal selection of maturating B cells [29]. Algeciras-Schimnich 
et al. [30] showed that multimerization of Fas is followed by the formation of micro-
aggregates and receptor clustering before the actual induction of apoptosis can proceed. 
Fas-induced apoptosis is considered to be dependent on death receptor translocation to 
rafts where receptor clustering and DISC formation takes place [31;32]. We hypothesized 
that rituximab-induced CD20 translocation to rafts induces concurrent clustering 
of multimerized Fas and subsequently allows formation of the DISC, resulting in the 
49
RITUxIMAB-MEDIATED SENSITIZATION TO FAS-INDUCED APOPTOSIS
3
activation of caspase-8. We investigated whether or not the DISC was formed in Ramos 
cells upon CD20-triggering by immune precipitating Fas and analysis of co-precipitated 
proteins like caspase-8 and FADD. As shown in Fig. 5A, a time-dependent recruitment of 
both caspase-8 and FADD to the DISC was observed in cross-linked rituximab-treated 
Ramos cells. As a positive control for immunodetection of caspase-8 and FADD, 10 µg of 
total lysate of untreated Ramos cells was applied on the same blot. To ensure that equal 
amounts of protein were used as starting material, equal fractions of the total lysates of 
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Figure 4. Rituximab-induced apoptosis is partly induced via caspase-8 activation. A, Ramos 
cells and the Ramos subline cells Ramos-XIAP, Ramos-FLIP, and Ramos-LZRS (all 1.0 x 106) were 
preincubated with 10µg/ml rituximab and incubated overnight with or without 15µg/ml CL (cross-
linking Ab) or with CL alone. DNA fragmentation was determined to measure the percentage of 
apoptotic cells. Experiments were performed in quadruplicate and the mean percentage of apoptosis 
is displayed along with the SEM. B, Ramos cells (1.0 x 106) were cultured overnight with rituximab, 
CL, or the combination. General caspase activation or specific caspase-8 activation was inhibited 
with 20 µM zVAD-FMK or zIETD-FMK. The percentage of apoptotic cells was determined after 16h 
measuring DNA fragmentation, and the mean percentage is displayed, including the SEM. C, Western 
blot lysates were prepared and blotted and blots were stained for PARP cleavage (118 and 89 kDa) to 
confirm DNA fragmentation results. D, Ramos cells were incubated as described before with 10µg/ml 
rituximab, 500 g/ml FasL plus 2.5µg/ml enhancer (FasL), or 500ng/ml soluble TRAIL. Where indicated, 
Ramos cells were preincubated with saturating amounts of blocking NOK-1 anti-FasL (αFasL) and 2E5 
anti-TRAIL (αTRAIL) Abs (10µg/ml). DNA fragmentation was determined by PI staining and the mean 
result of triplicate assays along with the SEM is displayed for each condition.
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Although we demonstrated that the classical DISC, initiating the death receptor pathway, 
was formed upon rituximab cross-linking, we wanted to make certain that CD20 triggering 
was the initiative stimulus for this complex to be formed. It is known that continuous 
processing of caspase-8 is necessary for efficient multimerization of the DISC [33]. 
This process is likely to be catalyzed by activated caspase-3, which can cleave initiator 
caspases like caspase-8 and is even reported to be a possible component of the DISC 
[34;35].
To exclude the possibility that the observed formation of the DISC via CD20 triggering 
is a secondary response resulting from activation of caspase-3 and/or -9, we used the 
Ramos-xIAP cell line in which the cleaving potential of these downstream effector-
caspases is completely blocked [36;37]. Indeed, DNA fragmentation in Ramos-xIAP cells 
was significantly inhibited confirming the involvement of effector caspases in the end-
stage execution of rituximab-induced apoptosis (Fig. 4A). In contrast, DISC formation by 
recruitment of caspase-8 and FADD in Ramos-xIAP and subsequent loss of mitochondrial 
transmembrane potential was found to be equivalent to the parental Ramos cells (Fig. 5, 
A and B). This shows that CD20 triggering is followed by an immediate formation of the 
DISC, which is not initiated via a downstream secondary caspase activating loop.
Figure 5. DISC isolation via Fas immune precipitation (IP). A, After culturing, either in control 
medium (untr) or with cross-linked rituximab for 10 min up to 120 min (2h), Ramos cells (10.0 x 106) 
were lysed gently, and Fas was immune precipitated using 2.0µg/ml anti-Fas APO1–3 Abs together 
with possible attached proteins of the DISC as described in the Materials and Methods. Western blots 
were prepared, followed by immunodetection of coprecipitated caspase-8 and FADD. As a positive 
control for the detected bands, one lane of 10µg of total lysate from untreated Ramos cells was 
displayed together with the IP samples. Total lysate controls of all samples are displayed in the small 
pictures to confirm that differences in intensity of the detected bands are not an effect of differences 
in general sample protein concentration. B, To exclude the interaction of caspase-9 and -3 activation, 
experiments were repeated using Ramos-XIAP cells. Both the displayed immune precipitation and the 
total lysate blots are representatives of three separate experiments.
 
Rituximab induces translocation of Fas to rafts
Fas-mediated apoptosis is dependent on translocation of Fas to rafts, where receptor 
clustering and DISC formation takes place. We hypothesized that the initiation of DISC 
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result from rituximab-induced receptor translocation into rafts. We therefore examined 
the membrane localization of CD20 and Fas following rituximab treatment. In untreated 
cells, both CD20 and Fas were present on the membrane in a homogeneous, dispersed 
pattern. In contrast, upon treatment with rituximab alone, this pattern changed both for 
CD20 and Fas into a patched pattern, indicating rapid translocation and clustering of both 
CD20 and multimerized Fas to raft-like domains upon CD20 stimulation (Fig. 6A). To study 
the translocation of DISC components, like Fas, caspase-8 and FADD into rafts upon 
rituximab triggering, we incubated Ramos cells with rituximab and subsequently isolated 
lipid rafts by sucrose-gradient ultracentrifugation. Translocation of Fas, caspase-8, and 
FADD to rafts was determined by Western blot analysis. As a control for proper lipid raft 
isolation, the blots were also probed for the lipid raft marker src-kinase Lyn (Fig. 6B). 
Indeed, Fas, caspase-8 and FADD, along with CD20 itself, were found in the raft fractions 
upon treatment of Ramos cells with rituximab.  
DISCUSSION
Rituximab sensitizes malignant B cells to several chemotherapeutic drugs via intracellular 
mechanisms influencing the pro- and antiapoptotic balance within the B cell. Recently, 
Vega et al. [26;7] reported that rituximab is capable of inducing sensitization to apoptosis 
induced by the death receptor Fas via increased Fas expression and concurrent inhibition 
of the NF- κB signaling pathway. In this study, we describe another mechanism involved in 
the sensitization of lymphoma B cells to Fas-induced apoptosis. Treatment with rituximab 
resulted in lateral translocation and clustering of CD20 and Fas at the membrane in raft-
like microdomains, resulting in the formation of a functional death-inducing signaling 
complex, and thus functional sensitization toward Fas-induced apoptosis induction. 
Rituximab has been described to cause modification of raft organization on the surface 
of B cells [33;38;39]. Also, binding by anti-CD20 Abs leads to CD20-multimerization and 
translocation of CD20 to lipid rafts where it can associate with other signaling molecules 
[10;40]. We hypothesized that rituximab-induced raft-reorganisation facilitates clustering 
of multimerized death receptors, thereby stimulating the recruitment and activation of 
caspase-8, resulting in death receptor signaling. A direct interaction between CD20 and 
death receptors or the death receptor pathway has, to our knowledge, not been described 
before. 
The decision to respond to Fas induced apoptosis was determined within the first 2h 
of treatment. We therefore focused on the early activation of caspases in the classical 
induction of apoptosis via rituximab cross-linking, to examine which cell death-inducing 
processes are initiated by CD20 stimulation. We show that the death receptor pathway 
plays a significant initiating role in CD20-mediated apoptosis. Although the involvement 
of caspase-8 activation in rituximab-mediated apoptosis has been described before, 
until recently this was generally believed to be a secondary result of activation of the 
mitochondrial pathway [21;40;41]. We show that caspase-8 is activated within 2h of 
rituximab cross-linking. This is accompanied by the activation of caspase-9, followed 
by PARP cleavage. Rituximab-induced apoptosis was inhibited by ectopic FLIP-
overexpression and by zIETD-FMK, demonstrating rituximab-induced apoptosis to be 
dependent on caspase-8 activation. This also further underlines that rituximab-induced 
apoptosis by itself is, at least partly, dependent on activation of the death receptor 
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pathway. Intertwining of rituximab-induced apoptosis with the functional activation of 
the death receptor pathway and its consequence for sensitization to anti-Fas-induced 
apoptosis induction was subsequently demonstrated at the molecular level using immune 
precipitation and fluorescence microscopy. We show that rituximab cross-linking leads to 










































Figure 6. Rituximab induces Fas translocation into raft-like lipid domains. A, Ramos cells (1.0 
x 106 cells/ml) were cultured for 15 min in presence or absence of TRITC-labeled rituximab (10µg/
ml) at room temperature. After fixation with paraformaldehyde, cells were stained with anti-Fas Abs 
(7C11) followed by goat anti-mouse IgM Alexa Fluor 488-conjugated Abs. Untreated cells were directly 
fixed with paraformaldehyde and subsequently stained with both anti-Fas/anti-mouse IgM Alexa Fluor 
488 and rituximab-TRITC. After staining, cytospots were prepared and analyzed on a Quantimet 600S 
digital analysis system (Leica Microsystems). B, Ramos cells (5.0 x 106 cells/ml) were incubated with 
10µg/ml rituximab without cross-linking Abs for 15 min at room temperature. After incubation, lysates 
were prepared, and lipid rafts were isolated by sucrose-gradient ultracentrifugation as described in 
Materials and Methods. After centrifugation, fractions were taken from top to bottom of the gradients 
and pooled into raft and nonrafts fractions. Western blotting and protein detection were performed as 
described before, and blots were stained for CD20 (35 kDa), caspase-8 (55 kDa), and FADD (28 kDa), 
the specific raft marker src-kinase Lyn (56 kDa), and the housekeeping protein Actin (36 kDa).
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To exclude the possibility that rituximab-mediated recruitment of caspase-8 and FADD 
to the DISC was the result of a secondary apoptotic signaling loop, initiated or amplified 
by the intrinsic/mitochondrial activation of caspase-9 and/or -3, we performed additional 
DISC immune precipitation experiments in Ramos cells overexpressing xIAP. xIAP acts as 
a potent inhibitor of proteolytically processed caspase-9 and -3, preventing downstream 
continuation of apoptosis signaling as well as secondary triggering of upstream caspases, 
such as caspase-8 [41;42]. In Ramos-xIAP cells, rituximab-induced formation of the DISC 
and upstream hallmarks of apoptosis (loss of mitochondrial transmembrane potential) 
were completely intact, confirming that the initiation of the death receptor pathway was 
a primary consequence of Fas redistribution into multimeric clusters and not a secondary 
effect of caspase-9 or caspase-3 activation. 
The clustering of Fas in rafts upon rituximab treatment in combination with the rituximab-
induced increase in expression of Fas described by Vega et al. [7] may contribute to an 
efficient DISC formation. Subsequently, caspase-8 is activated, providing an essential 
step for the execution of apoptosis. The dependence on adequate levels of activated 
caspase-8 may explain the typical divergence in the kinetics of progression of apoptosis 
observed after incubation with anti-Fas Abs alone vs the combined treatment of rituximab 
and anti-Fas Abs (Fig. 2C). Possibly, anti-Fas Abs alone do not induce sufficient activation 
of caspase-8 for persistent induction of apoptosis. Co-treatment with rituximab could 
provide B cells with an essential signal for enhanced Fas expression and clustering, 
resulting in an optimized condition for DISC formation, amplification of caspase-8 
activation, and, subsequently, to a sustained intracellular delivery of the apoptotic signal. 
Based on the use of PP2 and calpeptin, which did not affect the intrinsic sensitivity toward 
agonistic anti-Fas Abs or the sensitization of the cells to anti-Fas-induced apoptosis by 
rituximab (data not shown), signaling via src kinases and calcium does not seem to 
be involved in the here described sensitization of B cells to Fas-induced apoptosis by 
rituximab. 
Within the Fas signaling cascade, it is not uncommon that clustering of Fas molecules, 
induced by either Fas overexpression or chemotherapy, can trigger activation of the 
death receptor pathway independent of Fas ligation by FasL [43]. For example, during 
clonal selection in the germinal center, B cells possess pre-assembled Fas-DISC, which 
enables ligand independent induction of apoptosis through Fas [29]. Fas trimerization 
alone, however, is not sufficient for induction and execution of apoptosis. Translocation 
of Fas to rafts, Fas clustering, and the subsequent formation of micro-aggregates all 
appear critical in the regulation of this process [33;39;43]. Vega et al. [7] described 
sensitization of B cells to Fas by rituximab via a pathway that involves inhibition of p38 
MAPK and the NF-κB signaling pathway, resulting in the inhibition of the transcription 
repressor yin-yang 1 and subsequent up-regulation of Fas expression by B cells [34]. 
In addition to this, we postulate here a mechanism for Fas sensitization by rituximab 
based on a CD20 stimulation-induced translocation of Fas into lipid rafts, followed by the 
recruitment of caspase-8 and FADD to raft domains and formation of the DISC. Although 
forced overexpression of IκB in Ramos cells did not affect the intrinsic sensitivity toward 
agonistic anti-Fas Abs or sensitization to anti-Fas-induced apoptosis by rituximab (data 
not shown), we did observe an increase in Fas expression following treatment of Ramos 
cells with rituximab. This is in concordance with the results published by Vega et al. [7]. 
54
CHAPTER 3
It is very well possible that the here described mechanism for sensitization of lymphoma 
B cells to anti-Fas Abs by rituximab is not limited uniquely to Fas. A similar phenomenon 
may occur for other ligands of the death receptor family or for unrelated apoptosis-
inducing agents. The capacity of rituximab to influence the membrane composition of 
B cells by inducing the translocation of other proteins into rafts might be an intrinsic 
feature of CD20, activated by this Ab, thereby inducing an efficient pro-apoptotic shift in 
the apoptotic balance of malignant B cells. Besides in Ramos cells, rituximab-mediated 
sensitization to anti-Fas-induced apoptosis was observed in Raji cells and BJAB cells, 
confirming the here described phenomenon to apply more broadly for lymphoma cells. 
However, results were less clear in primary lymphoma cells, which was due to a high 
threshold for experimental induction of apoptosis in general (data not shown). The here 
described findings extend the clinical options for anti-lymphoma therapies combining 
rituximab with apoptosis inducing agents, targeting either the mitochondrial pathway 
(e.g., chemotherapy), the death receptor pathway (e.g., FasL or TRAIL), or both. The 
rationalized implementation of rituximab and CD20 as key regulators of B cell apoptosis 
could significantly improve rituximab-mediated treatment strategies for CD20-positive B 
cell malignancies in the upcoming years. 
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The clinical efficacy of the CD20-specific chimeric monoclonal antibody rituximab 
is significantly hampered by intrinsic or acquired resistance to therapy. 
rituximab activates antibody-dependent cellular cytotoxicity/complement-
dependent cytotoxicity–dependent lysis but also induces apoptosis by cross-
linking of its target antigen CD20. recent reports indicate that this apoptotic 
activity of rituximab can be synergized by cotreatment with Fas agonists. Here, 
we report on a strategy designed to exploit and optimize the synergy between 
rituximab and Fas signaling by genetically fusing a rituximab-derived antibody 
fragment to soluble Fas ligand (sFasL). The resultant fusion protein, designated 
scFvrit:sFasL, potently induced CD20-restricted apoptosis in a panel of 
malignant B-cell lines (10 of 11) and primary patient-derived malignant B cells 
(two of two non–Hodgkin lymphoma and five of six B cell chronic lymphocytic 
leukemia). ScFvRit:sFasL efficiently activated CD20 and Fas apoptotic signaling, 
resulting in a far superior proapoptotic activity compared with cotreatment 
with rituximab and Fas agonists. scFvrit:sFasL lacked activity toward normal 
human B cells and also lacked systemic toxicity in nude mice with no elevation 
of aspartate aminotransferase and alanine aminotransferase levels or liver 
caspase-3 activity. In conclusion, scFvRit:sFasL efficiently activates CD20 and 
Fas-apoptotic signaling and may be useful for the elimination of malignant B 
cells.
INTRODUCTION
The tumoricidal activity of the CD20-specific chimeric monoclonal antibody (mAb) 
rituximab predominantly depends on the presence of fully functional immune effector 
mechanisms in the treated patient, such as antibody-dependent cellular cytotoxicity and 
complement-dependent cytotoxicity [1]. In addition, part of the tumoricidal activity of 
rituximab has been attributed to the direct activation of apoptosis via cross-linking of cell 
surface–expressed CD20 on malignant B cells [2]. 
Rituximab has markedly improved clinical responses in non–Hodgkin lymphoma (NHL). 
Unfortunately, 50% of patients with aggressive B-NHL have primary refractory disease or 
develop relapses after treatment with rituximab and chemotherapy, whereas the efficacy 
of rituximab is limited in B cell chronic lymphocytic leukemia (B-CLL) patients [3]. Thus, 
the development of alternative rituximab-based approaches with enhanced tumoricidal 
activity is warranted, especially toward rituximab-resistant malignant B cells that 
currently escape from therapy. In this respect, it has recently been shown that rituximab-
mediated CD20 apoptotic signaling synergizes the proapoptotic activity of various death 
receptor agonists. For instance, cotreatment with rituximab and recombinant human 
sTRAIL synergistically activates apoptosis [4]. Analogously, we and others have recently 
shown that cotreatment with rituximab and an agonistic anti-Fas mAb also synergistically 
activates apoptosis in malignant B cells [5;6]. Importantly, although clinical use of anti-
Fas antibodies is deemed impossible due to liver toxicity [7–9], the potential feasibility 
of exploiting Fas apoptotic signaling using soluble Fas ligand (sFasL) has recently been 
reestablished [10;11]. 
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Homotrimeric sFasL is nontoxic to normal cells but also lacks tumoricidal activity [12]. 
In contrast, sFasL hexamers and secondary aggregated sFasL trimers are highly active 
toward tumor cells but are also toxic to liver cells [13–15]. Thus, to exploit activation 
of Fas apoptotic signaling for cancer therapy, therapeutic strategies have to meet 
the prerequisite of strictly localized activation of Fas at the tumor cell surface. This 
prerequisite can be met by genetic fusion of sFasL to a tumor-selective scFv antibody 
fragment, yielding a trimeric scFv:sFasL fusion protein [10;11]. Like sFasL trimers, soluble 
trimeric scFv:sFasL fusion proteins are inactive or poorly active. However, they acquire 
strong tumoricidal activity after specific binding to a preselected cell surface–expressed 
target antigen. 
Here, we generated a fusion protein comprising a rituximab-derived antibody fragment 
(scFvRit) genetically fused to sFasL, scFvRit:sFasL, with the aim of exploiting and 
optimizing the recently reported synergy between CD20 and Fas apoptotic signaling. 
Importantly, scFvRit:sFasL activated both CD20 and Fas apoptotic signaling, resulting 
in a far superior proapoptotic activity compared with cotreatment with rituximab and 
Fas agonists. scFvRit:sFasL potently induced CD20-restricted apoptosis in a panel of 
malignant B-cell lines and primary patient-derived malignant B cells (two of two NHL 
and five of six B-CLL). In contrast, scFvRit:sFasL lacked activity toward normal human B 
cells and lacked systemic toxicity in nude mice. In conclusion, scFvRit:sFasL efficiently 




Actinomycin D (stock solution, 2mg/mL in ethanol) and FasL-neutralizing mAb Alf2.1 
were from Sigma (Sigma-Aldrich Chemie B.V.). The caspase-8 inhibitor zIETD-FMK (stock 
solution, 10mg/mL in DMSO) and the total caspase inhibitor zVAD-FMK (stock solution, 
10mg/mL in DMSO) were from Calbiochem (VWR International B.V.). Working solutions of 
all reagents were prepared by serial dilutions in standard culture medium. Anti–caspase-8 
Table 1. Patient characteristics and percentage of specific apoptosis induction by 
scFvRit:sFasL. Abbreviations f, female; m, male; n.d., not detected
antibody was from Cell Signaling Technology. Anti-Fas mAb 7C11 was from Beckman 
Coulter. Rituximab is a chimeric mAb, comprising human IgG1–derived constant domains 
and VH and VL domains derived from the CD20-specific murine mAb 2B8. Rituximab was 
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provided by Roche Nederland B.V. Secondary cross-linking polyclonal goat anti-human 
(GαHu) antibody was from Jackson Immunoresearch Laboratories. CD19-TRITC was from 
IQ Products. PE-conjugated anti-FasL was from Alexis. Peptide Rp10-L is a 12-mer linear 
peptide (ITPWPHWLERSSG), previously selected from a phage-display peptide library to 
mimic the CD20 epitope recognized by rituximab [16]. Rp10-L peptide was produced and 
purified by Pepscan Systems. scFvCD7:sFasL was described previously [11]. 
Cell lines
CD20-positive B-cell lines are BJAB, Ramos, Jy, CA5-I, Jiyoyo, DEV, SJO, NALM-6, 
and Raji. CD20-positive B-cell lines PR-1 and Z-138 were gifts of Prof. Dr. Martin Dyer 
(Medical Research Council Toxicology Unit, University of Leicester). The CD20-negative 
T-cell line MOLT16 was a gift of Prof. Dr. Martin Gramatzki (Division of Stem Cell and 
Immunotherapy, Second Medical Department, University Clinic Schleswig-Holstein). 
Chinese hamster ovary-K1 (CHO-K1) cells were obtained from the American Type Culture 
Collection. All cell lines were cultured in RPMI (Cambrex) supplemented with 10% FCS at 
37°C in humidified 5% CO2 atmosphere. 
Isolation of peripheral blood lymphocytes and B cells
Peripheral blood lymphocytes (PBL) were isolated as previously described [17]. B cells 
were obtained by negative selection procedures using the MoFlo high-speed cell sorter 
(Cytomation). For experiments, cells were resuspended at 2.0 x 106 cell/ml in 48-well 
plates in RPMI supplemented with 10% human pooled serum. 
Construction of scFvRit
The synthetic DNA sequence encoding scFvRit was generated by splice by overhang 
extension PCR technology using published sequence data of the VH and VL domains of 
the murine anti-CD20 mAb 2B8 that are present in rituximab. The VH and VL sequences 
were genetically linked via a flexible peptide linker [(GGGGS)3]. Moreover, restriction 
enzyme sites SfiI (GGCCCAGCCGG) and NotI (GCGGCCGC) were added to the 5’-end and 
3’-end of the sequence, yielding a 756-bp DNA fragment designated SfiI-scFvRit-NotI. 
Construction of scFvRit:sFasL
The coding sequence of scFvRit:sFasL was inserted in the previously described vector 
pEE14 [11]. Important features of this vector are the murine  light-chain leader peptide 
encoded upstream of two multiple cloning sites that are separated by a 26-residue 
in-frame linker sequence. In the downstream multiple cloning site of pEE14, a PCR-
truncated 539-bp DNA fragment encoding the extracellular domain of human sFasL was 
inserted. The upstream multiple cloning site of pEE14 was used to insert DNA fragment 
SfiI-scFvRit-NotI after digestion with restriction enzymes SfiI and NotI and standard DNA 
ligation reaction, yielding plasmid pEE14-scFvRit:sFasL. 
Eukaryotic production of scFvRit:sFasL fusion protein
Fusion protein scFvRit:sFasL was produced using CHO-K1 cells and the glutamine 
synthetase selection/amplification system, essentially as previously described [18]. Briefly, 
CHO-K1 cells were transfected with pEE14-scFvRit:sFasL using Fugene-6 reagent (Roche 
Diagnostics). Transfectant CHO-K1 cells with amplified expression of scFvRit:sFasL were 
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subjected to single-cell cloning using a high-speed cell sorter (Cytomation). Subsequently, 
individual clones were assessed for stable secretion of scFvRit:sFasL using a FasL-specific 
ELISA according to manufacturer’s recommendations (10P’s BVBA) yielding a CHO-K1 
production cell line stably secreting 1.3µg/mL scFvRit:sFasL. scFvRit:sFasL-containing 
supernatant was harvested by centrifugation (10,000x g, 10 min), protein was purified 
using affinity tag purification and size exclusion chromatography was used to isolate 
homotrimeric scFvRit:sFasL. 
CD20-specific binding of scFvRit:sFasL
CD20-specific binding of scFvRit:sFasL was analyzed by incubating CD20-positive BJAB 
cells (1.0 x 106 cells) with scFvRit:sFasL (1.34µg/mL) in the presence or absence of peptide 
Rp10-L (20mM) or parental mAb rituximab (5µg/mL). CD20-specific binding was analyzed 
by flow cytometry using PE-conjugated anti-FasL mAb. Incubations were performed for 
45 min at 0°C and were followed by two washes with serum-free medium. 
CD20-restricted induction of apoptosis by scFvRit:sFasL
Tumor cells were seeded at 0.25 x 106 per well in a 48-well plate and, unless indicated 
otherwise, were treated for 16h with the indicated concentrations of scFvRit:sFasL in the 
presence or absence of rituximab (5µg/mL), mAb ALF2.1 (1µg/mL), zIETD-FMK (10µM), 
or zVAD-FMK (10µM). Assay used to assess apoptosis was Annexin V/propidium iodide 
staining for phosphatidyl serine exposure on the outer cell membrane; flow cytometric 
analysis of exposure of phosphatidyl serine on the outer membrane was performed 
using an AnnexinV–FITC/propidium iodide kit (Nexins). Loss of mitochondrial membrane 
potential (∆Ψ) was analyzed with the cell-permeant green-fluorescent lipophilic dye 
DiOC6 (Molecular Probes) as previously described [11]. Immunoblot analysis of caspase-8 
activation was performed as described previously [17]. Caspase-8 and caspase-3 
activities were assessed using luminescent assays Caspase-Glo 8 and Caspase-Glo 3/7 
(Promega Benelux B.V.). Luminescence was quantified using an ELISA plate reader. 
Differential quantification of apoptosis in target and bystander cells in mixed culture 
experiments
CD20-positive target cells were labeled with red fluorescent dye DiI (Molecular probes) by 
incubating cells (1.0 x 106 cells/mL) for 5 min at 37°C in serum-free medium containing 
5µM DiI, after which cells were washed thrice with standard medium. For experiments, 
DiI-labeled target and nonlabeled bystander cells were mixed at indicated ratios (final 
cell concentration of 0.5 x 106 cells per well in a 48-well plate). Apoptosis was separately 
evaluated in target and bystander cells by phosphatidyl serine exposure to the outer cell 
membrane or by ∆Ψ. 
Quantification of the effect of cotreatment of cells with rituximab and anti-Fas mAb 7C11 
The effect of combination treatment of cells with rituximab and anti-Fas mAb 7C11 was 
quantified using the cooperativity index (CI). CI was calculated as (sum of apoptosis 
induced by single-agent treatment) / (apoptosis induced by cotreatment). CI was qualified 
as follows: CI <0.9, synergy; 0.9< CI <1.1, additive; CI >1.1, antagonistic. 
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CD20-restricted induction of apoptosis in patient-derived leukemic cells
Leukocytes from patients with B-CLL (n=6) and NHL (n=2) were obtained after informed 
consent (for individual characteristics, see Table 1 ). For experiments, lymphocytes were 
isolated and plated in a 48-well plate at a concentration of 2 x 106 cells/mL, after which 
cells were treated for 16h with scFvRit:sFasL (8ng/mL). Apoptosis was determined by 
Annexin V/propidium iodide staining. Specific apoptosis was calculated using the formula 
(experimental apoptosis–spontaneous apoptosis)/(100–spontaneous apoptosis)x 100%. 
Assessment of in vivo toxicity of scFvRit:sFasL
Nude mice were intraoccularly injected with scFvRit:sFasL (30µg), Flag-tagged sFasL 
(2.5µg), secondarily cross-liked with anti-Flag mAb M2 (25µg) and anti-Flag mAb alone 
(25µg). Mice were continuously monitored for changes in behavior. After 24h, mice were 
sacrificed, and organs and blood were collected. Isolated blood was used to determine 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels as a measure 
of tissue damage. Isolated livers were analyzed for caspase-3/caspase-7 activity using 
the Caspase-Glo 3/7 assay according to manufacturer’s recommendations (Promega). 
Animal care and all experiments performed were in accordance with federal guidelines 
and have been approved by university and state authorities. 
Statistical analysis
Data reported are mean values of at least three independent experiments plus SE. P 
values were determined using two-sided, unpaired Student’s t test. A statistically 
significant difference was defined as P<0.05. 
RESULTS
CD20-specific binding and induction of apoptosis by scFvRit:sFasL
Incubation of CD20-positive BJAB cells with scFvRit:sFasL resulted in binding to the cell 
surface of BJAB cells (Fig. 1A, 2 ). Binding of scFvRit:sFasL was strongly inhibited by molar 
Table 2. Characterization of CD20 and Fas expression and EC50 values of B-cell lines for 
scFvRit:sFasL NOTE: Expression levels of CD20 and Fas are represented as mean fluorescent 
intensity. Mean fluorescent intensity values are representatives of three independent binding 
experiments. For the calculation of EC50 values, listed tumor cell lines were treated with scFvRit:sFasL 
or scFvCD7:sFasL up to a concentration of 100ng/mL.
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excess of peptide Rp10-L, a peptide that neutralizes CD20-specific binding by rituximab 
(Fig. 1A, 3). Similar competition data were obtained with rituximab (Fig. 1A, 4). Of note, 
the high molar excess of peptide Rp10-L (>500-fold) and rituximab (>5-fold) required 
to block scFvRit:sFasL points to a high avidity–type binding of trimeric scFvRit:sFasL to 
CD20. Subsequently, the apoptotic activity of scFvRit:sFasL was determined on a panel 
of CD20-positive cell lines and the CD20-negative T-cell line MOLT16. Treatment with low 
concentrations of scFvRit:sFasL potently induced apoptosis in all but one of the CD20-
positive cell lines tested (for EC50 concentrations, see Table 2 ). In contrast, treatment 
with MOCK-scFv:sFasL, targeted at the T-cell marker CD7, showed no or only minimal 
activity toward all B-cell lines tested (Table 1 and Fig. 1B). Induction of apoptosis by 
scFvRit:sFasL was specifically inhibited by cotreatment with a molar excess (>5-fold) of 
parental mAb rituximab (Fig. 1B), indicating that the apoptotic activity of scFvRit:sFasL 
critically depends on selective binding to cell surface–expressed CD20. 
This selective binding to cell surface–expressed CD20 equips scFvRit:sFasL with the 
possibility to activate Fas-apoptotic signaling in neighboring CD20-negative tumor 
cells. We assessed this so-called bystander effect by treatment of mixed cultures of 
CD20-positive target cells (BJAB) and CD20-negative bystander cells (MOLT16) with 
scFvRit:sFasL, followed by separate assessment of apoptosis in BJAB and MOLT16 cells. 
In these experiments, treatment with scFvRit:sFasL was associated with strong induction 
of apoptosis in MOLT16 bystander cells, which was specifically inhibited by cotreatment 
with rituximab (Fig. 1C). In these bystander experiments, the level of apoptosis in BJAB 
target cells was identical to treatment of BJAB cells alone (data not shown). 
In a direct comparison of scFvRit:sFasL with CD20-signaling induced by rituximab, 
scFvRit:sFasL showed superior apoptotic activity even when rituximab was secondarily 
cross-linked to enhance its proapoptotic activity (Ramos, P<0.0001, difference = 
–58.3±2.5; BJAB, P<0.0001, difference = –91.6±5.0; Nalm-6, P=0.0004, difference = 
–55.1±7.9; Fig. 1D). Of note, in most cell lines tested, rituximab-mediated apoptosis did 
not exceed 50% even at a concentration of 20µg/mL (data not shown). 
The apoptotic activity of scFvRit:sFasL is superior to cotreatment with rituximab and 
anti-Fas. 
To determine the efficacy of induction of apoptosis by scFvRit:sFasL, we compared 
scFvRit:sFasL treatment with the recently reported synergistic combination of rituximab 
and anti-Fas mAb 7C11. Cotreatment of Ramos cells with optimal concentrations of 
rituximab (5µg/mL) and mAb 7C11 (2µg/mL) synergistically induced apoptosis (CI, 0.79; 
Fig. 2A ). Strikingly, treatment with only 5ng/mL of scFvRit:sFasL induced apoptosis in 
over 95% of tumor cells, indicative of a quantitatively superior apoptotic activity of this 
agent (P<0.0001, difference = –52.7±4.9; Fig. 2A). 
To exclude that this difference in apoptotic activity was due to the use of different Fas-
agonists (i.e., anti-Fas on the one hand and sFasL on the other hand), Ramos cells were 
also subjected to cotreatment with rituximab and a control scFv:sFasL fusion protein 
with specificity for CD19. CD19 has no known or detectable apoptosis-related signaling 
activity. Consequently, the scFvCD19:sFasL fusion protein can be used to exclusively 
activate Fas-dependent apoptotic signaling in a manner similar to scFvRit:sFasL. 
Importantly, the apoptotic activity of cotreatment with rituximab and scFvCD19:sFasL 
did not significantly differ from the apoptotic activity observed for rituximab and anti-
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Fas (Fig. 2A). Moreover, dose-response curves for scFvRit:sFasL and scFvCD19:sFasL 
on Ramos cells revealed a striking difference in their activity (Fig. 2B). ScFvRit:sFasL 
induced >95% apoptosis (96.9%; Fig. 2B), whereas a 30-fold higher concentration of 
scFvCD19:sFasL only induced 40% apoptosis (40.2%; Fig. 2B). Taken together, these 
results strongly point to a quantitatively superior apoptotic activity of scFvRit:sFasL that 
proceeds via both Fas and CD20. 
scFvRit:sFasL activates CD20 apoptotic signaling 
Proof for the presence of CD20 apoptotic signaling by scFvRit:sFasL was obtained when 
various tumor cell lines were treated with scFvRit:sFasL in the presence of the FasL-
neutralizing mAb Alf2.1 (Fig. 2C). Treatment of BJAB and Raji cells with scFvRit:sFasL in 
the presence of mAb Alf2.1 completely abrogated its apoptotic activity (BJAB, P=0.0002, 
difference = 80.7±9.8; Raji, P<0.0001, difference = 46.6±5.8). 
Figure 1. CD20-restricted binding and induction of apoptosis by scFvRit:sFasL. A, CD20-
positive BJAB B cells were incubated with control antibody, anti–FasL-PE (1), scFvRit:sFasL (2), and 
scFvRit:sFasL in the presence of peptide Rp10-L (3) or mAb rituximab (4). Cell surface binding was 
assessed by flow cytometry using PE-conjugated anti-FasL mAb. B, BJAB, Raji, Ramos, and PR-1 cells 
were treated with scFvRit:sFasL (5ng/mL) in the presence or absence of mAb rituximab or with the 
CD7-targeted fusion protein scFvCD7:sFasL (100ng/mL). C, BJAB target cells and MOLT16 bystander 
cells were mixed at the indicated ratios and treated for 16h with scFvRit:sFasL. Differential fluorescent 
labeling of the target, and bystander population was used to separately assess the induction of 
apoptosis in MOLT16 bystander cells. D, Ramos, BJAB, and Nalm-6 cells were treated with rituximab, 
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In contrast, mAb Alf2.1 failed to inhibit induction of apoptosis by scFvRit:sFasL in Ramos 
and PR-1 cells. In fact, the apoptotic activity of scFvRit:sFasL toward PR-1 cells was 
significantly increased upon coincubation with mAb Alf2.1 (P<0.0001, difference = 
17.3±2.1). Apparently, induction of apoptosis upon treatment with scFvRit:sFasL and 
mAb Alf2.1 in Ramos and PR-1 cells proceeds via CD20 signaling, whereas induction 
of apoptosis by scFvRit:sFasL and mAb Alf2.1 in BJAB and Raji cells results from Fas 
signaling. Of note, these results do not exclude the presence of Fas or CD20 signaling in 
the respective cell lines in the absence of mAb Alf2.1. 
scFvRit:sFasL activates dual Fas and CD20 apoptotic signaling 
To assess whether dual activation of CD20 and Fas signaling could occur upon treatment 
with scFvRit:sFasL, Ramos cells were treated with scFvRit:sFasL. At early time points, 
scFvRit:sFasL induced typical Fas-associated apoptotic features, including procaspase-8 
processing within 3h and initiator caspase-8 and effector caspase-3 proteolytic activity 
within 6h (Fig. 2D). Despite early caspase-8 processing, caspase-8 inhibitor zIETD-FMK 
or overexpression of the caspase-8 inhibitor cFLIPL did not significantly block apoptosis 
after 24h of treatment (Fig. 3A and B , respectively). Similarly, overexpression of effector 
caspase inhibitor x-linked inhibitor of apoptosis protein (xIAP) failed to inhibit apoptosis 
induced by scFvRit:sFasL (Fig. 3B). In contrast, overexpression of the mitochondrial anti-
apoptotic protein Bcl-2 abrogated the activity of scFvRit:sFasL (Fig. 3C). 
Subsequent time course experiments with Ramos cells revealed that the apoptotic 
activity of scFvRit:sFasL was comparable with the activity of scFvCD19:sFasL during the 
initial 6h of treatment (open squares and open triangles, respectively; Fig. 3D), most 
likely as a result of the activation of Fas signaling by both reagents. In contrast, at later 
time points, scFvRit:sFasL-induced apoptosis proceeded to >90%, whereas induction of 
apoptosis by scFvCD19:sFasL did not further increase after 6 h and reached a maximum 
of only 40%. In a similar time-course experiment with Ramos.cFLIPL cells, the apoptotic 
activity of scFvRit:sFasL only became apparent 6h after start of treatment (Fig. 3D, 
solid squares), whereas the apoptotic activity of scFvCD19:sFasL was fully abrogated 
(Fig. 3D, solid triangles). Together, these results strongly suggest that scFvRit:sFasL can 
simultaneously activate Fas-apoptotic signaling, apparent within the first 6h in Ramos 
cells, and CD20-apoptotic signaling, apparent at later time points. 
Of note, treatment with rituximab and anti-Fas or scFvCD19:sFasL was abrogated by 
caspase-8 inhibition or overexpression of xIAP (Fig. 3A and B), which suggests that Fas-
mediated caspase signaling is critical for apoptosis induced by rituximab and anti-Fas, as 
well as scFvCD19:sFasL. 
scFvRit:sFasL induces potent apoptosis in primary patient-derived tumor B cells 
Treatment of primary malignant B cells of leukemic NHL and B-CLL patients with 
scFvRit:sFasL resulted in specific induction of apoptosis in two of two NHL and seven 
of eight B-CLL (Table 2). For the patient-derived B-CLL cells, the median induction of 
apoptosis by scFvRit:sFasL was 40.4% (interquartile range, 15.2-50.3%). Induction of 
apoptosis by scFvRit:sFasL was dose dependent (Fig. 4A ) and exceeded the induction of 
apoptosis by scFvCD19:sFasL (P=0.0083, difference = 30.2±4.8; Fig. 4B). Of note, cell 
surface expression of CD19 was higher than CD20 (data not shown), suggesting that the 
difference in activity is not due to preferential or higher binding of scFvRit:sFasL. 
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scFvRit:sFasL lacks toxicity in nude mice
Previously, Samel et al. reported that a homotrimeric scFv:sFasL fusion protein, targeted 
to the stroma marker FAP, is nontoxic for murine liver in vivo [10]. Indeed, treatment 
of nude mice with a high amount of scFvRit:sFasL (30µg per mouse) did not reveal any 
liver toxicity, as evidenced by normal blood AST levels, ALT levels, and a lack of liver 
caspase-3/caspase-7 activity (Fig. 4C). In contrast, treatment with secondarily cross-
linked sFasL was associated with severe toxicity in mice with >30-fold increase in AST-
levels (P=0.0027, difference = 1.3x105±1.9x104), a >140-fold increase in ALT-levels 
(P<0.0001, difference = 1.3x105±3.7x103), and a 15-fold increase in caspase-3/caspase-7 
activity (P=0.0065, difference = 37.3±7.2). 
scFvRit:sFasL lacks toxicity toward purified normal B cells and PBLs
Treatment with rituximab induces a massive depletion of normal B cells [19], which is most 
likely a result of activation of antibody-dependent cellular cytotoxicity and/or complement-
dependent cytotoxicity by the Fc domain of rituximab. Because scFvRit:sFasL does not 
Figure 2. scFvRit:sFasL shows superior apoptotic activity compared with cotreatment with 
rituximab and anti-Fas. A, Ramos cells were treated for 24h with rituximab, anti-Fas, rituximab + 
anti-Fas, scFvCD19:sFasL, rituximab + scFvCD19:sFasL, or scFvRit:sFasL. B, Ramos cells were treated 
with an increasing concentration of scFvRit:sFasL or scFvCD19:sFasL. C, BJAB, Raji, Ramos, and PR-1 
cells were treated with scFvRit:sFasL in the presence or absence of FasL-neutralizing mAb Alf2.1. 
D, Ramos cells were treated for the indicated time points with scFvRit:sFasL (5ng/mL), after which 
caspase-8 processing and activation was assessed by immunoblotting for caspase-8 and Caspase-Glo 
8 assay and caspase-3 activation with Caspase-Glo 3/7 assay. In A–C, apoptosis was assessed by ∆Ψ 
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contain an Fc domain but does activate CD20-signaling, we subsequently assessed 
whether the simultaneous binding to CD20 and Fas induced unwanted apoptotic effects 
in purified normal CD20-positive B cells. However, scFvRit:sFasL did not significantly 
induce apoptosis in these cells (medium, 15.5%; scFvRit:sFasL, 24.0%; Fig. 4D). 
Binding of scFvRit:sFasL to normal B cells may lead to an innocent bystander effect 
toward other human blood cells, e.g., T cells. However, treatment of PBLs, containing 
10% B cells, with scFvRit:sFasL did not reveal significant apoptotic activity in any of the 

































































































































































Figure 3. scFvRit:sFasL simultaneously activates CD20 and Fas apoptotic signaling. A, 
Ramos cells were treated for 24h with rituximab, anti-Fas, rituximab + anti-Fas, scFvRit:sFasL, 
or scFvCD19:sFasL in the presence or absence of caspase-8 inhibitor zIETD-FMK. B, Ramos cells 
retrovirally transduced with empty vector (Ramos.EV), cFLIPL (Ramos.cFLIPL), or XIAP (Ramos.
XIAP) were treated with rituximab, anti-Fas, rituximab + anti-Fas, and scFvRit:sFasL. C, Ramos cells 
retrovirally transduced with empty vector (Ramos.EV), cFLIPL (Ramos.cFLIPL), Bcl-2 (Ramos.Bcl-2), 
or XIAP (Ramos.XIAP) were treated with medium control or scFvRit:sFasL (5ng/mL). D, Ramos and 
Ramos.cFLIPL cells were treated with scFvRit:sFasL or scFvCD19:sFasL for the various indicated time 
points. Apoptosis was assessed by . **, P<0.01; ***, P<0.0001; n.s., not significant
DISCUSSION
Here, we reported on a novel strategy designed to exploit and optimize the synergy 
between rituximab-induced CD20 and Fas apoptotic signaling by genetically fusing a 
rituximab-derived antibody fragment to sFasL. Selective and high affinity binding of 
the resultant scFvRit:sFasL fusion protein to CD20 leads to its accretion at the tumor 
cell surface and to concomitant potent apoptotic activity in B-cell lines and primary 
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NHL and B-CLL patient-derived B-cell tumor cells at low picomolar concentrations. The 
anti-tumor activity of scFvRit:sFasL depends on binding to cell surface CD20, because 
co-treatment with parental mAb rituximab strongly inhibited the induction of apoptosis 
by scFvRit:sFasL. Interestingly, there is no clear correlation between the expression 
levels of either CD20 or Fas and the proapoptotic activity of scFvRit:sFasL (Table 1). 
Thus, although CD20-specific accretion to the tumor cell surface is required for the pro-
apoptotic activity of scFvRit:sFasL, the sensitivity of each respective cell line is most 
likely a result of not only CD20 and Fas expression, but also of the intricate interplay of a 
variety of intracellular modulators of apoptosis, for instance cFLIPL and pro-apoptotic or 
anti-apoptotic Bcl-2 family members. 
A distinguishing feature of scFvRit:sFasL is that it does not only induce Fas apoptotic 
signaling but also induces apoptosis via a CD20-dependent signaling pathway. The specific 
binding to CD20 and the simultaneous monocellular or bicellular binding to Fas confers 
potent CD20 signaling activity to scFvRit:sFasL. This is exemplified by the fact that the 
CD20-mediated signaling of scFvRit:sFasL was detected at picomolar concentrations, 
whereas activation of CD20 signaling by rituximab typically required micromolar 
concentrations. Although not investigated here, this efficient CD20 signaling could be a 
result of scFvRit:sFasL–induced hypercross-linking of CD20. Hypercross-linking of CD20 
by a dextran polymer of rituximab has recently been shown to strongly potentiate CD20-
mediated induction of apoptosis [20]. In line with this hypothesis, the proapoptotic activity 
of scFvRit:sFasL on PR-1 cells was further increased upon coincubation with mAb Alf2.1. 
Apparently, secondary cross-linking of PR-1 cells further potentiates CD20 signaling. 
Such a potentiation of apoptosis is an effect also known to occur upon secondary cross-
linking of rituximab [21]. 
Intriguingly, CD20 apoptotic signaling induced by scFvRit:sFasL did not critically depend 
on caspase signaling. In contrast, apoptosis by secondarily cross-linked rituximab or by 
cotreatment with rituximab and anti-Fas did depend on caspase signaling. Apparently, 
CD20 signaling can vary markedly, depending on the manner of cross-linking, e.g., 
experimental secondary cross-linking of the Fc domain of rituximab versus cross-linking 
of CD20 by simultaneous CD20 and Fas binding of scFvRit:sFasL. Based on the fact that 
caspase activity is not required while Bcl-2 overexpression blocks scFvRit:sFasL activity, 
it seems likely that DNases released from the mitochondria may be involved in CD20 
apoptotic signaling by scFvRit:sFasL. 
Primary refractory disease or the development of relapses after rituximab treatment 
has been attributed to several mechanisms, including intrinsic or acquired resistance to 
complement-dependent cytotoxicity due to overexpression of CD55 and CD59 [22–24]. 
Because scFvRit:sFasL directly induces apoptosis, which solely requires the cross-linking 
of CD20 and Fas, scFvRit:sFasL may be particularly relevant for patients with poor or 
absent complement-dependent cytotoxicity. In addition, treatment with rituximab has 
been proposed to lead to the development of CD20-negative relapses in some patients, 
possibly due to tumor cell heterogeneity [25;26]. For scFvRit:sFasL, the reciprocal 
activation of Fas by CD20-immobilized scFvRit:sFasL opens up the possibility to induce 
apoptosis in neighboring FasL-sensitive leukemic cells that have lost CD20 expression. 
In our mixed culture experiments, bystander tumor cells were eliminated at target to 
bystander ratio as low as 1:99. This potent bystander effect of scFvRit:sFasL may help to 
prevent the occurrence of CD20-negative relapses. 
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Initial reports on Fas agonists described severe toxic effects toward murine hepatocytes. 
More recently, this toxicity has been ascribed to multimers or aggregates of sFasL, 
whereas homotrimeric sFasL is nontoxic to liver cells. In an initial screening for toxicity, 
treatment with up to 30µg of scFvRit:sFasL did not induce liver damage in nude mice, 
which indicates that homotrimeric scFvRit:sFasL is inactive and nontoxic toward normal 
cells. Moreover, scFvRit:sFasL was devoid of apoptotic activity toward normal human 






































































































































Figure 4. scFvRit:sFasL potently induces apoptosis in primary patient-derived malignant B 
cells and shows no toxicity in nude mice or isolated human B cells/PBLs. A, dose-dependent 
induction of apoptosis by scFvRit:sFasL in B-CLL cells (n=5). B, B-CLL cells (n=2) were treated for 
16h with scFvRit:sFasL or with scFvCD19:sFasL. C, nude mice were injected with anti-Flag mAb 
M2 (designated SHAM), scFvRit:sFasL, or Flag-FasL + mAb M2. After 24h of treatment, mice were 
sacrificed and blood AST levels, ALT levels, and caspase-3/caspase-7 activity in isolated liver samples 
were determined. D, purified human B cells or PBLs were treated for 16h with scFvRit:sFasL or 
actinomycin D. In all experiments, apoptosis was assessed by AnnexinV/PI staining. **, P<0.01; n.s., 
not significant.
e.g., a human CD20 transgenic animal, as well as pharmacokinetic studies, are required 
to accurately assess the applicability of scFvRit:sFasL. 
In conclusion, the simultaneous and synergistic activation of CD20 and Fas apoptotic 
signaling by scFvRit:sFasL provides a novel and promising therapeutic approach for the 
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Gemtuzumab ozogamicin (GO) is a calicheamicin-conjugated antibody directed 
against CD33, an antigen highly expressed on Acute Myeloid Leukemic (AML) 
cells. CD33-specific binding triggers internalization of GO and subsequent 
hydrolytic release of calicheamicin. Calicheamicin then translocates to the 
nucleus, intercalates in the DnA structure and subsequently induces double-
strand DnA breaks. GO is part of clinical practice for AML, but is frequently 
associated with severe side-effects. Therefore, combination of GO with other 
therapeutics is warranted to reduce toxicity, while maximizing therapeutic 
selectivity. We hypothesized that the histone deacetylase inhibitor valproic acid 
(VPA) sensitizes AML cells to GO, since VPA-induced histone hyper-acetylation 
opens the chromatin structure, whereby the DnA intercalation of calicheamicin 
should be augmented. We found that clinically relevant concentrations of VPA 
potently augmented the tumoricidal activity of GO towards AML cell lines and 
primary AML blasts. Moreover, VPA treatment indeed augmented the DnA 
intercalation of calicheamicin and enhanced DnA degradation. Importantly, 
synergy was restricted to CD33-positive AML cells and did not require caspase 
activation. In conclusion, the synergistic pro-apoptotic activity upon co-
treatment of AML cells with VPA and GO indicates the potential value of this 
strategy for AML.
INTRODUCTION
The immunotoxin gemtuzumab ozogamicin (GO; Mylotarg) comprises a powerful 
tumoricidal calicheamicin derivative chemically linked to an antibody that specifically 
targets the internalizing transmembrane protein CD33 [1]. CD33 is highly expressed on 
leukemic blasts of a majority of Acute Myeloid Leukemia (AML) patients [2], whereas 
CD33 is not expressed on normal hematopoietic stem cells nor on non-hematopoietic 
cells [3]. Importantly, expression of CD33 has also been reported on leukemic stem cells 
[4], further establishing CD33 as a promising target antigen in AML.
Binding of GO to CD33 leads to internalization and subsequent dissociation of the 
calicheamicin derivative in the lysosome, whereupon the toxin translocates to the nucleus. 
In the nucleus, calicheamicin binds in the minor groove of the DNA double-helix and 
induces sequence specific double-strand breaks [5], ultimately resulting in apoptosis. 
GO is approved for relapsed AML (≥60 years) and for patients for which conventional 
chemotherapy is contra-indicated [6]. GO has a generally acceptable safety profile 
[7], but nevertheless is associated with severe toxicity in some patients, including 
hepatotoxicity [8] and severe myelosuppression [9]. Therefore, the rational design of 
combinatorial approaches of GO with other therapeutics is warranted in order to achieve 
optimal tumoricidal activity with reduced toxicity.
A promising candidate for such a combinatorial approach is valproic acid (VPA), which in 
recent phase II clinical trials showed promising single agent activity towards AML [10]. 
VPA has been part of clinical practice for many years as an anti-convulsant [11]. More 
recently, VPA was reported to be a histone deacetylase inhibitor that shows promising 
tumoricidal activity [12;13]. Treatment with VPA induces a hyper-acetylated state of 
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histones [14], resulting in a more open chromatin structure. Consequently, the DNA 
becomes more accessible to intercalating agents [14] and transcription of a limited set 
of genes is altered [15], rendering the cells more prone to apoptosis. Therefore, we 
hypothesized that treatment of AML cells with VPA should augment calicheamicin binding 
capacity and potentiate the apoptotic activity of GO. 
METHODS
Chemicals and reagents.
Gemtuzumab ozogamicin (Wyeth-Ayerst Laboratories, St Davids, PA) was dissolved at 
a stock concentration of 1mg/ml in dH2O and stored at -80°C. The histone deacetylase 
inhibitor valproic acid (Sigma Aldrich, Zwijndrecht, The Netherlands) was dissolved at a 
stock concentration of 100mM in dH2O, and stored at -20°C. The pan-caspase inhibitor 
Z-VAD-FMK (Calbiochem, San Diego, CA) was dissolved at 10mM in DMSO and stored at 
-20°C. 
Cell Culture.
The CD33-positive AML cell lines U-937 [16] and THP-1 and the CD33-negative B-cell line 
Ramos were purchased from the American Type Culture Collection (ATCC, Manassas, 
VA). All cell lines were cultured in RPMI (Cambrex, East Rutherford, NJ) supplemented 
with 10% fetal calf serum at 37°C in a humidified 5% CO2 atmosphere under standard 
conditions. For all experiments, cells were seeded at 2.5x106 cells/well in a 6 well plate.
Apoptosis assays.
Apoptosis was assessed by: Phoshatidylserine exposure (PS); PS exposure was analyzed 
by flow cytometry using the AnnexinV-FITC/PI kit (VPS Diagnostics, Hoeven, The 
Netherlands) according to manufacturer’s protocol. Loss of mitochondral membrane 
potential (Δψ); Δψ was analyzed using the cell-permeant green-fluorescent lipophilic 
dye DiOC6 (Molecular Probes, Eugene, OR). After treatment, cells were harvested by 
centrifugation (300g for 5 minutes), incubated for 20 minutes at 37°C with 0.1 µM DiOC6 
in fresh medium, washed once with PBS and analyzed by flow cytometry. Caspase-3 
processing by immunoblot; Cell lysates were prepared essentially as described 
previously [17]. 30μg of lysate was separated by SDS-PAGE (12.5% AA) under reducing 
conditions and transferred to nitrocellulose (Bio-Rad, Veenendaal, The Netherlands) by 
electroblotting. Blots were incubated with a primary polyclonal antibody, directed at 
the N-terminus of caspase-3, followed by an appropriate secondary HRPO-conjugated 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Specific binding was visualized 
by chemoluminescence (Roche diagnostics, Almere, the Netherlands). Incubations were 
performed for 1.5h in PBS, 5% skim milk and were followed by 3 washes with PBS 
containing 0.1% Tween-20. Caspase-3/7 activity; Briefly, 1.0x105 cells were plated per 
well in a 96 wells-plate and incubated for 24h with or without VPA and GO. Activation 
of caspase-3/-7 was assessed by the caspase-Glo™3/7 assay kit (Promega, Mannheim, 
Germany) according to the manufacturer’s protocol.
Synergy was quantified using the cooperativity index (CI=sum of apoptosis of single 





















































































































































Figure 1. VPA potently augments CD33-restricted apoptotic activity of GO. (A) The CD33-
positive AML cell lines THP-1 and U-937 and the CD33-negative B-cell line Ramos were treated for 
24h with GO (1, 2.5 and 2.5µg/ml respectively) in the absence or presence of VPA (1mM). Apoptosis 
was assessed by Δψ. Indicated values are means + SEM of three independent experiments. (B) 
U-937 cells were subjected to increasing concentrations of GO (0-2.5µg/ml) in the presence or 
absence of VPA (1mM) for 24h. Apoptosis was assessed by Δψ. Indicated values are means ± SEM 
of three independent experiments. * represents p<0.05; *** represents p<0.001. (C) U-937 cells 
were subjected to single agent treatment or co-treatment with GO (2.5µg/ml) and VPA (1mM). At 
various time-points, apoptosis was assessed by determination of PS exposure. (D) U-937 cells were 
subjected to single agent and co-treatment with GO (2.5μg/ml) and VPA (1mM) for 24h, after which 
caspase-3/-7 activity was assessed as described in Methods. Analysis of pro-caspase 3 processing 
was performed by immunoblotting. (E) U-937 cells were subjected to single agent treatment or co-
treatment with GO (2.5µg/ml) and VPA (1mM) in the presence or absence of the pan-caspase inhibitor 
Z-VAD-FMK (20μM). Apoptosis was assessed by determination of PS exposure. Indicated values 
are means + SEM of three independent experiments. (F) Primary AML blasts (n=2) were subjected 
to single agent treatment and co-treatment with VPA (0.5mM) and GO (2.5µg/ml). Apoptosis was 
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CI=1 was termed additive and CI>1 was termed antagonistic. Statistical analysis was 
performed using the two tailed Student’s t-test. 
 
Assessment of DNA-intercalation by calicheamicin
The effect of VPA on the DNA-intercalation of calicheamicin was assessed by fluorescence 
microscopy using intact GO. Staining against the IgG4 Fc-domain of intact GO provides a 
convenient and rapid method to indirectly determine DNA intercalation of the calicheamicin 
moiety. CD33-negative Ramos cells were incubated for 24h in the absence or presence of 
VPA (1mM), spotted on microscope slides and permeabilized with acetone. Subsequently, 
cells were incubated with 100μl PBS containing 250μg/ml GO (15 min/RT), washed 
twice and fixed with 4% paraformaldehyde. Specific binding was analyzed using anti-
Human IgG-biotin followed by Cy3-conjugated streptavidin (DAKO Cytomation, Glostrup, 
Denmark). DAPI was used to stain nuclei. Staining was evaluated using a Quantimed-
600S fluorescence microscope (Leica Camera, Solms, Germany).
Assessment of DNA degradation by GO.
U-937 cells were incubated for 24h in the absence or presence of VPA (1mM). Subsequently, 
DNA was isolated using the DNA-easy isolation kit (Qiagen, Venlo, The Netherlands). 
Isolated DNA (3μg) was treated with GO (400μg/ml) in the presence of the reducing 
agent dithiothreitol (5mM) for 18h at 37°C and subsequently analyzed for fragmentation 
on an 0.8% agarose gel.
Synergistic apoptosis induction by GO and VPA in patient-derived CD33-positive AML
Isolated patient-derived AML cells, containing over 50% blasts, were treated for 24h with 
GO, VPA and a combination of GO and VPA at the indicated concentrations. Subsequently, 
apoptosis was assessed by determination of PS exposure. Percentage of specific apoptosis 
was calculated using the following formula: specific apoptosis = (experimental apoptosis 
- spontaneous apoptosis)/(100 - spontaneous apoptosis) x 100% 
RESULTS AND DISCUSSION
Despite the generally acceptable safety profile of GO [7], treatment is still associated 
with severe toxicity in some patients. In order to reduce the severity or prevalence 
of toxicity, the rational design of combinatorial strategies with other therapeutics that 
augment the tumoricidal activity of GO is warranted. Hereby, the minimally required dose 
of GO can be reduced, while maximizing therapeutic selectivity. To test our hypothesis 
that the histone deacetylase inhibitor VPA is a promising candidate for combination 
with GO, CD33-positive and CD33-negative cell lines were co-treated with VPA and GO. 
In the CD33-positive AML cell lines U-937 and THP-1 co-treatment with VPA and GO 
synergistically activated apoptosis (Fig. 1A, CI of 0.45 and 0.87, respectively). Moreover, 
synergistic apoptosis induction by VPA and GO was dose-dependent and significant at all 
concentrations tested (Fig. 1B). Similar results were obtained when cells were co-treated 
with GO and the histone deacetylase inhibitors sodium butyrate (NaBu) and trichostatin 
A (TSA) (data not shown), further confirming our hypothesis that histone deacetylase 
inhibition augments GO-induced apoptosis in CD33-positive cells. In contrast, co-
treatment of CD33-negative Ramos cells with VPA and GO did not significantly induce 
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apoptosis and was even antagonistic (Fig. 1A, CI of 1.9), indicating that the synergistic 
effect of GO and VPA critically depends on the CD33-specific binding and subsequent 
processing of GO.
Intriguingly, time course experiments revealed a synchronized induction of apoptosis 
within 20-24 hours of treatment with VPA and GO (Fig. 1C), a finding suggestive of an 
underlying cell cycle arrest. However, no differences in cell cycle status were found 
between single agent treatment and co-treatment (data not shown), thus excluding a 
prominent role for cell cycle arrest.
Apoptosis upon co-treatment with VPA and GO was characterized by processing and 
activation of caspase-3 (Fig. 1D). However, AML cells subjected to co-treatment in the 
presence of a pan-caspase inhibitor were still eliminated by apoptosis (Fig. 1E), which 
indicates that caspase activity is dispensable for the execution of apoptosis.
Importantly, the synergistic pro-apoptotic effect on AML cell lines was detected at 
concentrations of VPA and GO realistically attainable in patient plasma [18]. Moreover, 
similar experiments on primary AML blasts demonstrated that these cells are even more 
susceptible to apoptosis induction by VPA and GO co-treatment (Fig. 1F, CI of 0.75). 
Recently, Marchion et al. demonstrated that VPA increases the accessibility of DNA to 
intercalating agents, such as the topoisomerase ll inhibitor epirubicin [14]. To assess 
whether VPA similarly increased the accessibility of DNA for the calicheamicin moiety 
of GO, we analyzed the intercalation of calicheamicin on permeabilized CD33-negative 
Ramos cells by fluorescence microscopy (Fig. 2A). Intact GO was used to indirectly 
assess DNA-intercalation of calicheamicin in the minor groove by staining against the 
IgG4 Fc-domain of GO. Compared to non-treated Ramos cells (Fig. 2A, panel 2) a marked 
increase in staining intensity was detected in VPA-treated cells, especially in the nucleus 
(Fig. 2A, panel 3), indicating that VPA augments the intercalation of calicheamicin. 
A
B





- + - + GO (400 µg/ml)
Figure 2. VPA enhances DNA-intercalation of calicheamicin and DNA degradation. (A) 
Fluorescence microcopy of enhanced DNA-intercalation of calicheamicin after VPA treatment. 
Ramos cells were treated for 24h with/without VPA (1mM), fixed, and assessed for intercalation of 
calicheamicin as described in Methods (original magnification 40X). (B) U-937 cells were treated 
for 24h with/without VPA (1mM), after which DNA was isolated. Isolated DNA was subjected to GO 
(400µg/ml), after which DNA-degradation was assessed as described in Methods. DNA-degradation 
was visualized on agarose gel.
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These results were confirmed using the histone deacetylase inhibitors NaBu and TSA, 
resulting in a similar increase in GO intercalation (data not shown). Importantly, DNA 
degradation by calicheamicin was also strongly enhanced in DNA isolated from VPA 
treated U-937 cells (Fig. 2B). Together, these data demonstrate that histone deacetylase 
inhibitors, of which VPA is of particular interest for AML, enhance CD33-restricted 
apoptosis induction by increasing the DNA-intercalation of calicheamicin, resulting in 
enhanced DNA-degradation and concomitant potent apoptosis induction.
In addition, although not investigated here, the respective down- or up-regulation of 
anti- or pro-apoptotic proteins by VPA may be involved in the observed synergistic pro-
apoptotic effect. 
In conclusion, the design of novel combinatorial treatment strategies of GO with other 
therapeutics is warranted in order to achieve high tumoricidal activity with potentially 
reduced or non-overlapping toxicity. In this respect, GO has already been combined 
with standard chemotherapeutics in clinical trials [19]. Here, we describe the strong 
synergistic pro-apoptotic effect of co-treatment of AML cells with the histone deacetylase 
inhibitor VPA and GO. Synergy is restricted to CD33-positive cells and is largely caspase-
independent, which might help to overcome chemotherapy resistance related to defects 
in caspase activation pathways [20]. Taken together, further pre-clinical exploration of 
this combinatorial strategy appears warranted to determine its potential clinical feasibility 
for AML.
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Gemtuzumab Ozogamicin (GO, Mylotarg) is a targeted therapeutic agent in which 
an anti-CD33 antibody is chemically coupled to a highly cytotoxic calicheamicin 
derivative via a hydrolysable linker. GO has improved the treatment outcome for a 
subgroup of AML patients, but its use is associated with severe myelosuppression 
and hepatotoxicity. Here, we report on a novel anti-leukemia agent, designated 
scFvCD33:sTrAIL, in which an anti-CD33 scFv antibody fragment is genetically 
linked to soluble TrAIL (sTrAIL). normal CD33-positive monocytes were fully 
resistant to prolonged treatment with scFvCD33:sTrAIL, whereas treatment with 
GO resulted in substantial cytotoxicity. The activity of scFvCD33:sTrAIL towards 
AML cells was up to 30-fold higher than GO. The CD33-restricted anti-leukemia 
activity of scFvCD33:sTrAIL remained stable during prolonged storage at 37°C, 
whereas GO showed a rapid increase in CD33-independent cytotoxicity. Moreover, 
scFvCD33:sTrAIL showed potent anti-leukemia activity towards CD33+ CML cells 
when treatment was combined with the Bcr-Abl tyrosine kinase inhibitor Gleevec. 
Importantly, ex vivo treatment of patient-derived CD33+ AML tumor cells with 
scFvCD33:sTrAIL resulted in potent apoptosis induction that was enhanced by 
valproic acid, mitoxantrone and 17-AAG. Taken together, scFvCD33:sTrAIL is 
superior to GO in terms of tumor selectivity, activity and stability, warranting its 
further development for the treatment of CD33-positive leukemia’s.
INTRODUCTION
Currently, the prognosis for Acute Myeloid Leukemia (AML) patients is poor with a 5-year 
survival rate of only 20% to 30% [1]. This poor prognosis is the result from substantial 
therapy-related morbidity and mortality and the frequent occurrence of therapy-resistant 
relapses [2;3]. AML cells express several myeloid lineage-specific antigens that may be 
exploited for antibody-based therapy, with CD33 being best characterized. The expression 
of CD33 on leukemic blasts is found in approximately 80-90% of AML patients [4], while 
CD33 expression on normal cells is limited to the myeloid lineage such as monocytes. 
The unique CD33 expression profile has fueled the clinical development of Gemtuzumab 
ozogamicin (GO), a targeted chemotherapy agent in which an anti-CD33 antibody is 
chemically coupled to a highly cytotoxic calicheamicin derivative via a hydrolysable linker. 
GO was approved by the FDA in the year 2000 as monotherapy for the treatment of 
CD33-positive AML in elderly patients who relapsed for the first time and were not eligible 
for standard chemotherapy regimens [5]. For this subgroup of AML patients efficacy of 
GO has been reported [6]
The mode of action of GO involves the antibody-mediated selective binding to cell surface-
expressed CD33 followed by internalization of GO and the subsequent hydrolytic release 
of the calicheamicin moiety in the acidic milieu of the lysosome. Next, calicheamicin 
translocates to the nucleus where it induces sequence-specific double strand DNA breaks 
resulting in apoptotic cell death [7]. A prominent side effect of GO treatment is that 
also normal CD33-positive cells, such as monocytes, are effectively eliminated leading 
to severe and sometimes life-threatening myelosuppression. Moreover, the pH-sensitive 
linker technology used in GO yields conjugates of rather poor thermostability which can 
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lead to inadvertently release of calicheamicin into the circulation resulting in toxicity in 
various normal cells and organs due to CD33-independent uptake of calicheamicin [8;9]. 
Moreover, AML cells with reduced or lost CD33 expression can escape from therapy 
yielding GO-refractory relapses. 
Therefore, novel AML-selective approaches are urgently needed that have improved anti-
tumor activity that is combined with a more favorable toxicity profile. In this respect 
a promising candidate appears to be the Tumor Necrosis Factor Related Apoptosis 
Inducing Ligand (TRAIL). TRAIL is a tumor-selective pro-apoptotic effector molecule that 
is expressed on various immune cells including T- and natural killer (NK)-cells on which 
it is involved in the elimination of virus-infected and transformed cells. TRAIL interacts 
with an elaborate receptor system comprising two agonistic receptors, TRAIL-R1 and 
TRAIL-R2, two antagonistic receptors, TRAIL-R3 and TRAIL-R4, and the soluble receptor 
osteoprotegerin (OPG). TRAIL is expressed as a homotrimeric transmembrane protein 
(memTRAIL) of which the extracellular domain can be proteolytically cleaved off, yielding 
soluble TRAIL (sTRAIL). Various recombinant forms of sTRAIL have shown potent 
tumoricidal activity both in vitro and in various xenografted tumor mouse models [10;11], 
with no or minimal activity towards normal cells [12;13]. Recently, potent anti-tumor 
activity of sTRAIL has been reported towards patient-derived AML cells. Herein, low 
doses of the proteasome inhibitor bortezomib primed refractory AML cells for enhanced 
TRAIL-mediated killing [14]. These results suggest that TRAIL-based approaches could be 
effective for treating AML patients, even for patients who are refractory to conventional 
chemotherapy.
However, the efficacy of conventional recombinant sTRAIL preparation is potentially 
hampered by the ubiquitous expression of TRAIL-receptors on numerous normal cells and 
tissues. In addition, TRAIL-R1 and TRAIL-R2 have differential cross-linking requirements 
for apoptosis signaling, with TRAIL-R2 being less sensitive to sTRAIL than TRAIL-R1 
[15]. As a result tumor cells that express TRAIL-R2 over TRAIL-R1 are less sensitive to 
treatment with sTRAIL. 
Previously, we have demonstrated that these limitations can be largely overcome by fusing 
a tumor-selective antibody fragment (scFv) to the N-terminus of human sTRAIL [16-20]. In 
one particular fusion protein, designated scFvCD7:sTRAIL, we employed an scFv antibody 
with specificity for CD7. The cell surface glycoprotein CD7 is abundantly expressed on 
most T cell malignancies and ~10% of AML. Expression of CD7 on normal blood cells 
is limited to T cells, thymocytes, NK-cells, and myeloid cells in early hematopoietic cell 
ontogeny. ScFvCD7:sTRAIL showed potent and CD7-restricted apoptotic activity towards 
human T-ALL cells with no or minimal toxicity in normal human blood and endothelial 
cells. Importantly, in mixed culture experiments of CD7-positive and CD7-negative tumor 
cells, scFvCD7:sTRAIL induced potent bystander apoptosis in CD7-negative tumor cells. 
This bystander activity is based on the principle that the targeted tumor cells are not only 
eliminated, but are also exploited to cross-link agonistic TRAIL receptors on neighboring 
tumor cells lacking the target antigen [16-18]. The anti-tumor bystander activity of the 
scFv:sTRAIL fusion protein format may prevent the escape from therapy of tumor cells 
with lost or reduced target antigen expression. Currently, scFvCD7:sTRAIL fusion protein 
is being developed for clinical evaluation. 
The promising leukemia-selective activity of scFvCD7:sTRAIL and its favorable safety 
profile prompted us to construct and pre-clinically evaluate an analogous scFv:sTRAIL 
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fusion protein with engineered specificity for CD33 and to compare it with GO. Here, we 
described a novel fusion protein, designated scFvCD33:sTRAIL, that is superior to GO in 
terms of in vitro tumor selectivity, activity, and stability.
Table 1. TRAIL-R1 and TRAIL-R2 cell surface expression. TRAIL-R expression is quantified as 
-= No Expression, += MFI <10,  ++= MFI 10-20, +++= MFI >20
MATERIAL AND METHODS
Anti-tumor agents
Stock solutions of mitoxantrone (4,5mM), 17-AAG (100mM) (Sigma Aldrich, Zwijndrecht, 
The Netherlands), and Gleevec (10mM) (Novartis Pharma, Arnhem, The Netherlands), 
were all prepared in DMSO. Stock solutions of valproic acid (100mM) (Sigma Aldrich, 
Zwijndrecht, The Netherlands) and GO (6,6µM), were prepared in sterile PBS. All stock 
solutions were aliquoted and subsequently stored at -80°C until used. 
Cell lines, leukocytes, monocytes and primary patients-derived AML cells
All cells were cultured in RPMI 1640 (Cambrex, New Jersey, New Hampshire, USA) 
supplemented with 10% FCS, at 37ºC in humidified 5% CO2 containing atmosphere. The 
following leukemia-derived cell lines were purchased from the ATCC (Manassas, USA): 
U-937 (AML, CD33-positive), MonoMac-6 (monocyte/macrophage-like cell line, CD33-
positive), K-562 (CML, CD33-positive), Jurkat (T-ALL, CD33-negative). Cell line BV-173 
(CML, CD33-positive) was purchased from the DSMZ (Braunschweig, Germany). Cell 
line MOLT-16 (T-ALL, CD33-negative) was a kind gift from Prof. Dr. Martin Gramatzki, 
University of Kiel, Germany. CD33-positive Jurkat cells (Jurkat.CD33) were generated 
by standard electroporation with the eukaryotic expression plasmid pcDNA6.hCD33 [21] 
and subsequent selection procedures. TRAIL-R1 and TRAIL-R2 cell surface expression 
levels were analyzed using Mouse-anti-Human TRAIL-R1 and TRAIL-R2 specific antibodies 
(Alexis, 10P’s, Breda, The Netherlands) followed by Goat-anti-Mouse-PE (Southern 
Biotech, ITK diagnostics, Uithoorn, The Netherlands). Mononuclear cells (CD33-positive) 
were isolated from healthy donors by density gradient centrifugation after which CD14-
positive monocytes were isolated by magnetic bead separation (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Primary AML tumor cells were obtained after informed consent 
from AML patients by isolation of peripheral blood mononuclear cells using standard 
density-gradient centrifugation (GE Healthcare, Diegem, Belgium). Patients had the 
following characteristics: patient #1, de novo AML, FAB M4eo CD33-positive; patient 
#2, de novo AML, FAB M5a, normal karyotype, mutated NPM1, without FLT3-ITD, CD33-
positive; patient #3, de novo AML, WHO secondary AML, loss of chromosome 7, CD33-
positive. 
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Figure 1. scFvCD33:sTRAIL induces potent and CD33-restricted apoptosis in leukemia cells. 
(A) Schematic representation of the recombinant fusion protein scFvCD33:sTRAIL, in which an CD33-
selective antibody fragment (scFvCD33) is genetically coupled via a flexible linker to soluble TRAIL 
(sTRAIL). (B) CD33-restricted binding of scFvCD33:sTRAIL was assessed using CD33-positive U-937 
cells. Cells were incubated with scFvCD33:sTRAIL (solid line) or with unconditioned medium (filled 
area). Specific binding was demonstrated by pre-incubating U-937 cells with the parental scFvCD33 
followed by incubation with scFvCD33:sTRAIL (dashed line). Binding of scFvCD33:sTRAIL was 
determined by flow cytometry using PE-conjugated anti-TRAIL mAb. (C) Dose-dependent (72ng/ml to 
1.45µg/ml) apoptosis induction in CD33-positive U-937 and MonoMac-6 AML cells by scFvCD33:sTRAIL. 
CD33-negative MOLT-16 cells are resistant to treatment with scFvCD33:sTRAIL. (D) The pro-apoptotic 
activity of scFvCD33:sTRAIL (1.45µg/ml) towards CD33-positive U-937 and MonoMac-6 AML cells is 
strongly inhibited in the presence of scFvCD33 (10 µg/ml) or a TRAIL-neutralizing (mAb 2E5, 4µg/
ml). In C and D, apoptosis was assessed by Δψ, indicated values are means ± SEM of at least three 
independent experiments. (E) Treatment with scFvCD33:sTRAIL (1.45µg/ml) induces caspase 8 
and PARP cleavage in MonoMac-6 cells. These apoptotic features are inhibited when treatment is 
performed in the presence of scFvCD33 (10µg/ml). (F) Apoptotic DNA fragmentation induced by 
scFvCD33:sTRAIL(1.45µg/ml) in MonoMac-6 was assessed by flow cytometric analysis using mAb F7-




Construction and production of scFvCD33:sTRAIL
Fusion protein scFvCD33:sTRAIL was constructed by using the DNA backbone of expression 
plasmid pEE14-scFvCD7:sTRAIL in which a CD7-selective scFv (scFvCD7) is genetically 
linked to the N-terminus of human sTRAIL [16]. Briefly, cDNA encoding the CD33-specific 
antibody fragment scFvCD33 was previously selected from a scFv phage-display antibody 
library prepared from the spleen of a CD33-immunized mouse [21]. The cDNA encoding 
scFvCD7 present in pEE14-scFvCD7:sTRAIL was swapped for the cDNA encoding scFvCD33 
by using the SfiI and NotI restriction enzyme sites and standard DNA-cloning techniques, 
yielding plasmid pEE14-scFvCD33:sTRAIL. Subsequently, this plasmid was transfected 
in CHO-K1 cells using Fugene-6 reagent (Roche Diagnostics, Almere, the Netherlands). 
Stable transfectants with amplified expression of fusion protein scFvCD33:sTRAIL were 
selected by the glutamine synthetase method [22]. Individual clones, obtained after 
single cell sorting using the MoFlo high-speed cell sorter (Cytomation, Fort Collins, USA), 
were analyzed for stable and amplified expression of fusion protein scFvCD33:sTRAIL. 
Culture medium containing fusion protein scFvCD33:sTRAIL was cleared by centrifugation 
(10.000x g, 10 min), filter sterilized, and stored at -80°C until used.
Analysis of apoptosis induction
The various tumor cell types were seeded at 2.5x105 cells/well in a 48-well plate and 
treated for 16h with scFvCD33:sTRAIL at the indicated concentrations. Induction of 
apoptosis was assessed using one or more of the following apoptosis assays: exposure of 
phosphatidylserine (PS); The early apoptotic feature of exposure of phosphatidyl serine 
on the outer membrane was analyzed by flow cytometry using an AnnexinV-FITC/PI kit 
(Nexins research, Kattendijke, The Netherlands) loss of mitochondrial membrane potential 
(∆Ψ); ∆Ψ was analyzed by flow cytometry using the cell-permeant green-fluorescent 
lipophilic dye DiOC6 (Molecular Probes, Eugene, USA) Immunoblot analysis of apoptosis; 
Induction of apoptosis was assessed by immunoblot analysis using anti-caspase-8 (Cell 
signaling technology, Beverly, MA, USA) and anti-PARP (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Cells were seeded in 6 well plates at a final concentration of 2.0x106 
cells/well and treated as indicated. Cell lysates were prepared and immunoblot analysis 
was performed essentially as described previously [16]. Detection of apoptotic DNA 
fragmentation; Apoptotic DNA-fragmentation was analyzed using mAb F7-26 (Alexis, 
Kordia Life Sciences, Leiden, The Netherlands) 
Percentage of experimental apoptosis was calculated using the following formula: 
specific apoptosis = (experimental apoptosis-spontaneous apoptosis)/ (100-spontaneous 
apoptosis) x100%
Thermostability of scFvCD33:sTRAIL versus GO
To assess and compare the thermostability of scFvCD33:sTRAIL and GO, stock solutions 
of scFvCD33:sTRAIL (0.24µM) and GO (6.58µM) were stored at 37°C. After 0, 24, 48 and 
72h of storage, CD33-negative MOLT-16 cells were treated for 16h with the indicated 
concentrations of either scFvCD33:sTRAIL or GO. In a control experiment CD33-positive 
U-937 AML cells were treated with scFvCD33:sTRAIL that was stored for 72h at 37°C. 
Quantification of bystander activity of scFvCD33:sTRAIL using mixed culture 
experiments 
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For mixed culture experiments, CD33-positive target tumor cells and CD33-negative 
bystander tumor cells were differentially labeled using the Vybrant cell labeling solution 
DiI (Invitrogen, Breda, The Netherlands). Briefly, Jurkat.CD33 cells were labeled with 
DiI, whereas Jurkat bystander tumor cells were not labeled. DiI-labeled Jurkat.CD33 
cells and non-labeled Jurkat bystander cells were mixed at the indicated ratio at a 
final concentration of 0.5 x 106 cells per well of a 24-well plate. After 6h of treatment 
with scFvCD33:sTRAIL or scFvC54:sTRAIL [19] cells were washed twice and incubated 
overnight, Jurkat.CD33 target cells and Jurkat bystander cells were separately evaluated 























































Figure 2. scFvCD33:sTRAIL is superior to GO in terms of activity, specificity and stability. 
(A) Comparison of the anti-AML activities of scFvCD33:sTRAIL, GO and the EpCAM-selective fusion 
protein scFvC54:sTRAIL. CD33-positive/EpCAM-negative U-937 cells were treated overnight with 
increasing concentrations of scFvCD33:sTRAIL (0.48nM to 9.6nM), GO (0.66nM to 329.0nM) or 
scFvC54:sTRAIL (2.4nM to 24nM). The EC50 for scFvCD33:sTRAIL and GO were calculated to be 
2.2nM and 71.3nM, respectively, indicating that scFvCD33:sTRAIL is 32-fold more potent than GO. 
Fusion protein scFvC54:sTRAIL showed no apoptotic activity towards U-937 cells (B) Comparison of 
cytotoxic apoptosis induction by scFvCD33:sTRAIL and GO towards normal CD33-positive monocytes. 
Monocytes were incubated for 48h with scFvCD33:sTRAIL (39.47nM) and GO (33.1nM). Treatment 
with scFvCD33:sTRAIL showed no signs of toxicity, whereas treatment with GO resulted in a marked 
induction of apoptosis in ~30% of the monocytes. Apoptosis was assessed by AnnexinV/PI staining. 
Indicated values are means + SEM of at least three independent experiments. (C) Comparison 
of thermostability of scFvCD33:sTRAIL and GO. CD33-negative MOLT-16 cells were treated with 
scFvCD33:sTRAIL (9.6nM) or GO (6.6nM) that was stored for either 24, 48 or 72h prior treatment 
at 37°C. CD33-negative MOLT-16 cells are resistant to scFvCD33:sTRAIL, whereas GO induces time-
dependent apoptosis in MOLT-16 cells. In B and C, apoptosis was assessed by Δψ, indicated values 
























































































































































Caspase 8 Caspase 3/7
Figure 3. Treatment with scFvCD33:sTRAIL conveys a potent anti-leukemia activity towards 
CD33-negative tumor cells. (A) Schematic representation of the mode of action of scFvCD33:sTRAIL. 
Binding of scFvCD33:sTRAIL to the target antigen CD33 results in accretion of scFvCD33:sTRAIL at 
the cell surface of CD33-positive cells. Subsequently, membrane-bound scFvCD33:sTRAIL induces 
fratricide apoptosis by reciprocal cross-linking of TRAIL-R1/R2 on neighboring CD33-positive target 
cells. Analogously, immobilized scFvCD33:sTRAIL on target cells can induce cross-linking of agonistic 
TRAIL receptors on the cell surface of a neighboring tumor cell devoid of CD33 expression, resulting 
in apoptosis induction of one or more bystander cells. Separate evaluation of apoptosis induction 
in (B) Jurkat.CD33 target cells and (C) Jurkat bystander cells by scFvCD33:sTRAIL. Jurkat.CD33 
target and Jurkat bystander cells were mixed at a 1:1 target-to-bystander ratio and treated with 
scFvCD33:sTRAIL (727ng/ml) or scFvC54:sTRAIL (727ng/ml). Treatment with scFvCD33:sTRAIL results 
in potent apoptosis induction in both CD33-positive target cells and CD33-negative bystander tumor 
cells, whereas identical treatment with scFvC54:STRAIL does not result in potent apoptosis in either 
Jurkat.CD33 target cells or Jurkat bystander cells Apoptosis was assessed by Δψ, indicated values are 
means ± SEM. After 3h treatment of scFvCD33:sTRAIL (727ng/ml) elevated activation of caspases 8 
(D) and 3/7 (E) was detected in both Jurkat.CD33 target cells and Jurkat bystander cells. 
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Activity of caspases 8 and 3/7 was measured in Jurkat.CD33 target and Jurkat bystander 
tumor cells after 3h of treatment with scFvCD33:sTRAIL. 
Thereto, DiI labeled Jurkat.CD33 target cells and non-labelled Jurkat bystander cells 
were separated using the MoFlo high-speed cell sorter (Cytomation, Fort Collins, USA) 
and subsequent caspase activation was measured using the Caspase-Glo 8 and 3/7 assay 
kits (Promega, Almere, the Netherlands) according to the manufacturer’s protocol.
Cooperativity index (CI) of co-treatment of scFvCD33:sTRAIL with anti-tumor agents
The effect of co-treatment of scFvCD33:sTRAIL with various anti-tumor agents was 
evaluated by calculation of the cooperativity index (CI), in which the sum of apoptosis 
induction by a given single-agent treatment is divided by apoptosis induction upon co-
treatment. CI was qualified as follows: CI <0.9, synergy; 0.9< CI <1.1, additive; CI >1.1, 
antagonistic
RESULTS AND DISCUSSION 
Here, we report on a novel fusion protein designated scFvCD33:sTRAIL, in which an anti-
CD33 scFv antibody fragment is genetically linked to sTRAIL (Fig. 1A). ScFvCD33:sTRAIL 
was designed to have enhanced and CD33-restricted anti-leukemia pro-apoptotic activity 
with no or minimal activity towards normal cells. 
An eukaryotic expression plasmid encoding the scFvCD33:sTRAIL fusion was constructed 
and subsequently transfected into CHO-K1 cells. Transfected CHO-K1 cells were 
selected for stable and amplified secretion of scFvCD33:sTRAIL in the culture medium, 
which identified producer clone 8B2 secreting 36.34µg/ml. Size-exclusion fast protein 
liquid chromatography (FPLC) indicated that scFvCD33:sTRAIL was produced as stable 
and homogeneous trimers in the absence of detectable protein aggregates (data not 
shown). 
TRAIL-R1 and TRAIL-R2 expression levels on CD33-negative and CD33-positive cell 
lines were assessed semi-quantitatively (Table 1). The results indicated that all cell 
lines used in this study express either one or both of the respective TRAIL receptors. 
Moreover, flowcytometric analysis demonstrated strong and CD33-selective accretion 
of scFvCD33:sTRAIL at the cell surface of CD33-positive U-937 AML cells, which was 
inhibited in the presence of a scFvCD33 antibody fragment (Fig. 1B)
Moreover, binding of scFvCD33:sTRAIL to CD33-negative MOLT-16 (T-ALL) cells was 
below detectable levels (data not shown). Together this indicates that the binding of 
scFvCD33:sTRAIL to the cell surface of CD33-positive tumor cells is almost exclusively 
attributable to its scFvCD33 domain. This can be explained by the fast on/slow off rates 
that are typical for antibodies and derivatives thereof, whereas TRAIL-TRAIL-receptor 
binding rates have very fast on/fast off binding rates typical for cytokine-cytokine 
receptor binding. Moreover, trimeric scFvCD33:sTRAIL contains three identical scFv 
reading heads, which enhances binding to CD33-positive cells by the associated avidity 
effect. Enhanced avidity has been shown to be beneficial for in vivo tumor targeting in 
antibody-based therapeutic strategies [23;24]. 
Next, we assessed the CD33-targeted apoptosis induction activity of scFvCD33:sTRAIL 
towards CD33-positive AML cells. Treatment with scFvCD33:sTRAIL at concentrations 
as low as 72ng/ml significantly induced apoptosis in U-937 and MonoMac-6 tumor cells 
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Figure 4. Anti-leukemia activity of scFvCD33:sTRAIL is enhanced by cotreatment with 
various anti-tumor agents. (A) MonoMac-6 and U-937 cells were treated with scFvCD33:sTRAIL 
(145ng/ml) alone or in combination with mitoxantrone (50nM), which resulted in enhanced apoptosis 
induction.(C=0.88 and CI=0.93, for MonoMac-6 and U-937 cells, respectively). (B) Co-treatment 
of scFvCD33:sTRAIL (363ng/ml) with either 1mM VPA or 200nM 17-AAG synergistically enhanced 
apoptosis induction in U-937 cells (CI=0.52 and CI=0.77, respectively). (C) The CD33-positive 
and Bcr-Abl positive CML cell lines K-562 and BV-173 are refractory to scFvCD33:sTRAIL (3.63µg/
ml) induced apoptosis. However, co-treatment of scFvCD33:sTRAIL with Gleevec (2µM) results in 
synergistic apoptosis induction in both cell lines (CI=0.36 and CI=0.54, respectively). Apoptosis was 
assessed by Δψ after 24h. All the indicated values are means ± SEM of at least three independent 
experiments. 
(16,7%, 9,1% respectively. Fig. 1C), and not in CD33-negative MOLT-16 cells. As evident 
from Table 1, MOLT-16 T-ALL cells highly express TRAIL-R2. Consequently, MOLT-16 cells 
are relatively insensitive to trimeric sTRAIL, while being highly sensitive to memTRAIL. 
These characteristics are ideally suited to demonstrate CD33-restricted activity of 
scFvCD33:sTRAIL. CD7-positive/CD33-negative MOLT-16 cells proved to be resistant to 
treatment with scFvCD33:sTRAIL with concentrations as high as 1.45µg/ml (Fig. 1C). 
Importantly, we previously demonstrated that MOLT-16 cells are highly sensitive to a CD7-
selective fusion protein designated scFvCD7:sTRAIL[16]. Fusion protein scFvCD7:sTRAIL 
is identical to scFvCD33:sTRAIL, except that it contains an anti-CD7 scFv (scFvCD7) 
instead of scFvCD33. 
Apoptosis induction in U-937 and MonoMac-6 cells by scFvCD33:sTRAIL was inhibited in 
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Apoptosis induction by scFvCD33:sTRAIL was characterized by caspase-8 cleavage (Fig. 
1E), PARP cleavage (Fig. 1E) and apoptotic DNA fragmentation (Fig. 1F). All these TRAIL-
associated apoptotic features were selectively inhibited when treatment was performed 
in the presence of scFvCD33 or mAb 2E5 (Fig. 1E and F)
Subsequently, we compared scFvCD33:sTRAIL with GO in terms of potency, toxicity and 
stability. The anti-leukemia activity of scFvCD33:sTRAIL, GO and the EpCAM-selective 
fusion protein scFvC54:sTRAIL were compared using CD33-positive/EpCAM-negative 
U-937 cells. From this experiment the EC50 for scFvCD33:sTRAIL was calculated to be 
2.2nM, whereas the EC50 for GO was 71.3nM.  Under the experimental conditions used the 
EpCAM-selective fusion protein scFvC54:sTRAIL did not induce apoptosis in U-937 cells 
(Fig 2A). These results indicate that scFvCD33:sTRAIL is 32 times more potent than GO, 
whereas scFvC54:sTRAIL shows no activity towards U-937 cells. A prominent toxic side 
effect of GO treatment comes from the fact that not only malignant but also all normal 
CD33-positive cells, such as monocytes, are targeted for destruction. Therefore, we 
compared toxicity of scFvCD33:sTRAIL and GO towards freshly isolated human monocytes. 
Treatment with scFvCD33:sTRAIL showed no signs of toxicity, whereas treatment with 
GO resulted in a marked induction of apoptosis in ~30% of the monocytes (Fig. 2B). 
This data corroborates with favorable toxicity profile that we previously reported for a 
series of analogous scFv:sTRAIL fusion proteins directed to various tumor-associated 
antigens including CD7, CD19, CD20, EpCAM, and EGFR [16-20;25]. None of these fusion 
protein variants showed signs of toxicity towards normal blood cells, endothelia cells, and 
hepatocytes [16-20;25]. From this we conclude that the intrinsic tumor-selective activity 
of sTRAIL is fully retained in the scFvCD33:sTRAIL fusion protein.
The anti-leukemia activity of GO critically relies on the timely intracellular release of the 
calicheamicin after internalization into CD33-positive tumor cells. However, the linker 
technology used in GO yields conjugates of rather poor thermostability, which can result 
in the inadvertently release of calicheamicin in the circulation and subsequent systemic 
toxicity due to CD33-independent uptake of calicheamicin in normal cells and tissues. We 
compared the thermostability and associated untargeted toxicity of scFvCD33:sTRAIL 
and GO by storing them for up to 72h at 37˚C. This revealed that CD33-negative MOLT-
16 cells were fully resistant to samples scFvCD33:sTRAIL from all storage time points 
evaluated, whereas treatment with identically stored GO resulted in a steep time-
dependent apoptosis induction (Fig. 2C). Importantly, scFvCD33:sTRAIL that was stored 
for 72h at 37˚C fully retained its CD33-restricted pro-apoptotic activity towards CD33-
positive U-937 cells (data not shown). Taken together, these data suggests a favorable 
toxicity profile for scFvCD33:sTRAIL, with a strongly reduced risk of myelosuppression 
and hepatoxitcity when systemically applied in human subjects. 
It has been reported that target antigen-negative tumor cells can escape from antibody-
based therapeutic approaches [26;27]. Previously, we demonstrated that scFv:sTRAIL 
fusion proteins not only eliminated targeted tumor cells, but also conveyed a potent 
therapeutic bystander effect toward neighboring tumor cells devoid of target antigen 
expression. Importantly, no toxic innocent bystander activity was observed towards 
normal cells [18]. In mixed culture experiments of CD33-positive and CD33-negative 
tumor cells, scFvCD33:sTRAIL induced potent bystander apoptosis in CD33-negative 
tumor cells. This bystander activity is based on the principle that CD33-positive tumor 
cells are not only eliminated by scFvCD33:sTRAIL, but are also exploited to cross-link 
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agonistic TRAIL receptors on neighboring tumor cells lacking CD33 expression (Fig. 3A) 
Jurkat.CD33 and Jurkat cells mixed at a ratio of 1:1 were treated for 6h with identical 
amounts of scFvCD33:sTRAIL (727ng/ml) or scFvC54:sTRAIL (727ng/ml). Differential 
analysis of apoptosis in the Jurkat.CD33 target cell population and the Jurkat bystander 
cell population demonstrated that scFvCD33:sTRAIL, but not scFvC54:sTRAIL, potently 
induced apoptosis to both the target- and bystander tumor cell populations. (Fig. 3B 
and C). Together this demonstrates that, in the presence of CD33-positive tumor cells, 
scFvCD33:sTRAIL has a potent anti-tumor bystander activity towards CD33-negative 
tumor cells. Previously, we demonstrated this potent anti-tumor bystander activity 
for various analogous tumor-selective scFv:sTRAIL fusion proteins [16-18]. This anti-
tumor activity may be important to eliminate cancer cells that would otherwise escape 
from GO-based therapy due to partial loss of target antigen expression. In contrast, no 
anti-leukemia bystander activity towards CD33-negative AML cells can be conveyed by 
GO since its activity critically dependents on consecutive steps of first internalization 
followed by intracellular processing and nuclear translocation of the calicheamicin toxin. 
Furthermore, separate evaluation of the activation of caspases 8 and 3/7 in Jurkat.CD33 
target and Jurkat bystander cells indicated that in both cell populations caspase 8 and 3/7 
are elevated after treatment with scFvCD33:sTRAIL (Fig. 3D and E). Currently, various 
new agents have been reported that have promising anti-leukemia activity, including 
type II topoisomerase inhibitor mitoxantrone, histone deacetylase inhibitor valproic 
acid (VPA) [28;29], Hsp90 inhibitor 17-AAG [30;31], and Bcr-Abl inhibitor Gleevec [32]. 
Combination treatment of scFvCD33:sTRAIL with mitoxantrone resulted in a synergistic 
apoptosis induction in MonoMac-6 and an additive apoptosis induction in U-937 tumor 
cells (CI=0.88 and 0.93 respectively, Fig. 4A) Treatment in which scFvCD33:sTRAIL is 
combined with either VPA or 17-AAG resulted in synergistic apoptosis induction in U-937 
cells with cooperativity indexes of CI=0.52 and CI=0.77, respectively (Fig. 4B). Of note, 
similar synergistic induction of apoptosis was observed when scFvCD33:sTRAIL treatment 
was combined with cytarabine (data not shown). This indicates that various combinatorial 
treatment regimens with novel anti-cancer agents can rapidly be designed that result in 
enhanced or synergized anti-AML activity of scFvCD33:sTRAIL. 
Subsequently, we assessed the anti-leukemia activity of scFvCD33:sTRAIL towards 
CD33-positive Chronic Myeloid Leukemia (CML) cells. About 95% of the CML cases are 
characterized by the Philadelphia translocation that is responsible for the production 
of Bcr-Abl, a constitutively active mutant tyrosine kinase that causes uncontrolled 
cellular proliferation. Bcr-Abl selective kinase inhibitor Gleevec (imatinib mesylate) was 
approved by the FDA for the treatment of CML, and is currently used as first line therapy. 
Unfortunately, gleevec-resistant relapses occur frequently after therapy interruption or 
cessation. Therefore, we evaluated the activity of scFvCD33:sTRAIL towards Bcr-Abl-
positive/CD33-positive CML cell lines K-562 and BV-173 and combined treatment with 
Gleevec. Both K-562 and BV-173 cells proved to be resistant to single agent treatment 
with scFvCD33:sTRAIL. This is in line with a recent report that demonstrated that the Bcr-
Abl translocation contributes to TRAIL-resistance [33]. However, when scFvCD33:sTRAIL 
treatment was combined with Gleevec synergistic apoptosis induction was observed in 
both K-562 and BV-173 cells (CI=0.36 and 0.54 respectively, Fig. 4C). This indicates that 
scFvCD33:sTRAIL may also be of therapeutic value for the treatment of CD33-positive 
CML when combined with Gleevec. 
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The activity of scFvCD33:sTRAIL towards AML tumor cell lines may not reliably reflect 
its activity towards primary patient-derived AML tumor cells. Therefore, we evaluated 
the anti-leukemia activity of scFvCD33:sTRAIL towards primary AML samples that were 
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Figure 5. Potent anti-leukemia activity of scFvCD33:sTRAIL towards primary patient-
derived AML cells. The anti-leukemia activity of scFvCD33:sTRAIL was assessed using primary AML 
cells that were freshly derived from 3 newly diagnosed AML patients. (A) AML cells isolated from 
patient #1 were treated overnight with scFvCD33:sTRAIL (14.5µg/ml) alone or in the presence of 
VPA (0.5mM), VPA co-treatment resulted in synergistic apoptosis induction (CI=0.46). (B) AML cells 
derived from patient #2 were subjected to treatment with scFvCD33:sTRAIL (14.5 µg/ml) alone or in 
combination with either VPA (0.5mM), Mitoxantrone (50nM) or 17-AAG (200nM). Combined treatment 
with VPA resulted in additive effect (CI=1.08), whereas co-treatment with mitoxantrone (CI=0.78) 
or 17-AAG (CI=0.76) resulted in a synergistic enhancement of apoptosis induction. (C) AML cells 
derived from patient #3 were treated overnight with scFvCD33:sTRAIL (14.5 µg/ml) and combined 
with either VPA (0.5mM), mitoxantrone (50nM) or 17-AAG (200nM). Co-treatment with VPA resulted 
in an antagonistic effect (CI=2.88), whereas co-treatment with mitoxantrone resulted in an additive 
effect (CI=1.00) and 17-AAG in a synergistic effect (CI=0.71). Apoptosis was assessed after 24h by 
AnnexinV/PI staining 
Single agent treatment with scFvCD33:sTRAIL potently induced apoptosis in 3 out of 3 
primary AML samples (Fig. 5A, B and C). Co-treatment with VPA enhanced apoptosis 
induction in 2 out of the 3 samples; in patient #1 apoptosis induction by scFvCD33:sTRAIL 
was synergistically enhanced (13.1% to 33.8% CI=0.46, Fig. 5A) whereas in patient #2 
apoptosis was additively enhanced (55.4% to 73.2% CI=1.08, Fig. 5B). Unexpectedly, in 
patient #3 scFvCD33:sTRAIL co-treatment with VPA resulted in an antagonistic effect 
(24.2% to 10.4% CI=2.88). Usually, addition of VPA potentiates the anti-proliferative 
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effects of anti-leukemia agents and increases sensitivity of tumor cells to apoptosis 
induction. However, the precise mode of action of VPA and other histone deacetylase 
inhibitors is currently not fully understood. We found no obvious explanation for the 
observed antagonistic effect. Further study to explain this finding is warranted.
Unfortunately, due to clinical conditions, the availability of blood from patient #1 was 
limited. Therefore, only samples from patient #2 and #3 were subjected to treatment 
with scFvCD33:sTRAIL which was combined with either mitoxantrone or 17-AAG. The 
results indicated that combination treatment with mitoxantrone, synergistically enhanced 
scFvCD33:sTRAIL induced apoptosis in patient #2 (55.4% to 81.5%; CI=0.78, Fig. 5B) 
and additively enhanced in patient #3 (24.2% to 54.0% CI=1.00, Fig. 5C). Hsp90 inhibitor 
17-AAG synergistically enhanced the anti-leukemia activity of scFvCD33:sTRAIL towards 
AML cells from both patients #2 and #3 (patient #2, 55,4% to 72,0% CI=0.76; patient 
#3, 24.2% to 40.3% CI=0.71 , Fig. 5B and C). 
In conclusion, scFvCD33:sTRAIL is a novel potent anti-leukemia agent with CD33-
restricted pro-apoptotic activity that shows no signs of toxicity towards normal monocytes. 
Moreover, scFvCD33:sTRAIL is superior to GO in terms of tumor selectivity, activity and 
stability. scFvCD33:sTRAIL showed an potent anti-AML bystander activity towards CD33-
negative tumor cells, which may be important for the elimination of AML cells with lost 
of heterogeneous CD33 expression. scFvCD33:sTRAIL showed promising anti-leukemia 
activity towards primary AML samples that were freshly derived from newly diagnosed 
AML patients. The activity of scFvCD33:sTRAIL could be enhanced by various novel anti-
tumor agents. Therefore, we conclude that further development of scFvCD33:sTRAIL 
may expand treatment options of CD33-positive leukemia’s. 
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Despite recent advances, treatment of leukemia is often not curative. new 
insights indicate that this may be attributable to a small population of therapy-
resistant malignant cells with self-renewal capacity and the ability to generate 
large numbers of more differentiated leukemia cells. These leukemia-initiating 
cells are commonly referred to as Leukemia stem Cells (LsCs). LsCs are 
regarded as the root of leukemia origin and leukemia recurrence after seemingly 
successful therapy. not surprisingly therefore, contemporary leukemia research 
has focused on ways to specifically eliminate LSCs, leading to the identification 
of several promising anti-LsC strategies. Firstly, LsCs may be eliminated by 
antibody- or ligand-based cell surface delivery of therapeutics such as naked 
antibodies, immunotoxins, and immunocytokines. This approach exploits LsC-
associated surface antigens, such as CD33, CD44, CD96, CD123 and CLL-1 for 
LsC-selective therapy and aims to spare normal hematopoietic stem cells. A 
second strategy aims to disrupt the interactions between LsCs and their highly 
specialized niche. These interactions appear to be pivotal for maintenance of the 
stem cell-like characteristics of LsCs. A third strategy centers on the selective 
modulation of aberrantly activated signaling pathways central to LsC biology. A 
fourth strategy, dubbed ‘epigenetic reprogramming’, aims to selectively reverse 
epigenetic alterations that are implicated in ontogeny and maintenance of LsCs. 
In this review, we will discuss the rationale for these LsCs-targeted strategies 
and highlight recent advances that may ultimately help pave the way towards 
selective LsCs-elimination.
INTRODUCTION
To a varying degree most leukemia types initially respond well to therapy with partial or 
even complete remissions. Unfortunately, after a period of minimal residual disease (MRD) 
many patients succumb to  refractory relapses of the disease. Recent insight indicates 
that the development of these relapses may be due to the selective continued survival 
of a small, but distinct, population of therapy-resistant tumor-initiating cells, commonly 
referred to as Leukemia Stem Cells (LSCs). LSCs are thought to originate either from 
normal hematopoietic stem cells (HSCs) or from more differentiated progenitor cells 
that have acquired malignant features. In the latter case, the progenitor cells have de-
differentiated and re-acquired stem cell-like characteristics via as yet undefined pathways 
[1;2]. Both LSCs and HSCs possess self-renewal capacity but are relative quiescent 
compared to more mature progenitors cells (see Fig. 1). However, LSCs typically have 
a much stronger capacity for cellular expansion than normal HSCs, probably due to an 
increase in symmetric self-renewal activity of LSCs [3].
LSCs were first identified in Acute Myeloid Leukemia (AML) by John Dick and colleagues 
[3;4] and have by now been found in all major forms of leukemia [3-6]. LSCs are 
experimentally defined as cells capable of serial engraftment in immunocompromised 
mice (see Fig. 1). Importantly, mice engrafted with these LSCs develop leukemia 
which resembles the patient’s original disease [7]. During this last decade substantial 
progress in the field of LSC research has led to the identification of many of the hallmark 
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characteristics of LSCs. Therapy-resistance is typical for LSCs which is thought to arise 
from (1) their relative quiescent cellular activity [8;9], (2) their array of self-protecting 
mechanisms [10], and (3) the highly protective microenvironment in which the LSCs 
resides [11]. 
Since curative treatment of leukemia will most likely require the elimination of LSCs, new 
strategies need to be designed that overcome the above-described features. Importantly, 
in this design care should be taken to spare normal HSCs. In this respect, strategies that 
target a distinct Achilles’ heel of the LSC biology appear to be particularly promising. 
Here, we review the rationale of different LSCs-specific strategies and highlight recent 
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Self-protective mechanisms            Chemo-sensitive
Protective niche
Figure 1. Hypotheses for the ontogeny of leukemia stem cells. LSCs can arise by somatic 
mutations in normal hematopoietic stem cells (HSC) or more mature progenitor cells can become 
malignant, de-differentiate and re-acquire stem cell-like characteristics. Currently, LSCs (typically 
CD34+CD38-) are defined by the ability to engraft in immunocompromised mice and initiate leukemia 
resembling the original patient’s disease. 
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LSC CELL SURFACE TARGETING APPROACHES
Cell surface antigens expressed on LSCs may be exploited for antibody- or ligand-
based therapeutic approaches. The ideal target antigen is exclusively and abundantly 
expressed on LSCs, thereby maximizing the therapeutic effect and minimizing off-target 
effects. Unfortunately, such an antigen has not been uncovered. However, a series of 
surrogate cell surface markers have been identified which have favorable LSCs-restricted 
expression profiles. These surrogate markers can be targeted with naked antibodies, 
which typically eliminate targeted cells via Antibody Dependent Cellular Cytotoxicity 
(ADCC) or Complement Dependent Cytotoxicity (CDC). However, some antibodies 
can directly interfere with the signaling activity by binding to receptor molecules and 
sensitize targeted cells to apoptosis induction [12] or directly induce apoptosis as 
reported for the anti-CD20 monoclonal antibody (mAb) Rituximab [13]. The tumoricidal 
potential of antibodies can be further enhanced by conjugating them to cytotoxic drugs 
or radionuclides. Alternatively, cell surface molecules may also be targeted using 
recombinant forms of their corresponding natural ligand. Ligand-based approaches have 
been used to deliver cytotoxic drugs to the target cell and to trigger apoptosis-inducing 
receptors. However, an obvious potential limitation to antibody-based and ligand-based 
therapy is the selective loss of the target antigen during therapy or the presence of target 
antigen-negative leukemia cells at the start of therapy. In this respect, fluctuations in 
the expression of cell surface markers on HSCs have been reported [14]. Therefore, the 
rational design of combinatorial antibody-based or ligand-based strategies that target 
two or more different LSC antigens simultaneously may prove the best way to prevent 
escape form therapy. Below, a selection of the most prominent cell surface molecules on 
LSCs and approaches for targeting these molecules are briefly reviewed (summarized in 
Fig. 2). 
LSC Target antigens 
CD33 belongs to immunoglobulin (Ig) superfamily and is a member of the sialoadhesin 
family of cellular interaction molecules [15;16]. The intracellular domain of CD33 contains 
an immunoreceptor tyrosine-based inhibitory motif (ITIM) domain which may function as 
a negative regulator of cellular differentiation [17]. CD33 expression is largely restricted 
to the myeloid lineage, however some expression is detected on certain peripheral blood 
lymphocytes. In leukemia, CD33 is expressed on blasts in the majority of AML patients. 
Importantly, it has been noted that CD33 is also expressed on AML-LSCs, but not on 
normal HSCs [18;19].
CD123 (IL-3Rα) is the alpha subunit that hetero-dimerizes with the IL3β chain to form the 
interleukin-3 receptor. CD123 is constitutively expressed on hematopoietic progenitors 
cells (HPCs), on which it is involved in proliferation and differentiation. Furthermore, 
CD123 is expressed on LSCs in AML [20], Chronic Myeloid Leukemia (CML), Myelodysplastic 
Syndrome (MDS) and Systemic Mastocytosis [18], but not on HSCs [21]. This expression 
profile indicates that CD123 might be a suitable target for the selective elimination of 
LSCs in various hematological malignancies. 
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C-type Lectin-Like Molecule-1 (CLL-1) is a heavily N-glycosylated transmembrane protein 
with an intracellular ITIM domain [22]. CLL-1 is exclusively expressed on cells of the 
hematopoietic lineage, including dendritic cells, granulocytes and monocytes [23]. In 
leukemia, CLL-1 expression is detected on 92% of all AML cases [23] on which a high 
expression at diagnosis correlates with an early relapse [24]. Importantly, CLL-1 is also 
expressed on AML-LSCs, but not on HSCs [24;25]. In line with these findings, it was 
demonstrated that sorted CD34+/CLL-1+ AML cells are able to engraft and generate CLL-1+ 
blasts after transplantation in Non-Obese Diabetic/ Severe Combined ImmunoDeficient 
(NOD/SCID) mice [24].
CD96 is a transmembrane protein belonging to the Ig superfamily. The extracellular 
domain of CD96 has three Ig-like regions and a stalk-like region which can be heavily 
O-glycosylated. The only ligand for CD96 identified thus far is CD155, also known as polio 
virus receptor [26]. On normal cells CD96 protein expression appears to be restricted 
to T and NK cells, while its expression was also detected on T cell -Acute Lymphoid 
Leukemia (ALL) cells and AML cells [27;28].  Recently, Hosen and colleagues identified 
that compared with normal HSCs in AML-LSCs CD96 mRNA levels are at least 200-
fold increased [28]. These mRNA expression data suggests that CD96 protein may be 
selectively over-expressed on AML-LSCs. In line with this finding, they demonstrated that 
CD96+ AML cells have a significantly higher engraftment potential then CD96- AML cells 
[28]. Therefore, the development of antibody-based or CD96 ligand-based therapeutics 
may have potential for the targeted elimination of CD96+ AML-LSCs.
Targeting LSCs with naked antibodies
Indications for the efficacy of targeting CD123+ AML-LSCs with naked antibodies is 
demonstrated by a preclinical study using the CD123 neutralizing antibody, mAb7G3 
[29]. Treatment with mAb7G3 inhibited engraftment and homing of human CD123+ 
AML-LSCs when injected in NOD/SCID mice. This effect of mAb7G3 was restricted to 
AML cells, since there was only a minor effect towards normal bone marrow (BM) cells. 
Furthermore, mAb7G3 treatment of NOD/SCID mice with pre-established AML reduced 
both the disease burden and the ability to transplant AML in secondary recipient mice 
(Lock R, et al. ASH Annual Meeting Abstracts 2007;110:161). 
 
Recently, in vitro treatment with naked anti-CLL-1 mAbs in the presence of serum resulted 
in efficient Complement Dependent Cytotoxicity (CDC) towards various CLL-1+ AML cell 
lines. In line with these findings, ex vivo treatment of primary AML blasts with naked anti-
CLL1 mAbs resulted in CDC in all samples tested. Furthermore, in a xenograft model one 
particular anti-CLL-1 mAb reduced the growth of established tumors by 38% (Korver W, 
et al. ASH Annual Meeting Abstracts 2008;112:4003). Together, these data indicate that 
targeting both CD123 and CLL-1 by naked antibodies might be a promising approach for 
the selective elimination of LSCs. 
Targeting LSCs with immunoconjugates
The expression of CD33 in AML has resulted in the development of several CD33-targeted 
experimental therapeutics [30;31] and the clinically applied anti-AML immunotoxin 
Gemtuzumab Ozogamicin (GO). GO consists of an anti-CD33 mAb that is chemically 
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coupled to a derivative of the calicheamicin-toxin. After CD33-selective binding, GO 
internalizes and ends up in the acidic milieu of lysosomes where the calicheamicin moiety 
is hydrolytically released. Subsequently, calicheamicin translocates to the nucleus 
and intercalates with the DNA, causing site-specific double-strand breaks resulting in 
apoptotic cell death [32]. In the United States, GO was approved by the FDA for use 
in patients over the age of 60 with relapsed AML who are not considered candidates 
for standard chemotherapy [33]. In this subset of patients, GO treatment resulted in a 
26% remission rate, albeit with sometimes considerable toxicity [34]. Recently, we have 
demonstrated that the activity of GO is strongly enhanced when treatment is combined 
with the epigenetic modifying drug valproic acid (VPA), a histone deacetylase inhibitor 
(HDACi). The co-treatment of AML cells with GO and VPA facilitated the intercalation of 
calicheamicin with the DNA, followed by synergistic apoptosis induction [35]. 
It has been reported that in vitro treatment of AML-LSCs with GO results in a median 
decrease in cellular viability with 46%, while normal HSCs were largely unaffected (Jawad 
M et al. ASH Annual Meeting Abstracts 2007;110:650). Therefore, it would be interesting 
to assess whether the anti-LSCs activity of GO can be further enhanced when treatment 
is combined with VPA. 
One potential resistance mechanism of AML-LSCs towards treatment with GO involves 
the increased expression and/or activity of drug efflux pumps. In this respect, it appears 
that P-glycoprotein (Pgp) expression confers resistance to GO and as such is associated 
with a worse clinical response [36]. Therefore, combination treatment of GO and Pgp 
inhibitors may enhance the therapeutic effect of GO towards Pgp-expressing LSCs. 
Alternatively, efflux pump-related resistance in AML-LSCs may be overcome using an 
anti-CD33 antibody conjugated to cytolytic radionuclides like 111In. In vitro experiments 
with an 111In-conjugated anti-CD33 mAb resulted in potent apoptosis in both chemo-
resistant CD33+, HL-60 AML cells and in primary AML cells. Indeed, efflux pump-related 
resistance was overcome by 111In since these AML cells expressed several drug efflux 
pumps including Pgp, Breast Cancer Resistance Protein 1 and Multidrug Resistance 
Protein 1 [37].
Currently, the efficacy of various CD123-targeted immunoconjugates is under 
investigation. In one particular approach CD123 is targeted by a fusion protein comprising 
a CD123-specific single chain fragment of the variable regions (scFv) antibody fragment 
that is genetically fused to a fragment of pseudomonas exotoxin A (PE38). This fusion 
protein, designated 26292(Fv)-PE38-KDEL, potently induced apoptosis in a variety of 
CD123+ leukemia cell lines [38]. It remains to be investigated whether 26292(Fv)-PE38-
KDEL can also eliminate CD123+ LSCs.
Targeting LSCs with ligand-based approaches
The cytokine IL3 has been used in fusion protein format to selectively deliver diphtheria 
toxin (DT) to CD123+ AML cells [39]. This IL3-DT fusion protein also selectively eliminated 
primitive AML progenitors, while normal progenitors where not affected [40]. Importantly, 
the IL3-DT fusion protein inhibited engraftment of human CD123+ AML-LSC cells when 
injected in NOD/SCID mice [40;41]. Recently, it was demonstrated that the pro-apoptotic 
activity of IL3-DT is enhanced when treatment is combined with Tumor necrosis factor 
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Related Apoptosis Inducing Ligand (TRAIL) [42]. Currently, a phase I clinical trial with 







































Figure 2. Antibody- and ligand-based approaches for the elimination of LSCs. The cell 
surface molecules CD96, CD123 (IL3Rα), CLL-1, CD33 and TRAIL-R1/R2 may be exploited for the 
selective elimination of LSCs. CD123 targeted strategies include mAb7G3, a fusion protein comprising 
an CD123-specific antibody fragment linked to pseudomonas endotoxin A (26292(Fv)-PE38-KDEL) 
and an IL3:diphtheria toxin (IL-3:DT) fusion protein. CLL-1 has been targeted with naked antibodies 
resulting in Complement Dependent Cytotoxicity. CD33 has been targeted with several experimental 
therapeutics, including radionuclides, a scFvCD33:sTRAIL fusion protein and the clinically applied 
immunotoxin Gemtuzumab Ozogamicin (GO). After CD33-selective binding, GO internalizes and ends 
up in the lysosomes. In the acidic milieu of the lysosomes, the calicheamicin moiety is hydrolytically 
released. Next, calicheamicin translocates to the nucleus and intercalates with the DNA, resulting 
in apoptotic cell death. Therapeutic strategies targeting the death-receptors, TRAIL-R1/R2, include 
activating anti-TRAIL-R1 and anti-TRAIL-R2 antibodies, recombinant preparations of soluble TRAIL 
(sTRAIL) and scFv:sTRAIL fusion proteins. Activation of TRAIL-R1/-R2 receptors results in the 
recruitment of the adaptor molecule FADD and caspase-8 to the death domains of these receptors. 
Assembly of this so-called death-inducing signaling complex (DISC) leads to sequential activation 
of caspase-8 and caspase-3, ultimately resulting in DNA damage and apoptosis. In some cell types, 
caspase-8 can cleave Bid (tBid) and thereby activate a mitochondrial amplification loop. This loop 
is characterized by cytochrome C release from the mitochondria and subsequent the sequential 
activation of caspase-9 and caspase-3.
Activation of apoptosis inducing receptors 
The agonistic TRAIL death receptors, TRAIL-R1 and TRAIL-R2 (also known as DR4 
and DR5, respectively) belong to the Tumor Necrosis Factor receptor family of death 
receptors. Ligation of these death receptors by TRAIL activates the extrinsic apoptotic 
pathway (reviewed in [43]). Hereupon, the adaptor protein FAS associated death domain 
(FADD) and the initiator caspase-8 are recruited to the intracellular death domains of 
these receptors. Assembly of this so-called death-inducing signaling complex (DISC) 
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leads to sequential activation of initiator and effector caspases and, ultimately, results 
in apoptotic cell death. In some cell types, the death-receptor pathway relies on an 
additional mitochondrial amplification loop that is activated by caspase-8-mediated 
cleavage of the BH3-only interacting domain death agonist (Bid) to a truncated form. Next, 
truncated BID (tBid) activates the mitochondrial pathway which involves cytochrome 
C and caspase-9. Intriguingly, apoptosis resulting from ligation of agonistic TRAIL-Rs 
appears to be restricted to malignant cells only, since normal cells appear to be resistant 
to TRAIL-R ligation. The mode of action of this tumor-selectivity of TRAIL-Rs ligation is 
still enigmatic.    
Currently, activating anti-TRAIL-R1 and anti-TRAIL-R2 antibodies, as well as recombinant 
preparations of soluble TRAIL (sTRAIL) are evaluated in clinical trials [44-47]. In our 
laboratory, we have developed a series of fusion proteins, consisting of a tumor-selective 
scFv antibody fragment genetically fused to sTRAIL. These scFv:sTRAIL fusion proteins 
are designed to enhance tumor-selective cell surface delivery of sTRAIL (reviewed in 
[48]). Pre-clinically, these scFv:sTRAIL fusion proteins demonstrate potent and target 
antigen-restricted apoptosis induction. To this end, we have exploited both antigens 
expressed on solid tumors including Epidermal Growth Factor Receptor [49-51]  and 
Epithelial Cell Adhesion Molecule [52;53], as well as antigens selectively expressed on 
leukemia cells including CD7 [54], CD19 [55] and CD33 [30].
Very recently, the expression of both TRAIL-R1 and TRAIL-R2 has been reported on 
LSCs. Comparing the gene expression profiles of AML-LSCs and HSCs, Majeti and 
colleagues demonstrated an increased expression of TRAIL-R1 and TRAIL-R2 in LSCs 
[56]. Furthermore, yong et al. demonstrated that in CML non-cycling  CD34+ cells have 
a significant higher expression of TRAIL-R1 and TRAIL-R2  than cycling CD34+ CML cells 
[57]. In line with this finding, sTRAIL significantly inhibited the clonogenic capacity of 
CD34+ AML cells without affecting the clonogenic capacity of normal CD34+ cells [58]. 
Together, these studies indicate that TRAIL-R1 and TRAIL-R2 receptors might be suitable 
candidates for the selective elimination of LSCs by targeted apoptosis induction. At 
present, we are assessing the efficacy of CD33- and CLL-1-selective scFv:sTRAIL fusion 
proteins for targeted apoptosis induction in AML-LSCs.
DISRUPTION OF THE LSCS-NICHE INTERACTION
In 1978, Schofield proposed that HSCs receive regulatory factors and signals within 
a specialized niche [59]. Currently, there are indications that these specialized niches 
are located in the bone marrow (BM), near the endosteum [60]. The endosteum is the 
inner surface located at the bone-BM interface and consisting mainly of osteoblasts and 
osteoclasts. More recent evidence indicates that also vascular and perivascular cells 
appear to contribute to these niche interactions as well (see review [61]). Signals within 
the HSCs niche regulate the normal survival, proliferation and differentiation of the HSCs. 
Recently, it was demonstrated that in leukemia the micromilieu in the HSCs niche appears 
to disturbed by the presence of Stem Cell Factor that is locally secreted by leukemia cells 
[62]. Furthermore, it has been demonstrated that intravenously injected AML-LSCs home 
to, engraft and subsequently reside in the endosteal region [63]. Such cellular tropism 
of AML-LSCs for a dedicate niche typically involves the coordinated signaling by various 
chemokines and adhesion molecules. Neutralization or inhibition of these signals may 
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be exploited for the selective elimination of LSCs. Below, a selection of recent studies 
is reviewed that collectively indicate that disruption of the LSCs-niche interactions may 
indeed form a therapeutic option for the elimination of LSCs (summarized in Fig. 3). 
Targeting the Stroma-derived factor-1(SDF-1)/CXCR4 axis 
Previously, it has been demonstrated that the chemokine SDF-1 (CxCL12) as expressed 
by reticular stromal cells in the BM is pivotal for homing of HSCs to their niche [64]. 
SDF-1 binds to the transmembrane receptor CxCR4 which is expressed on HSCs [64;65], 
leukemic blasts and AML-LSCs [66]. Of note, a high expression of CxCR4 in AML correlates 
with a negative prognosis [67;68]. The pivotal role of CxCR4 in retention of HSCs in the 
niche is clearly demonstrated by the mobilization of HSCs by the CxCR4 antagonist 
AMD3100 [69]. 
The interaction of leukemia cells with cell adhesion molecules in the niche typically reduces 
their sensitivity to cytotoxic therapies, a process known as cell adhesion-mediated 
drug resistance (CAM-DR). Inhibition of CxCR4 by the specific inhibitors AMD3100 and 
AMD3465 sensitized AML cells for cytotoxic therapies [70-72]. Most likely, treatment with 
the CxCR4 inhibitors mobilizes AML cells, thereby reducing CAM-DR and sensitizing the 
AML cells for cytotoxic therapy. 
Tavor and colleagues demonstrated that the anti-CxCR4 mAb12G5 significantly inhibits 
homing of AML cells to the BM of recipient mice. Notably, treatment of mice with 
established AML with mAb12G5 reduced the leukemic burden in the BM, blood and spleen. 
Importantly, similar treatment did not affect the levels of engrafted HPCs [66]. 
Additionally, lowering available SDF-1 levels in leukemia might offer a therapeutic strategy. 
Recently, the medicinal herb-derived compound berberine was shown to inhibit SDF-1 
production by stromal cells, thereby impairing the migration of AML blasts and AML-LSCs 
in vitro [73]. Together these results indicate the importance of a properly functioning 
SDF-1/CxCR4 axis for homing and retention of AML blasts and AML-LSCs. Therefore, the 
SDF-1/CxCR4 axis appears to be a suitable target candidate for the selective elimination 
of AML-LSCs.
Targeting Very Late Antigen 4 (VLA-4)  
The β1-integrin, VLA-4,  has a vital role in the retention of HPCs in the BM niche by 
immobilizing these cells [74]. The interaction of VLA-4 on AML cells with fibronectin on 
stromal cells initiates the phosphatidylinositol-3-OH kinase (PI3K) pro-survival pathway. 
Activation of the PI3K pathway in AML cells contributes to CAM-DR, which might explain 
the observation that VLA-4 expression on AML cells is correlated with a negative prognosis 
for AML patients. In line with this, Matsunaga and colleagues demonstrated that inhibition 
of VLA-4 interaction with fibronectin sensitized AML cells to cytosine arabinoside (Ara-C). 
This was demonstrated in a mice model for MRD in which they applied VLA-4 neutralizing 
antibodies to prevent the interaction with fibronectin [75]. Using the same MRD model, 
they recently demonstrated that a fibronectin-based synthetic peptide, designated FNIII14 
[76], also sensitized AML cells to Ara-C [77]. Both approaches may be of considerable 




CD44 is a transmembrane receptor capable of binding several ligands, including hyaluronic 
acid which is abundantly expressed in the endosteal region [78]. On HSCs, CD44 serves 
as a homing receptor by interacting with E-selectin and L-selectin expressed in the BM 
[79]. Since CD44 is expressed on both CML-LSCs and AML-LSCs [80;81], neutralization of 
CD44-binding might impair the homing and retention of LSCs in the BM. 
In CML, about 95% of the cases is characterized by the presence of the oncogenic fusion 
protein Bcr-Abl, a constitutively active mutant tyrosine kinase that causes uncontrolled 
cellular proliferation. The Bcr-Abl inhibitor Imatinib Mesylate induces remissions in the 
majority of CML patients. However, Imatinib appears to be unable to eradicate quiescent 
CML-LSCs [82], which might explain why the majority of CML patients relapse upon 
treatment discontinuation. Therefore, novel therapeutics for the selective elimination of 



























Figure 3. Disruption of the LSC-niche interaction. The LSC-niche interaction can be disrupted by 
targeting VLA-4, CXCR4, CD44 and Rac1. Binding of LSCs-expressed VLA-4 to fibronectin in the BM 
initiates the PI3K pro-survival pathway and cell adhesion-mediated drug resistance (CAM-DR). The 
VLA-4-fibronectin interaction has been disrupted by mAbs and the synthetic peptide FNIII14. CXCR4 
has been targeted with mAb12G5 and the specific inhibitors AMD3100 and AMD3465. Furthermore, 
the concentration of the CXCR4 ligand, SDF-1, can be lowered using berberine. The interaction of 
CD44 with the niche has been disrupted by mAbH90 and mAbIM7. The compound, NSC23766, has 
been utilized to specifically inhibit Rac1. 
In a series of elegant experiments, Krause and colleagues demonstrated that CD44 
expressed on Bcr-Abl+ CML-LSCs is essential for homing of these cells in recipient mice. 
Thereto, they performed a competitive homing assay in which the relative contribution 
of Bcr-Abl-transduced CD44+ BM cells and Bcr-Abl-transduced CD44- BM cells in the 
development of CML was analyzed. Both cells types were mixed and injected intravenously 
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in irradiated recipients mice. After CML development, the animals were sacrificed and the 
relative contribution of the two distinct cell populations was analyzed. This revealed that 
Bcr-Abl-transduced CD44+ BM cells contributed 5 times more to the development of CML 
than Bcr-Abl-transduced CD44- BM cells. CML development by the two different cell types 
was similar when injected intrafemorally. These results indicate that CD44 is necessary 
for homing of intravenously injected Bcr-Abl transduced cells to the BM. Importantly, 
anti-CD44 antibody treatment significantly prolonged survival of NOD/SCID recipient 
mice upon transplantation with CML-LSCs [80]. 
Simultaneously, the group of John Dick obtained similar results by targeting CD44 in AML. 
Treatment with the CD44-activating mAbH90 inhibited AML-LSCs homing to the BM niche 
and altered the fate of the AML-LSCs resulting in an efficient and selective elimination of 
the AML-LSCs [81]. Together, these studies clearly indicate a rationale for targeting CD44 
to selectively eliminate CML-LSCs and AML-LSCs. Therefore, an evaluation of the efficacy 
of targeting CD44 in both CML and AML patients seems warranted.
Targeting Rac
The Rac subfamily of the Rho-family of GTP-ases is implicated in cell adhesion and 
motility. The family consists of three members Rac1, Rac2 and Rac3. Rac1 is ubiquitously 
expressed [83], while Rac2 expression is limited to the hematopoietic system [84] and 
Rac3 is selectively expressed in the brain [85]. Rac1-/- HSCs and progenitors are unable 
to reconstitute hematopoiesis in irradiated recipient mice upon transplantation [86]. 
Moreover, it has been shown that Rac is overexpressed on CD34+ cells derived from AML 
patients. Rac appears to contribute to an enhanced migration and adhesion capacity of 
CD34+ cells to BM stromal cells.
Gao and colleagues [87] generated a Rac1 inhibitor, designated NSC23766, that 
significantly delayed leukemia development in a murine tumor model [88] and strongly 
reduced the clonal expansion of CD34+ AML cells [89]. Together, these promising data 
warrants further pre-clinical assessment of Rac1 inhibition for the elimination of LSCs.  
TARGETING ABERRANT MOLECULAR PATHWAyS
Both, HSCs and LSCs rely on similar molecular pathways for their maintenance and self-
renewal. However, in LSCs these pathways are often aberrantly regulated. LSCs appear 
to be particular dependent on these deregulated pathways to maintain their malignant 
phenotype. This strong dependence indicates that therapeutic intervention in these 
pathways might be exploitable for the selective elimination of LSCs. Thus far, several of 
these deregulated pathways have been identified (e.g. the Hedgehog and Wnt pathways). 
The selective targeting of these pathways may yield promising anti-LSCs activity.
Compounds such as arsenic trioxide and parthenolide have been assessed for their capacity 
to induce apoptosis in LSCs. However, the pathways in which these compounds intervene 
are currently not completely understood. Therefore, further delineation of their specific 
molecular targets may contribute to development of more and rationally designed LSCs 
targeted therapeutics. Below, we provide a selection of aberrantly regulated pathways 
present in LSCs and a selection of chemical compounds that may have potential for the 
elimination of LSCs (summarized in Fig. 4).  
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The Hedgehog (Hh) pathway
The Hh pathway is involved in HSCs self-renewal [90] and is initiated by binding of 
one of the three Hh ligands, Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) or desert 
Hedgehog (Dhh) to the transmembrane receptor Patched. Upon binding of Hh to Patched 
the inhibiting effect of Patched on the transmembrane receptor Smoothened (Smo) is 
relieved (reviewed in [91]). Next, Smo can activate Hh targets genes via the Gli family 
of transcription factors. Amongst these Hh targets genes are CyclinD/E [92] and B-cell-
specific Moloney murine leukemia virus insertion site 1 (Bmi-1) [93] which are involved in 
cell proliferation and self-renewal, respectively. The Hh pathway can be inhibited by the 
chemical compound cyclopamine, which stabilizes Smo in its inactive form [94]. In a very 
recent study conducted by Zhao and colleagues the role of Smo in Bcr-Abl+ CML-LSCs 
was analyzed [95]. Thereto, Bcr-Abl-transduced normal HPCs and Bcr-Abl-transduced 
Smo-/- HPCs were transplanted in irradiated recipient mice after which the development 
of CML was compared. More than 90% of the mice transplanted with Bcr-Abl-transduced 
normal HPCs developed CML. In contrast, only 47% of the mice developed CML when 
transplanted with Bcr-Abl-transduced Smo-/- HPCs. When the Bcr-Abl-transduced HSCs 
were transplanted in mice, all recipient mice died from CML within four weeks. However, 
when these transplanted mice were treated with cyclopamine, 60% of the animals were 
still alive after 7 weeks. Furthermore, CML cells freshly isolated from cyclopamine-treated 
mice were unable to effectively repopulate secondary recipients. This corroborates 
with the strong reduction (up to 14-fold) of CML-LSCs in cyclopamine-treated mice. 
Additionally, cyclopamine treatment of human CML cell lines and primary CML samples 
reduced their clonogenic capacity. Importantly, the authors indicate that Smo inhibition 
by cyclopamine may also impaired the propagation of Imatinib-resistant human CML 
cells in xenografts [95].
The Wnt pathway
Wnt is implicated in HSCs self-renewal and proliferation [96] and is overexpressed in many 
different types of human cancers [97]. Thus far, three distinct Wnt signaling pathways 
have been described of which the canonical pathway is most prominently involved in 
leukemia. The key mediator of the canonical pathway is β-catenin. Normally, β-catenin is 
degraded rapidly after synthesis by the multiprotein destruction complex (MDC), which 
tags β-catenin for proteasomal degradation. The MDC consists of axin, adenomatous 
polyposis coli (APC) and glycogen-synthase kinase 3β (GSK-3β). Upon binding of Wnt to 
its receptors Frizzled and LRP5/6, the MDC becomes destabilized and therefore unable 
to tag β-catenin for degradation. Consequently, β-catenin accumulates and is able to 
translocate to the nucleus. In the nucleus β-catenin complexes with T-cell factor (TCF), B 
cell lymphoma 9 (Bcl-9) and pygo to induce TCF target genes expression [98], including 
the oncogenes C-MyC [99], Cyclin-D1 [100] and the cell surface antigen CD44 [101]. 
In AML, several oncogenic fusion proteins, such as AML-1⁄eight twenty one (AML1-ETO), 
promyelocytic leukemia ⁄ retinoic acid receptor alpha (PML⁄RARα) and promyelocytic 
leukemia zinc finger (PLZF⁄RARα) [102] can activate the Wnt signaling pathway. 
Furthermore, evidence is emerging that indicate an aberrant Wnt signaling pathway in 
LSCs [56] (extensively reviewed in ref [103]). In this respect, it has been shown that 
β-catenin plays a pivotal role in self-renewal of both HSCs as well as CML-LSCs [104]. 
Furthermore, very recently β-catenin has been implicated in the survival of Imatinib 
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resistant CML-LSCs in Bcr-Abl induced CML [105]. Therefore, modulation of Wnt signaling 
in the LSCs may contribute to their selective elimination.
There are several possibilities to inhibit the Wnt signaling pathway.  Wnt signaling can be 
inhibited by extracellular proteins (reviewed in [106]) which scavenge Wnt and thereby 
prevent Wnt from binding to its receptors. These Wnt binding proteins include secreted 
Frizzled-related proteins (sFRP), Wnt inhibitory factor 1 (wif-1) and Cerberus. Moreover, 
members of the Dickkopf (DKK) family can directly bind the Wnt receptor and thereby 
prevent Wnt-induced signaling. In this respect, very recently it appeared that the anti-
proliferative effects of human mesenchymal stem cells towards CML cells is at least partly 
attributable to secretion of DKK-1 [107]. Additionally, also very recently two natural 
compounds, CGP049090 and PKF 115-584 [108], have been identified that disrupt the 
TCF/β-catenin complex. In AML these compounds possess potent tumoricidal activity 
[109]. It would be worthwhile to assess the possibilities of inhibition of the Wnt signaling 
pathway for the elimination of LSCs. 
Aldehyde dehydrogenases (ALDH) enzymes 
ALDH are a group of cytosolic enzymes that catalyzes the conversion of intracellular 
aldehydes. The ALDH superfamily consists of seventeen members [110] of which two 
members, cytosolic aldehyde dehydrogenase class-1A1 (ALDH1A1) and class-3A1 
(ALDH3A1), have been implicated in tumor drug resistance against oxazaphosphorines 
(e.g. cyclophosphamide) [111]. ALDH enzyme activity, including the activity of ALDH1A1 
and ALDH3A1, can be assessed using activatable fluorescent substrates. ALDH enzyme 
activity measurements enables the identification and isolation of HSCs [112], breast 
cancer stem cells [113], liver cancer stem cells [114] and AML-LSCs [115]. Manipulation 
of ALDH1A1 and ALDH3A1 expression or activity may be used to sensitize AML-LSCs to 
chemotherapy, especially to oxazaphosphorines. In this respect, the ALDH1 inhibitor, 
diethylamino-benzaldehyde (DEAB) might be utilized for sensitizing AML-LSCs to treatment 
with chemotherapeutic agents. Unfortunately, DEAB appeared to be very instable in vivo 
[116] . Therefore, the development of novel DEAB-analogues with enhanced stability is 
warranted. All-trans Retinoic Acid (ATRA), an established clinically applied anti-leukemia 
agent, appears to downregulate both ALDH1A1 and ALDH3A1 which may be beneficial for 
the selective elimination of LSCs [111]. In this respect, treatment of Acute Promyelocytic 
Leukemia (APL) and AML cells with ATRA resulted in differentiation of tumor cells and 
stimulation of cell cycling [117]. Therefore, we suggest that the combination treatment of 
oxazaphosphorines and ATRA may have potential for the elimination of LSCs. 
Phosphatase and tensin homologue (PTEN)
PTEN is the second most commonly mutated gene in human malignancies, including 
hematopoietic malignancies [118;119]. Normally, PTEN inhibits cell proliferation and 
cell survival by negatively regulating the PI3K pathway [120]. In this respect, yilmaz 
and colleagues recently compared the effect of PTEN inactivation in HSCs and LSCs 
[121]. Conditional deletion of PTEN resulted in the development of myeloproliferative 
disorder in 17 out of 19 mice which in the majority culminated in leukemia. In the HSCs, 
deletion of PTEN was characterized by an elevated cell cycle progression and an impaired 
replenishment of the HSCs pool, thus finally resulting in a depletion of HSCs. Apparently, 
PTEN deletion facilitates leukemogenesis while it depletes HSCs. These effects of PTEN 
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deletion appear to be mediated by mammalian target of rapamycin (mTOR), since 
treatment with the mTOR inhibitor rapamycin reversed the effects. Therefore, rapamycin 
treatment seems to be a promising approach for the selective elimination of LSCs while 
sparing HSCs. 
However, Ito and colleagues recently reported on a contradictory effect of rapamycin 
[122]. They investigated the role of the tumor-suppressor promyelocytic leukemia 
protein (PML) in CML. Their results demonstrated that PML-deficient CML-LSCs are less 
quiescent than wild-type CML-LSCs, resulting in LSCs exhaustion. Furthermore, deletion 
of PML in HSCs also results in exhaustion and consequently impairment in long-term 
hematopoietic reconstitution. Since PML deficiency in both HSCs and LSCs is characterized 
by an increased mTOR activity they assessed the effect of rapamycin treatment. Here, 
rapamycin rescued the typical PML-deficient phenotype, thus exhaustion of the CML-
LSCs and HSCs was prevented. Together, these seemingly contradictory results of mTOR 
inhibition in the elimination of LSCs indicate that further delineation of the role of mTOR 
in LSCs is needed. 
Of note, since arsenic trioxide is known to decrease PML levels, Ito and colleagues 
continued with assessing arsenic trioxide for the elimination of CML-LSCs [122]. Treatment 
with arsenic trioxide resulted in the exit of the CML-LSCs from quiescence and therefore 
the CML-LSCs might become exhausted and more vulnerable to chemotherapeutics. 
Importantly, this cell cycle entry appeared to be more profound in LSCs than in HSCs, 
thereby generating a possible therapeutic window for the treatment of CML-LSCs by 
arsenic trioxide. 
4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8) 
TDZD-8 was designed as a non-ATP competitive inhibitor of GSK-3β for the treatment of 
Alzheimer’s disease [123]. However, Guzman and colleagues uncovered potent tumoricidal 
activity of TDZD-8 towards leukemia cells. In a series of experiments they demonstrated 
that TDZD-8 exhibit strong anti-leukemia effects towards AML, CLL, ALL and blast crisis 
CML cells, without apparent toxic effects towards normal BM cells. Since a panel of 
other GSK-3β inhibitors did not possess any comparable activity, the anti-leukemia effect 
is probably not governed by the inhibition of GSK-3β. This notion is supported by the 
observation that β-catenin, of which the degradation is in part mediated by GSK-3β, 
is elevated in CML-LSCs. Moreover, very recently GSK-3β missplicing was observed in 
CML-LSCs and not in HSCs [124], together indicating that GSK-3β is dispensable for 
leukemogenesis. 
Importantly, TDZD-8 induced apoptosis in AML-LSCs and CML-LSCs without affecting 
HSCs [125]. In line with this, TDZD-8 specifically reduced the engraftment potential 
of AML-LSCs and not of HSCs. TDZD-8 is a highly hydrophobic agent which may result 
in a rapid loss of membrane integrity in leukemic cells by TDZD-8 insertions in the 
cellular membrane. The absence of this effect in HSCs might indicate that there is crucial 
difference in the membrane composition of LSCs and HSCs [125], which might open 
novel avenues for the selective elimination of LSCs. 
Parthenolide (PTL)
PTL is a compound, derived from the plant feverfew, which eliminates cancer cells via 
reactive oxygen species and the inhibition of NF-kB [126-128]. Guzman and colleagues 
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analyzed the effects of PTL and Ara-C on AML blasts and AML-LSCs. Apoptosis induction 
in the AML blasts by Ara-C was more pronounced than by PTL. However, PTL potently 
induced apoptosis in AML-LSCs, whereas Ara-C exhibited only minimal apoptotic activity. 
Importantly, the PTL concentration necessary for significant AML-LSCs elimination had 
only a modest effect on HSCs [129]. Moreover, PTL treatment significantly reduced the 
engraftment potential of AML-LSCs, while PTL treatment did not affected  the engraftment 
of HSCs [129]. 
Despite the favorable characteristics, the clinical application of PTL is probably 
hampered by its poor water solubility. Therefore, Guzman and colleagues generated a 
series of parthenolide analogues aiming to identify an active compound with improved 
pharmacological properties [130]. Recently, they identified a novel compound, designated 
dimethylamino analog of parthenolide (DMAPT), which exhibits similar activity as PTL. 
However, when formulated as a fumarate salt, DMAPT had 1000-fold enhanced water 
solubility, resulting in a 70% bioavailability of orally applied DMAPT [130]. In contrast to 
PTL, oral administration of DMAPT did result in plasma concentrations sufficient to exert 
an anti-leukemia effect in both rodent and canine models. 
EPIGENETIC REPROGRAMMING OF LSCS
The step-wise conversion of a normal cell to a leukemic cell typically involves the activation 
of oncogenes and anti-apoptotic genes and the inactivation of tumor suppressor and 
pro-apoptotic genes [131]. Frequently, gene expression in leukemic cells is altered by 
epigenetic reprogramming (reviewed in [132]). 
Epigenetic reprogramming is characterized by various distinct chromatin modifications. 
Chromatin consists of histone proteins and DNA. The central unit of the chromatin 
structure is an octamer of core histone proteins, referred to as the nucleosome. The 
distance between adjacent nucleosomes and thus the compaction of the chromatin in 
between, defines two types of chromatin. Euchromatin is the open type of chromatin with 
a relative low compaction which allows access of the transcription machinery to the DNA, 
while heterochromatin is the condensed form in which the transcription machinery can 
not access the DNA and reflects an inactive state. There are several types of modifications 
that can alter the accessibility of the transcription machinery to the DNA. The best studied 
are DNA and histone methylation which are associated with heterochromatin and histone 
acetylation which is associated with euchromatin. 
Normal stems cells rely on Polycomb group (PcG) proteins to repress genes encoding 
transcription factors required for differentiation including the homeotic (HOx) genes 
[133]. It is postulated that methylation of promoter regions of those repressed genes 
could lock in stem cell phenotypes and initiate abnormal clonal expansion and thereby 
predispose to cancer [134;135]. Repression of genes by the PcG proteins is initiated by the 
Polycomb Repressor Complex 2 (PRC2) containing the histone methyltransferase EZH2, 
after which the Polycomb Repressor Complex 1 (PRC1) further maintains the repression. 
The PRC1 comprises amongst others Bmi-1, which is essential for self-renewal of HSCs 
[136]. Of note, in both AML and CML patients Bmi-1 is overexpressed compared to normal 
CD34+ BM cells. Patients with an elevated Bmi-1 expression have less chance of achieving 
complete remission, higher chance of relapse and reduced duration of survival [137;138]. 
Moreover, very recently Wang and colleagues have shown that the dysregulation of a 
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chromatin-binding plant homeodomain (PHD) finger can cause hematological malignancies 
[139]. Normally, PHD fingers respond to certain histone methylation states [140;141]. In 
AML however, chromosomal translocations are observed which results in the fusion of 
a PHD finger to a common leukemia fusion partner called NUP98 [142-144]. Wang and 
colleagues compared the transcriptome profile of BM progenitor cells transduced with 
such a fusion protein with control cells. This analysis indicated that in the cells transduced 
with this fusion protein several genes were upregulated including HOxA9 and MEIS1 





























































Figure 4. Targeting aberrantly regulated pathways and epigenetic reprogramming 
Aberrantly regulated Wnt and Hedgehog pathways have been identified in LSCs and therefore might 
be suitable candidates for therapeutic intervention. At the cell surface, binding of Wnt to LRP5/6 
and Frizzled destabilizes the Multiprotein Destruction Complex (MDC), which in the absence of Wnt 
signaling facilitates the degradation of β-catenin. As a result of Wnt binding to its receptors, β-catenin 
accumulates and translocates to the nucleus where it complexes with TCF, Bcl-9 and pygo to induce 
the expression of several genes including c-myc, cyclin-D and CD44. Extracellularly, the Wnt signaling 
pathway can be inhibited by the scavengers sFRP, Wif1 and Cerberus and the DKK-family members 
which prevent Wnt binding to its receptor. Intracellularly, Wnt signaling can be inhibited by the 
compounds CGP049090 and PKF115-584, which disrupt the TCF/β-catenin complex. The Hedgehog 
pathway is initiated by binding of a ligand (Shh, Ihh or Dhh) to the receptor Patched. Hereupon, 
Smoothened becomes activated and via the Gli family of transcription factors induces the expression 
of several target genes including CyclinD/E and Bmi-1. The Hedgehog pathway can be inhibited by 
cyclopamine which stabilizes Smoothened in its inactive form. Binding of Growth factors (GF) to 
Growth Factor Receptors (GFR) or binding of VLA-4 to fibronectin induces activation of PI3K. This 
pro-survival signaling pathway is characterized by the conversion of PIP2 to PIP3 and subsequent 
downstream signaling via several proteins, including mTOR. Normally, PTEN functions as an inhibitor 
of the PI3K pathway. Pharmacologically, both rapamycin and arsenic trioxide (via PML) can alter 
mTOR activation. The enzymes ALDH1A1 and ALDH3A1 have been implicated in Multi Drug Resistance 
(MDR) and can be inhibited by DEAB and ATRA. The anti-leukemia activity of parthenolide (PTL) is 
characterized by the inhibition of NF-қB and the generation of ROS. The compound TDZD-8 can also 
inhibit NF-қB activation and might influence LSCs membrane integrity. Frequently, gene expression 
in leukemic cells is altered by epigenetic reprogramming. Therefore, reprogramming the epigenetic 
status using decitabine or HDACi appears promising for the elimination of LSCs.
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can induce leukemia, which is dependent on the expression of Bmi-1 [146], suggesting 
that Bmi-1 inhibitors may contribute to the elimination of LSCs.
However, also drugs with a more general epigenetic modification activity may have 
clinical relevance in attacking LSCs. This is evident from the clinical application of the 
demethylating agent decitabine, which is approved for the treatment of MDS. Decitabine 
inhibits DNA methyltransferases (DNMT) and therefore has a broad range of action by 
tipping the balance towards euchromatin. Intriguingly, decitabine exerts differential 
effects in LSCs and HSCs, which is probably due to differences in their epigenomic 
status. In LSCs treatment with decitabine results in differentiation, whereas decitabine 
treatment of HSCs results in enhanced self-renewal (Negrotto S et al. ASH Annual Meeting 
Abstracts 2008;112:201). Furthermore, it was demonstrated that decitabine treatment 
reactivated more genes in bladder cancer cells than in normal fibroblasts [147]. These 
studies indicate that general epigenetic modifications can exert differential effects in 
LSCs and HSCs, which might be utilized for the selective elimination of LSCs.  
Other general epigenetic modulators are HDACi such as suberoylanilide hydroxamic acid 
(SAHA), 4-phenylbutyric acid (PBA) and VPA. HDACi can also tip the balance toward 
euchromatin and have shown to induce apoptosis in leukemia (see Fig. 4). In clinical trials 
VPA monotherapy was well tolerated, but showed disappointing anti-leukemia effects 
(reviewed in [148]). However, combination treatment of VPA with other anti-cancer 
agents showed significantly enhanced and sometimes synergistic anti-tumor effects 
[35;149-151]. 
MicroRNA’s (miRs) are small, non-coding, single stranded RNA sequences that regulate 
gene expression by binding to mRNA molecules. Interestingly, upon co-treatment with 
decitabine and PBA, miRs appear to be differential reactivated in cancer cells and normal 
cells [152]. Saito and colleagues have shown that the transcription of one particular miR, 
miR-127, was increased upon combination treatment of decitabine and PBA. Subsequently, 
they identified that a predicted target of miR-127, BCL6, was downregulated [152]. This 
indicates that not only epigenetic silenced protein-coding sequences, but also miRs 
can be reactivated upon treatment with demethylating agents and HDACi. This opens 
novel avenues for modifying proteins levels in LSCs and therefore may be exploited to 
eliminate LSCs.    
CONCLUSIONS AND PERSPECTIVES 
The specific elimination of LSCs in hemato-oncology is a research area still in its infancy. 
Currently, researchers are at the brink of identifying biological processes imperative to 
LSCs biology. Elucidation of these LSCs-specific characteristics is of eminent importance 
for the rational design of novel LSCs targeted therapies. It is anticipated that the 
successful elimination of LSCs will have tremendous impact on leukemia therapy. Several 
strategies appear promising for the elimination of LSCs, including targeting LSC-selective 
cell surface antigens, disrupting LSCs-niche interactions, targeting aberrantly regulated 
pathways and epigenetic reprogramming of LSCs. Several studies utilizing these strategies 
have generated promising pre-clinical results. However, the vast majority of the data is 
obtained by xenografting LSCs in severely immunocompromised recipient mice. It is 
evident that the data obtained using these models can not be extrapolated directly to the 
clinical situation. Furthermore, it is likely that multifaceted therapy combining several 
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strategies will be the most effective approach. Therefore, rational designed combinatorial 
approaches and multi-modality targeting of LSCs are warranted. Subsequent, these 
combinatorial strategies have to prove to be safe and effective in clinical trials. 
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Currently, the majorities of AML patients eventually relapse and develop 
refractory disease indicating that novel and preferably targeted approaches 
are urgently needed. recently, C-type Lectin-Like Molecule-1 (CLL-1) has been 
identified as a cell surface marker expressed in ~90% of the AML patients. 
Importantly, CLL-1 is expressed on AML blasts and CD34+/CD38- AML stem cells, 
but not on normal hematopoietic stem cells. Moreover, this expression profile 
is retained under all conditions of treatment and disease. This prompted us 
to develop a novel approach for the targeted elimination of CLL-1+ AML and 
AML stem cells.  To this end, a CLL-1-specific antibody fragment (scFvCLL-1) 
was genetically fused to soluble forms of the pro-apoptotic proteins TrAIL 
(sTrAIL) and FasL (sFasL), yielding fusion proteins scFvCLL-1:sTrAIL and 
scFvCLL-1:sFasL, respectively. Both fusion proteins potently induced CLL-1-
restricted apoptosis in AML cell lines and primary AML cells. Moreover, CD34+/
CD38- AML stem cells were sensitive to treatment with scFvCLL-1:sTrAIL and 
scFvCLL-1:sFasL. In contrast, human CLL-1- hepatocytes were fully resistant to 
treatment, whereas CLL-1+ monocytes showed moderate sensitivity to scFvCLL-
1:sFasL. In conclusion, treatment with scFvCLL-1:sTrAIL and scFvCLL-1:sFasL 
results in AML-restricted apoptosis including the CD34+/CD38- AML stem cells. 
This novel approach may be of value for the treatment of AML
INTRODUCTION
Currently, the majority of Acute Myeloid Leukemia (AML) patients succumb within five 
years due to therapy-related morbidity and mortality and the frequent occurrence of 
therapy-resistant relapses [1;2]. These relapses are considered to result from drug-
resistant AML stem and progenitor cells present in the bone marrow. The use of antibody-
based therapeutics appears to be a promising approach for the treatment of relapsed 
AML as is exemplified by the CD33-targeted immunotoxin Gemtuzumab Ozogamicin (GO). 
CD33 is a myeloid cell surface marker absent on normal hematopoietic stem cells but 
expressed in about 90% of AML patients [3]. 
Currently, GO is indicated for the treatment of a small subset of patients with CD33+ 
AML in first relapse who are 61 years of age or older and who are not considered 
candidates for standard cytotoxic chemotherapy [4]. Unfortunately, GO treatment is 
frequently associated with significant side-effects including severe hepatotoxicity and 
myelosuppression [5;6]. This and other observed toxicities may be attributable to the 
untimely off-target release of calicheamicin, the highly cytotoxic agent that is chemically 
coupled to the anti-CD33 antibody domain of GO via a rather unstable hydrolysable linker 
[7].
Overall, only a minority of AML patients benefits from GO treatment suggesting that AML 
stem cells are heterogeneous in their CD33 expression. Indeed various reports indicate 
that the CD34+/CD38- AML stem cells express variable amounts of CD33 [8;9]. Therefore, 
the curative elimination of AML may require novel agents that more effectively target 
and eliminate AML stem and progenitor cells with a more favorable toxicity profile. In 
this respect, C-type Lectin-Like Molecule-1 (CLL-1) appears to be attractive alternative 
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target antigen to CD33. CLL-1 is expressed in ~90% of the AML patients [10] in which 
expression appears to be retained under all conditions of treatment and disease [11]. In 
peripheral blood, both monocytes and granulocytes show moderate CLL-1 expression, 
while CLL-1 is completely absent in other tissues [10]. Importantly, CLL-1 is  expressed on 
the CD34+/CD38- AML stem cells and the CD34+/CD38+ AML progenitor cells, whereas it is 
not expressed on normal hematopoietic stem cells [11;12]. Interestingly, CLL-1 and CD33 
appear to complement each other as therapeutic targets, since 33% of the CLL-1- AML 
samples express CD33, and 67% of the CD33- samples express CLL-1 [10].
Previously, we reported on an alternative CD33-targeted anti-AML agent, designated 
scFvCD33:sTRAIL, in which an anti-CD33 scFv antibody fragment is genetically linked to 
sTRAIL [7]. TRAIL is a homotrimeric transmembrane protein that belongs to the TNF-
family of death ligands that also includes death ligand FasL.  In vivo, TRAIL and FasL can 
be proteolytically processed into soluble molecules (sTRAIL and sFasL, respectively). 
Several recombinant forms of sTRAIL and sFasL have been described that show 
promising pro-apoptotic activity against various forms of cancer including AML [10;11]. 
In this respect, TRAIL is of particular interest since it exclusively induces apoptosis in 
malignant cell types, while fully sparing normal cells. Our experiments with fusion protein 
scFvCD33:sTRAIL indicated that it is superior to GO in terms of in vitro selectivity, activity 
and stability, without any toxicity towards normal CD33+ monocytes [7]. 
The favorable expression profile of CLL-1 and the promising AML-selective activity of the 
scFvCD33:sTRAIL fusion protein prompted us to construct and pre-clinically evaluate two 
new fusion proteins with engineered specificity for CLL-1, designated scFvCLL-1:sTRAIL 
and scFvCLL-1:sFasL, respectively. Here, we present pre-clinical data indicating that 
these novel fusion proteins have promising tumor-restricted activity towards AML cell 
lines and primary AML cells, including the CD34+/CD38- AML stem cells and the CD34+/
CD38+ AML progenitor cells.  
MATERIAL AND METHODS
Antibodies and reagents
Antibodies and reagents used in this study are: PE-conjugated anti-TRAIL (Diaclone SAS, 
Besancon, France), PE-conjugated anti-FasL (Santa Cruz Biotechnology, Heidelberg, 
Germany), TRAIL-neutralizing mAb2E5 (Alexis, Kordia Life Sciences, Leiden, The 
Netherlands), FasL-neutralizing mAbAlf2.1 (Santa Cruz, Heidelberg, Germany), anti-
activated caspase-3 (asp175; Cell Signaling Technology, Leiden, the Netherlands), Goat-
anti-Rabbit-TRITC (Jackson ImmunoResearch Europe Ltd, Suffolk, England), magnetic 
bead-labeled anti-CD14 (Miltenyi Biotec, Bergisch Gladbach, Germany),  anti-CD34-APC 
and anti-CD38-PE (IQ-products, Groningen, The Netherlands). 
A stock solution (10mM) of 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5dione (TDZD-8, 
Sigma-Aldrich, Zwijndrecht, The Netherlands) was prepared in DMSO and stored -20˚C. 
TDZD-8 is a non-ATP competitive inhibitor of GSK-3β originally designed for the treatment 
of Alzheimer’s disease [13] that shows potent tumoricidal activity towards AML cells, 
including the CD34+/CD38- stem cell population [14].
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Monocytes, hepatocytes, cell lines and primary AML cells
All cells were cultured and maintained in RPMI 1640 (Cambrex, New Jersey, New Hampshire, 
USA) supplemented with 10% FCS, at 37ºC in humidified 5% CO2 containing atmosphere. 
Leukemia cell lines U-937 (AML, CLL-1+), HL-60 (AML, CLL-1+) and Ramos (B-CLL, CLL-
1-) were purchased from the ATCC (Manassas, USA). CLL-1+ transfectant Ramos cells 
(Ramos.CLL-1) were generated by electroporation with the eukaryotic expression plasmid 
pCLL-1-IRIS2-EGFP, containing a cDNA encoding CLL-1 and EGFP separated by an internal 
ribosome entry site (IRIS) sequence. Monocytes were isolated from healthy donors by 
standard density gradient centrifugation and subsequent magnetic bead separation of 
CD14+ cells. Primary hepatocytes were purchased from Tebu-Bio (Heerhugowaard, The 
Netherlands) and cultured according to the manufacturer’s recommendations. Primary 
AML tumor cells were obtained after informed consent from AML patients by isolation of 
peripheral blood mononuclear cells using standard density-gradient centrifugation (GE 
Healthcare, Diegem, Belgium).
 
Construction and production of fusion proteins scFvCLL-1:sTRAIL, scFvCLL-1:sFasL and 
chimeric minibody scFvCLL-1:Fc
The cDNA sequence of scFvCLL-1 was synthesized using standard splice-by-overhang-
extension PCR technology according to published VH and VL sequence data. The cDNA 
encoding scFvCD7 was removed from the previously described eukaryotic plasmids 
pEE14-scFvCD7:sTRAIL [15] and pEE14-scFvCD7:sFasL [16], using unique SfiI and 
NotI restriction enzyme sites. Standard recombinant DNA technology was used to 
insert cDNA encoding scFvCLL-1 yielding plasmids pEE14-scFvCLL-1:sTRAIL and pEE14-
scFvCLL-1:sFasL. Plasmids were transfected in CHO-K1 cells using the Fugene-6 reagent 
(Roche Diagnostics, Almere, The Netherlands). Stable transfectants were generated 
by the glutamine synthetase selection method [17]. This procedure generated CHO-K1 
production cell lines A17 and D58 that stably secreted the respective fusion protein 
into the culture medium (5.5μg/ml scFvCLL-1:sTRAIL and 260ng/ml scFvCLL-1:sFasL, 
respectively). A chimeric scFvCLL-1:Fc minibody was constructed by removing the cDNA 
encoding sTRAIL from plasmid pEE14-scFvCLL-1:sTRAIL using unique xhoI and HindIII 
restriction enzyme sites and subsequent replacement by a cDNA encoding the Fc domain 
of human IgG1 using standard recombinant DNA technology.
 
CLL-1 selective binding of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL
CLL-1 selective binding activity of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL was analyzed 
by flow cytometry (FACSCalibur, BD biosciences) In short, 1.0x106 Ramos.CLL-1 were 
incubate with either scFvCLL-1:sTRAIL (550ng/ml) or scFvCLL-1:sFasL (26ng/ml) in the 
absence or presence of the competing minibody scFvCLL-1:Fc (2.4µg/ml). Binding of the 
respective fusion proteins was detected by using either a PE-conjugated anti-TRAIL or 
a PE-conjugated anti-FasL mAb. In control experiments non-specific binding of fusion 
proteins was assessed using wild-type Ramos cells (CLL-1-) Incubations were performed 
for 45 minutes at 0°C and were followed by 2 washes with serum-free medium.
 
CLL-1 restricted apoptosis induction by scFvCLL-1:sTRAIL and scFvCLL-1:sFasL 
Various leukemia cells were seeded at 1.0x106 cells/ml in a 48-wells plate and treated 
for 24 hours with the indicated concentrations of scFvCLL-1:sTRAIL or scFvCLL-1:sFasL, 
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in the presence or absence of the competing minibody scFvCLL-1:Fc (2.4µg/ml) or the 
death ligand neutralizing mAb2E5 or mAbAlf2.1 (1µg/ml). Apoptosis was assessed as 
described below. 
 
Assessment of apoptosis induction 
The leukemia cells were seeded at density of 1.0x106 cells/ml in a 48-wells plate and 
subsequently treated for 24hours. Monocytes and hepatocytes were plated at a density 
of 3,5 x105 cell/ml in 96 wells plate and allowed to adhere for 24h. Subsequent adhered 
monocytes and hepatocytes were treated for 24h with scFvCLL-1:sTRAIL (550ng/ml) 
or scFvCLL-1:sFasL (26ng/ml). Induction of apoptosis was assessed using one of the 
following apoptosis assays: Exposure of phosphatidylserine (PS); The early apoptotic 
feature of exposure of phosphatidyl serine on the outer membrane was analyzed by 
flow cytometry using an AnnexinV-FITC (Nexins research, Kattendijke, The Netherlands) 
according to manufacturer’s instructions. Loss of mitochondrial membrane potential 
(∆Ψ ); ∆Ψ was analyzed by flow cytometry using the cell-permeant green-fluorescent 
lipophilic dye DiOC6 (Molecular Probes, Eugene, USA) essentially as described previously 
[15]. Caspase-3/7 activation; The hallmark apoptotic feature of caspase-3/7 activation, 
was measured using the caspase-Glo™ 3/7 assay kit (Promega, Mannheim, Germany) 
according to manufacturer’s protocol. Loss of viability; was determined with the MTS 
assay kit (Promega) according the manufacturer’s recommendations. The formation of 
formazan was analyzed by measuring the absorbance at 490nm using a Victor3 multilabel 
plate reader (Perkin Elmer, Groningen, The Netherlands). 
Percentage of experimental apoptosis was calculated using the following formula: 
specific apoptosis = (experimental apoptosis-spontaneous apoptosis)/ (100-spontaneous 
apoptosis) x 100%. 
Quantification of bystander activity of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL using mixed 
culture experiments 
Tumor progression and/or tumor heterogeneity frequently result in the appearance of 
tumor cells that no longer express the relevant target antigen. Consequently, these 
tumor cells are able to escape from conventional antibody-based approaches [18;19]. 
Figure 1. CLL-1-restricted binding by scFvCLL-1:sTRAIL and scFvCLL-1:sFasL. (A) Both 
scFvCLL-1:sTRAIL and (B) scFvCLL-1:sFasL bind strongly to Ramos.CLL-1 cells (solid line). This binding 
is inhibited by pre-incubation with the chimeric scFvCLL-1:Fc minibody (dashed line). Furthermore, 












Previously, we have demonstrated that our scFv:sTRAIL and scFv:sFasL fusion protein 
approach not only eliminates target antigen expressing tumor cells, but also exploits 
them to relay the pro-apoptotic activity towards neighboring tumor cells, including 
tumor cells that lack the relevant target antigen [7;16;20;21]. This anti-tumor activity 
is usually indicated by the term bystander activity. To quantify the bystander activity 
of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL we treated mixtures of CLL-1+ tumor cells 
and CLL-1- bystander tumor cells and subsequently evaluated apoptosis induction in 
both tumor cell populations separately. To this end Ramos.CLL-1 tumor cells and CLL-1- 
Ramos bystander tumor cells were differentially labeled using the Vybrant cell labeling 
solution (Invitrogen, Breda, The Netherlands). Ramos.CLL-1 (1.0x106 cells/ml) cells were 
labeled with 5µM DiO (Invitrogen, Breda, The Netherlands) for 5min at 37˚C in serum 
free medium, followed by three washes with culture medium. Next, labeled Ramos.CLL-
1 cells were mixed at 1:1 ratio with unlabelled Ramos bystander cells at a density of 
0.5x106 cells/well of a 48-wellsplate and treated with scFvCLL-1:sTRAIL. After incubation 
the cells were spotted on microscope slides and incubated with an antibody specific 
for activated caspase-3, followed by incubation with Goat-anti-Rabbit-TRITC. Cell nuclei 
were counterstained with DAPI (Sigma-Aldrich). Computer-coded fluorescent images 
were obtained using a standard fluorescence microscope (Leica DM-RxA, Leica Camera, 
Solms, Germany) equipped with a CCD camera (Leica DC350 Fx) and utilizing dedicated 
acquisition software (Leica QwinPro). 
For flowcytometric quantification of bystander activity, DiI-labeled (Invitrogen) Ramos.
CLL-1 target cells were mixed at a 1:1 ratio with unlabeled Ramos bystander cell and treated 
with either fusion protein. After treatment, the differential fluorescent characteristics of 
the two cell populations were used to separately assess the induction of apoptosis (∆Ψ) 
using flowcytometric analysis.
Treatment of primary AML cells with fusion protein scFvCLL-1:sTRAIL or scFvCLL-1:sFasL
From 10 AML patients, leukemic cells were freshly isolated and plated at a density of 
1.0x106 cells/ml of a 48-wellsplate. Primary AML cells were treated for 24h with either 
scFvCLL-1:sTRAIL (550ng/ml) or scFvCLL-1:sFasL (26ng/ml) alone or in combination with 
TDZD-8 (5μM). AnnexinV-FITC staining was performed to assess apoptosis induction in 
the total AML cell population. Apoptosis induction in CD34+/CD38- AML stem cell and 
CD34+/CD38+ AML progenitor cell populations was assessed by flowcytometric analysis 
using anti-CD34-APC, anti-CD38-PE and AnnexinV-FITC.
Assessment co-treatment with TDZD-8
The effect of co-treatment of the respective fusion proteins with TDZD-8 (5µM) was 
evaluated by calculating the cooperativity index (CI), in which the sum of the average 
apoptosis induction by single-agent treatment is divided by the average apoptosis 
induction upon co-treatment. CI was qualified as follows: CI <0.9, synergy; 0.9< CI <1.1, 
additive; CI >1.1, antagonistic. 
RESULTS
CLL-1-specific cell surface binding of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL.
The CLL-1-specific binding of scFvCLL-1:sTRAIL (Fig. 1A) and scFvCLL-1:sFasL(Fig. 1B) 
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was assessed by flowcytometry. Analysis of this data demonstrated CLL-1-specific 
accretion of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL at the cell surface of Ramos.CLL-1 
cells. Cell surface binding was inhibited by pre-incubation with the competing minibody 
scFvCLL-1:Fc. No binding of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL to Ramos cells (CLL-
1-) was observed. These data indicate that both scFvCLL-1:sTRAIL and scFvCLL-1:sFasL 
specifically bind to cell surface expressed CLL-1.
Figure 2. CLL-1-restricted apoptosis induction by scFvCLL-1:sTRAIL and scFvCLL-1:sFasL. 
Dose-dependent apoptosis induction in CLL-1+ U-937, HL-60 and Ramos.CLL-1 cells and no apoptosis 
induction in wild-type Ramos cells by (A) scFvCLL-1:sTRAIL (22ng/ml – 550ng/ml) or (B) scFvCLL-
1:sFasL (0.52ng/ml – 26ng/ml). (C) Apoptosis induction in U-937 cells by scFvCLL-1:sTRAIL (550ng/
ml) and scFvCLL-1:sFasL (26ng/ml) is strongly inhibited by either pre-incubation with the chimeric 
scFvCLL-1:Fc minibody or by incubation with a TRAIL or FasL neutralizing mAb (2E5 or Alf2.1, 
respectively). (D) Apoptosis induction in U-937 cells by scFvCLL-1:sTRAIL (550ng/ml) and scFvCLL-
1:sFasL (26ng/ml) is characterized by caspases-3/7activation. This caspase 3/7 activation is inhibited 
by pre-incubation with the chimeric scFvCLL-1:Fc minibody or by incubation with a TRAIL or FasL 
neutralizing mAb. In A, B and C apoptosis was assessed by analysis of Δψ, indicated values are means 
± SEM of at least three independent experiments.
CLL-1-restricted apoptosis induction by scFvCLL-1:sTRAIL and scFvCLL-1:sFasL.
Next, the apoptotic activity of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL towards CLL-1+ cell 
lines U-937, HL-60 and Ramos.CLL-1 cells was assessed. Both, scFvCLL-1:sTRAIL (Fig. 
2A) and scFvCLL-1:sFasL (Fig. 2B) dose-dependently (range 0-550ng/ml and 0-26ng/ml, 
respectively) induced apoptosis in the CLL-1+ leukemia cells only. The anti-tumor activity 
of scFvCLL-1:sTRAIL was strongly inhibited after pre-incubation with the competing 
minibody scFvCLL-1:Fc or the TRAIL-neutralizing mAb 2E5 (data shown for U-937 cells 
A B
C D


















































































































only). Likewise, the anti-tumor activity of scFvCLL-1:sFasL towards U-937 cells was 
strongly inhibited after pre-incubation with the competing minibody scFvCLL-1:Fc or the 
FasL-neutralizing mAbAlf2.1 (Fig. 2C). Additionally, the activation of caspases-3/7 was 
assessed as one of the hallmark features of the death ligand induced apoptotic pathway. 
Both, treatment with scFvCLL-1:sTRAIL or scFvCLL-1:sFasL resulted in a potent activation 
of caspase-3/7. This activation was inhibited when the cells were pre-treated with either 
minibody scFvCLL-1:Fc or the respective death ligand-neutralizing mAb (Fig. 2D). Taken 
together, these data demonstrate that both scFvCLL-1:sTRAIL and scFvCLL-1:sFasL 
potently induce target antigen-restricted apoptosis in CLL-1+ tumor cells. 
Figure 3. scFvCLL-1:sTRAIL and scFvCLL-1:sFasL convey apoptotic bystander activity 
towards CLL-1- tumor cells. (A) Immunofluorescence analysis of activated caspase-3 (red 
fluorescence) in mixed cultures of Ramos.CLL-1 target cells (green fluorescence) and wild-type (CLL-1-
) Ramos bystander cells. All cells were counterstained with the nuclear dye DAPI (blue fluorescence). 
In the left panel: absence of activated caspase-3 in untreated cells. In the middle panel: strong 
activation of caspases-3 in both the target cells and the bystander cells upon treatment with scFvCLL-
1:sTRAIL (550ng/ml). In the right panel: activation of caspases-3 by scFvCLL-1:sTRAIL is inhibited 
by incubation with the TRAIL neutralizing mAb 2E5. (B) Flowcytometric analysis of the apoptosis 
induction by scFvCLL-1:sTRAIL (550ng/ml) or scFvCLL-1:sFasL (26ng/ml) in mixed cultures containing 
Ramos.CLL-1 target cells and wild-type Ramos bystander cells. The bystander apoptosis induction by 
the fusion proteins is inhibited by incubation with the TRAIL and FasL neutralizing mAb’s (2E5 and 
Alf2.1, respectively). Apoptosis was assessed by analyzing Δψ. Indicated values are means ± SEM of 
at least three independent experiments. 
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Bystander apoptosis by scFvCLL-1:sTRAIL and scFvCLL-1:sFasL towards CLL-1- leukemia 
cells.
The bystander effect of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL is based on the principle 
that targeted CLL-1+ tumor cells are not only eliminated, but are also exploited to convey a 
therapeutic effect towards neighboring tumor cells that are devoid of CLL-1 expression.
Using a caspase-activatable fluorescent peptide and fluorescence microscopy strong 
activation of caspases-3 was visualized in CLL-1- bystander tumor cells (Fig. 3A) after 
treatment with scFvCLL-1:sTRAIL. Activation of caspase-3 was abrogated in both the 
target and bystander tumor cells when pre-treated with minibody scFvCLL-1:sTRAIL or 
the TRAIL-neutralizing mAb2E5.
Next, flowcytometric analysis was used to quantify the bystander activity of scFvCLL-
1:sTRAIL and scFvCLL-1:sFasL. A mixed tumor cell culture containing Ramos.CLL-1 
target cells and Ramos bystander cell was treated with scFvCLL-1:sTRAIL (550ng/ml) 
or scFvCLL-1:sFasL (26ng/ml). This analysis demonstrated potent bystander activity for 
both scFvCLL-1:sTRAIL and scFvCLL-1:sFasL fusion proteins towards CLL-1- leukemia cells 
(26.9±1.1% and 47.7±6.8% respectively). Furthermore, treatment in the presence of the 
relevant death ligand-neutralizing mAb inhibited bystander activity down to 1.7±0.8% 
and 3.0±0.5% respectively (Fig. 3B). 
Treatment of CLL-1+ normal monocytes and CLL-1- normal hepatocytes
Flowcytometric analysis demonstrated that normal resting CD14+ monocytes express 
significant levels of CLL-1 (Fig. 4A). However, treatment with scFvCLL-1:sTRAIL resulted in 
a minimal reduction in cell viability of the normal monocytes (3.5±6.0%) and a moderate 
reduction in viability by scFvCLL-1:sFasL (23.1±7.1%) (Fig. 4B). Flowcytometric analysis 
indicated that normal human hepatocytes do not express CLL-1 (Fig. 4C), Treatment with 
scFvCLL-1:sTRAIL and scFvCLL-1:sFasL did not reduce the viability of the hepatocytes 
(-11.9±6.0% and -4.0±1.8%, respectively) (Fig. 4D). 
Apoptosis induction in primary AML cells 
The anti-tumor activity of scFvCLL-1:sTRAIL (550ng/ml) and scFvCLL-1:sFasL (26ng/
ml) was assessed towards primary AML samples that were freshly derived from 10 
individual AML patients. The average apoptosis induction in these 10 samples by scFvCLL-
1:sTRAIL was 11.1±4.5% and 36.9±7.3% by scFvCLL-1:sFasL. In addition, we combined 
the scFvCLL-1:sTRAIL or scFvCLL-1:sFasL treatment of the 10 AML samples with 5µM 
TDZD-8. This co-treatment synergized the apoptosis induction of both fusion proteins 
For scFvCLL-1:sTRAIL this resulted in an average apoptosis induction of 41.3±14.0% 
(CI=0.65) and for scFvCLL-1:sFasL in 44.0±8.4% (CI=0.89) (Fig. 5A). 
Furthermore, since CLL-1 is also expressed on CD34+/CD38- AML stem cells and CD34+/
CD38+ AML  progenitor cells we analyzed apoptosis induction in these populations of 3 
AML samples. In the CD34+/CD38- AML stem cell population, treatment with scFvCLL-
1:sTRAIL resulted in an average apoptosis in 30.9±10.1% of the cells. The activity of 
scFvCLL-1:sFasL resulted in apoptosis in 22.4±8.4% of the CD34+/CD38- AML cells. 
Moreover, we also assessed the apoptosis induction in these CD34+/CD38- AML cells upon 
co-treatment with TDZD-8. Surprisingly, the apoptotic activity of both scFvCLL-1:sTRAIL 
and scFvCLL-1:sFasL was antagonized when combined with 5µM TDZD-8. For scFvCLL-
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1:sTRAIL this resulted in apoptosis in 31.4±13.6% (CI=1.39) of the CD34+/CD38- AML 
cells and  22.4±8.4% (CI=1.55) for scFvCLL-1:sFasL (Fig. 5B). 
In the CD34+/CD38+ progenitor cell population, the average apoptosis induction by 
scFvCLL-1:sTRAIL (550ng/ml) was 24.9±11.2% and 9.6±8.5% by scFvCLL-1:sFasL (26ng/
ml). In the CD34+/CD38+ AML progenitor cell population co-treatment with 5µM TDZD-8 
Figure 4. Assessment of the viability of CLL-1+ monocytes and CLL-1- hepatocytes upon 
incubation with  scFvCLL-1:sTRAIL or scFvCLL-1:sFasL. (A) Normal human CD14+ monocytes 
express CLL-1. (B) The viability of the monocytes is not reduced upon incubation with 550ng/ml 
scFvCLL-1:sTRAIL (3.5±6.0%) and moderate reduced by 26ng/ml scFvCLL-1:sFasL (23.1±7.1%). (C) 
Normal human Epidermal Growth Factor Receptor-positive (EGFR+) hepatocytes do not express CLL-1. 
(D) The viability of the hepatocytes is not reduced upon incubation with 550ng/ml scFvCLL-1:sTRAIL 
(-11.9±6.0%) 26ng/ml or scFvCLL-1:sFasL (-4.0±1.8%). Viability is assessed by the MTS-assay. 
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synergized the apoptotic activity of the fusion proteins. This synergistic activity resulted 
in an average apoptosis induction in 31.9±13.8% (CI =0.82) of the CD34+/CD38+ cells by 
scFvCLL-1:sTRAIL. The activity of scFvCL-1:sFasL in combination with TDZD-8 resulted in 
apoptosis in 20.7±7.0% (CI =0.53) of the CD34+/CD38+ cells (Fig 5C).  
DISCUSSION 
In order to achieve curative treatment of AML novel targeted approaches are needed that 
effectively eliminate all malignant cell types that are present in AML, including AML stem 
cells, AML progenitor cells, and target-antigen negative mutant AML cells, while sparing 
normal cells. 
Recently, it was uncovered that C-type Lectin-Like Molecule-1 (CLL-1) is expressed at 
the tumor cell surface in ~90% of the AML patients [10;12]. Unlike CD33, the CLL-1 
expression appears to be retained under all conditions of treatment and disease [11]. 
Importantly, CLL-1 is expressed on CD34+/CD38- AML stem cells and CD34+/CD38+ AML 
progenitor cells but not on normal hematopoietic stem cells [11]. 
This unique expression profile of CLL-1 prompted us to develop a novel targeted approach 
that aims for the safe and selective elimination of CLL-1+ malignant cells in AML. To 
this end, a CLL-1-specific antibody fragment (scFvCLL-1) was genetically fused to soluble 
forms of the pro-apoptotic proteins TRAIL (sTRAIL) and FasL (sFasL), yielding fusion 
proteins scFvCLL-1:sTRAIL and scFvCLL-1:sFasL, respectively.  
We selected pro-apoptotic proteins sTRAIL and sFasL for this purpose because of their 
potent intrinsic anti-tumor activity. In this respect, sTRAIL appears to be a particularly 
promising since it has potent pro-apoptotic activity towards AML cells, while fully sparing 
normal cells.  
Flowcytometric analysis demonstrated strong and specific binding for both scFvCLL-
1:sTRAIL and scFvCLL-1:sFasL to cell surface-expressed CLL-1 on AML cells that could 
be inhibited by the competing minibody scFvCLL-1:Fc. Moreover, both scFvCLL-1:sTRAIL 
and scFvCLL-1:sFasL showed strong CLL-1-restricted pro-apoptotic activity towards 
CLL-1+ AML cell lines and to Ramos tumor B cells that ectopically expressed CLL-1. The 
anti-tumor activity of scFvCLL-1:sTRAIL was strongly inhibited after pre-treatment with 
the competing minibody scFvCLL-1:Fc or the TRAIL-neutralizing mAb2E5. Likewise, the 
anti-tumor activity of scFvCLL-1:sFasL was strongly inhibited after pre-treatment with 
scFvCLL-1:Fc or the FasL-neutralizing mAbAlf2.1. Both treatment with scFvCLL-1:sTRAIL 
or scFvCLL-1:sFasL of AML cells resulted in a potent activation of caspase-3/7, one of 
the hallmark features of the death ligand induced apoptotic pathway. Taken together, 
these data demonstrate that both scFvCLL-1:sTRAIL and scFvCLL-1:sFasL potently induce 
target antigen-restricted apoptosis in CLL-1+ tumor cells. 
It has been reported that target antigen-negative leukemia cells can escape from 
conventional antibody-based therapeutic approaches [18;19]. Previously, we have 
demonstrated that scFv:sTRAIL and scFv:sFasL fusion proteins have potent anti-tumor 
bystander activity [7;16;20;21]. This anti-tumor bystander activity is based on the fact 
that these fusion proteins not only eliminate the respective target antigen-positive tumor 
cells, but also convey potent apoptotic signals towards neighboring tumor cells that are 
devoid of this target antigen. Here, we demonstrate similar promising bystander activities 
for fusion proteins scFvCLL-1:sTRAIL and scFvCLL-1:sFasL. In mixed culture experiments, 
140
CHAPTER 8
in which CLL-1+ target tumor cells and CLL-1- bystander tumor cells were mixed at a ratio 
of 1:1, fusion protein scFvCLL-1:sTRAIL eliminated up to 27% of the CLL-1- bystander 
tumor cells. 
At the same target to bystander tumor cells ratio a bystander effect of up to 48% was 
observed for fusion protein scFvCLL-1:sFasL. The potent bystander activity observed for 
both fusion proteins may help to prevent the escape of CLL-1-negative tumor cells from 
CLL-1-targeted therapy.
Figure 5. Apoptosis induction in the total AML cell population and in CD34+/CD38- and 
CD34+/CD38+ AML cells. (A) Total population of AML cells, (B) CD34+/CD38- AML stem cells and 
(C) CD34+/CD38+ AML progenitor cells were treated either alone with scFvCLL-1:sTRAIL (550ng/
ml) or scFvCLL-1:sFasL (26ng/ml) or in combination with 5µM TDZD-8. Apoptosis was assessed by 
AnnexinV-FITC staining
Subsequently, we assessed the activity of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL 
towards normal human cells. In contrast to GO, normal human CLL-1+ monocytes proved 
to be fully resistant to treatment with scFvCLL-1:sTRAIL and only moderately sensitive 
to treatment with scFvCLL-1:sFasL (23.1±7.1%). In addition, primary normal human 
hepatocytes appeared to be fully resistant to both scFvCLL-1:sTRAIL and scFvCLL-1:sFasL. 
The absence of activity towards CLL-1+ monocytes and CLL-1- hepatocytes indicates a 
favorable toxicity profile for both scFvCLL-1:sTRAIL and scFvCLL-1:sFasL.  
Next, we assessed the ex vivo activity of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL towards 
primary patient-derived AML cells. Treatment with either scFvCLL-1:sTRAIL or scFvCLL-
1:sFasL resulted in an induction of apoptosis in 10 out of 10 primary AML samples 
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Previously, the GSK-3β inhibitor TDZD-8 has been shown to induce apoptosis in AML 
cells, including the CD34+/CD38- AML stem cells[14]. In all patient-derived AML samples 
tested in our study the anti-tumor activity of both scFvCLL-1:sTRAIL and scFvCLL-1:sFasL 
was synergistically enhanced when treatment was performed in the presence of TDZD-8 
(41.3±14.0%; CI=0.65 and 44.0±8.4%; CI=0.89, respectively). This suggests that the 
anti-AML activities of both scFvCLL-1:sTRAIL and scFvCLL-1:sFasL may be significantly 
enhanced when used in combination with other anti-AML drugs.
Currently, the concept is generally accepted that CD34+/CD38- AML stem cells and CD34+/
CD38+ AML progenitor cells are the root of recurrences in AML patients. Therefore, the 
selective elimination of these cells is imperative in order to achieve curative therapy 
[22;23]. Unfortunately, AML stem cell populations appear to be particularly resistant to 
conventional therapeutic approaches. To address this issue we assessed the activity of 
scFvCLL-1:sTRAIL and scFvCLL-1:sFasL towards CD34+/CD38- AML stem cells and CD34+/
CD38+ AML progenitor cells in three patient-derived AML samples. Both scFvCLL-1:sTRAIL 
and scFvCLL-1:sFasL proved to have marked anti-tumor activity towards CD34+/CD38- 
AML stem cells (30.9±10.1% and 22.4±8.4%, respectively) and the CD34+/CD38+ AML 
progenitor cells (24.9±11.2% and 9.6±8.5%, respectively). 
These results indicate that AML blasts are more sensitive to treatment with scFvCLL-
1:sFasL than  CD34+/CD38- AML stem cells (36.9±7.3% and 22.4±8.4%, respectively). 
Conversely, CD34+/CD38- AML stem cells appeared to be more sensitive to treatment 
with scFvCLL-1:sTRAIL than AML blast cells (30.9±10.1% and 11.1±4.5%, respectively). 
The observed differential sensitivity of CD34+/CD38- AML stem cells for scFvCLL-1:sTRAIL 
may be explained by the reported upregulated expression of TRAIL-R1 and TRAIL-R2 on 
the CD34+/CD38- AML stem cells [24]. 
Taken together our data indicates that in single agent treatment schemes both 
scFvCLL-1:sTRAIL and scFvCLL-1:sFasL show promising activity towards patient-derived 
CD34+/CD38- AML stem cells and CD34+/CD38+ AML progenitor cells. Previously, Guzman 
et al. reported that treatment with TDZD-8 induced rapid and selective death in both 
CD34+/CD38- AML stem cells  and CD34+/CD38+ AML progenitor cells [14]. Therefore, 
we assessed whether the activity of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL towards the 
AML stem cells and AML progenitor cells could be synergized by TDZD-8 co-treatment. 
Our data indicate that CD34+/CD38+ AML progenitor cells are indeed more sensitive 
when treatment with scFvCLL-1:sTRAIL or scFvCLL-1:sFasL is combined with TDZD-8 
(31.9±13.8%; CI=0.82 and 20.7±7.0%; CI=0.53, respectively). Intriguingly, for unknown 
reasons, no enhanced effect of combination treatment with TDZD-8 was observed 
towards CD34+/CD38- AML stem cells. 
In conclusion, we devised a novel CLL-1 targeted approach that may be of value for the 
effective elimination of the major malignant cell types that are present in AML, including 
AML stem cells and AML progenitor cells, while sparing normal cells such as CLL-1+ 
monocytes and CLL-1- normal hepatocytes.  Moreover, the anti-tumor bystander activity 
of these fusion proteins may help to prevent the emergence of CLL-1- AML mutant cells. 
Furthermore, the single agent activity of scFvCLL-1:sTRAIL and scFvCLL-1:sFasL may 
be enhanced by combination treatment with novel anti-AML small inhibitory molecules 
such as TDZD-8. Further pre-clinical development of both scFvCLL-1:sTRAIL and scFvCLL-
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The studies described in this thesis aim to selectively target and eliminate the malignant 
cell types as present in various forms of leukemia’s and lymphoma’s. To this end, we 
developed and pre-clinically assessed a series of novel recombinant fusion proteins in 
which a leukemia-selective scFv antibody fragment is genetically fused to soluble forms 
of the pro-apoptotic death ligands TRAIL or FasL. The various scFv:death ligand  fusion 
proteins described were all designed to induce apoptosis by cross-linking of agonistic 
death receptors on tumor cells only after their specific binding to a predefined leukemia-
associated cell surface antigen.
The data presented indicate that this approach appears to be highly efficient in eliminating 
cell lines as well as patient-derived tumor samples derived from several forms of 
leukemia’s and lymphoma’s.
Despite advances in T-cell leukemia therapy, only a minority of patients achieves long 
term tumor-free survival with conventional chemotherapy at the cost of significant and 
often irreversible toxic side effects. Therefore, we developed a scFv:sFasL fusion protein 
for the selective delivery of sFasL to the T-cell leukemia associated antigen CD7, which 
we report in chapter 2. In normal cells CD7 expression is limited to T- and myeloid cells 
in early hematopoietic cell ontogeny, thymocytes, NK cells, and to a distinct subset 
of peripheral blood T-cells. However, due to the abundant expression of CD7 on acute 
T cell leukemia, CD7 has been utilized for the targeted delivery of several mAb-toxin 
conjugates in both pre-clinical studies and clinical trials [1;2]. 
Our experiments demonstrate that soluble homotrimeric scFvCD7:sFasL is inactive and 
acquires tumoricidal activity only after specific binding to tumor cell surface-expressed 
CD7. Treatment of T-ALL cell lines and patient-derived T-ALL, PTCL, and CD7-positive AML 
cells with homotrimeric scFvCD7:sFasL revealed potent and CD7-restricted apoptosis 
induction that could be augmented by various anti-cancer drugs. Importantly, identical 
treatment did not affect normal human PBLs and endothelial cells. Interestingly, 
scFvCD7:sFasL also showed apoptotic activity towards a subset of normal CD7+ activated 
T cells. In this respect, it is well established that fratricidal Fas/FasL interactions between 
activated T-cells are paramount to the effective resolution of an immune response [3]. 
Therefore, scFvCD7:sFasL may also be utilized for the targeted elimination of pathogenic 
T-cells in autoimmune disease.  Currently, we are assessing the activity of scFvCD7:sFasL 
towards pathogenic and activated synovial T cells isolated from Rheumatoid Arthritis 
patients.
In chapter 3 we studied a mode of action of the CD20-specific monoclonal antibody 
Rituximab. CD20 is a cell surface antigen that is highly expressed on malignant B-cells. 
The biological function of CD20 is currently largely unknown, but CD20 appears to be 
active in pro-apoptotic cell signaling events inside cell surface microdomains (rafts)[4]. 
Rituximab is currently applied in the clinic for the targeted elimination of malignant 
B-cells [5]. The elimination by Rituximab occurs via three distinct mechanisms, Antibody 
Dependent Cellular Cytotoxicity (ADCC), Complement Dependent Cytotoxicity (CDC) and 
CD20-mediated apoptotic signaling [6]. In this study, we demonstrate that Rituximab 
sensitizes lymphoma B cells to Fas-induced apoptosis in a caspase-8-dependent manner. 
However, blocking the death receptor ligands Fas ligand or TRAIL, using neutralizing 




is not involved in CD20-mediated cell death. Instead, we demonstrate that Rituximab-
induced apoptosis involves membrane clustering of Fas molecules that leads to formation 
of the death-inducing signaling complex (DISC) and downstream activation of the death 
receptor pathway. In addition, treatment with Rituximab resulted in lateral translocation 
and clustering of CD20 and Fas at the membrane in raft-like microdomains, resulting 
in the formation of a functional death-inducing signaling complex, and thus functional 
sensitization toward Fas-induced apoptosis induction.
Although, Rituximab has markedly improved clinical responses in non-Hodgkin lymphoma 
(NHL) it is often not curative. This is exemplified by the primary refractory disease or 
the development of relapses after treatment with Rituximab in approximately 50% of 
patients with aggressive B-NHL [7]. Furthermore, the efficiency of Rituximab treatment of 
B-chronic lymphocytic leukemia (B-CLL) patients is limited. Since, we have demonstrated 
that Rituximab sensitizes lymphoma B cells to Fas-induced apoptosis, we designed a 
strategy to exploit and optimize the synergy between Rituximab and Fas-signaling, which 
is reported in chapter 4. Thereto, we genetically fused a Rituximab-derived antibody 
fragment to sFasL, yielding fusion protein scFvRit:sFasL. In this study we demonstrate 
that scFvRit:sFasL efficiently activated CD20- and Fas-apoptotic signaling, resulting in 
a far superior pro-apoptotic activity in comparison to co-treatment with Rituximab and 
Fas-agonists. Importantly, scFvRit:sFasL potently induced CD20-restricted apoptosis 
in a panel of malignant B-cell lines and primary patient-derived malignant B-cells (2/2 
NHL and 5/6 B-CLL). In contrast, scFvRit:sFasL lacked activity towards normal human 
B-cells and lacked systemic toxicity in nude mice. In conclusion, the simultaneous and 
synergistic activation of CD20- and Fas-apoptotic signaling by scFvRit:sFasL provides a 
novel and promising therapeutic approach for the elimination of malignant B-cells.
Next, we focused on antibody-based targeted therapy for AML. Currently, the five-year 
survival rate of patients diagnosed with AML is only a dismal 20-30%. This low survival 
rate is partly due to therapy-related mortality and the frequent occurrence of therapy-
resistant relapses [8]. Conventional treatment of AML consists of intense chemotherapeutic 
regimens, which is especially poorly tolerated in elderly patients. Therefore a subset of 
AML patients is treated with the CD33-targeted immunotoxin Gemtuzumab Ozogamicin 
(GO). GO comprises an anti-CD33 specific monoclonal antibody that is chemically linked 
to the potent toxin calicheamicin via a rather instable hydrolysable linker. CD33 is a cell 
surface antigen which is highly expressed on AML blasts in approximately 85% of the AML 
patients. Upon binding of GO to CD33, the immunoconjugate-antigen complex internalizes 
and ends up in the lysosomes. In the acidic milieu of the lysosomes the hydrolysable 
linker of GO is cleaved, whereupon the calicheamicin translocates to the nucleus. In 
the nucleus, calicheamicin intercalates in the minor groove of the DNA double-helix and 
induces sequence-specific double-strand DNA breaks, ultimately resulting in apoptotic 
cell death [9]. However, GO treatment is associated with dose-limiting toxicity, including 
hepatotoxicity and severe myelosuppression [10]. Therefore, combinatorial approaches 
of GO with other therapeutics in order to achieve enhanced tumoricidal activity with 
reduced toxicity is warranted.
In chapter 5, we describe a novel combinatorial approach for the treatment of CD33+ 
AML, consisting of GO and Valproic Acid (VPA). VPA is a drug that is safely being used for 
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the treatment of seizures. However, recently it became apparent that VPA also exhibited 
anti-AML activity. In addition, it was demonstrated that VPA functions as a histone 
deacetylase inhibitor (HDACi). Treatment of cells with HDACi results in a hyper-acetylated 
state of histones, which is characterized by a more open chromatin structure [11]. 
Therefore, we hypothesized that VPA treatment of CD33+ AML cells should augment GO 
induced apoptosis by facilitating calicheamicin intercalation in the DNA. Our experiments 
demonstrate that clinically relevant concentrations of VPA potently augmented the 
tumoricidal activity of GO towards AML cell lines and primary AML blasts. Moreover, VPA 
treatment indeed augmented the DNA intercalation of calicheamicin and enhanced DNA 
degradation. Since both therapeutic agents are well documented and clinically available 
the proposed combination treatment of GO and VPA could enter clinical trials rapidly.
In chapter 6 we report on a novel anti-leukemia agent, designated scFvCD33:sTRAIL, in 
which an anti-CD33 scFv antibody fragment is genetically linked to soluble TRAIL (sTRAIL). 
ScFvCD33:sTRAIL was designed to have potent and CD33-restricted anti-leukemia pro-
apoptotic activity with no or minimal activity towards normal cells. In this study, we 
compared the in vitro selectivity, activity, and stability of scFvCD33:sTRAIL with GO. In 
this respect, the EC50 for apoptosis induction in CD33+ AML cells by scFvCD33:sTRAIL 
was calculated to be 2.2nM, whereas the EC50 for GO was 71.3nM. Indicating that the 
apoptotic activity of scFvCD33:sTRAIL was up to 30-fold higher than GO. A prominent 
toxic side effect of GO treatment comes from the fact that not only malignant but also 
all normal CD33+ cells, such as monocytes, are targeted for destruction. Therefore, 
we compared toxicity of scFvCD33:sTRAIL and GO towards freshly isolated human 
monocytes. Treatment with scFvCD33:sTRAIL showed no signs of toxicity, whereas 
treatment with GO resulted in a marked induction of apoptosis in ~30% of the monocytes. 
Furthermore, the anti-leukemia activity of GO critically relies on the timely intracellular 
release of the calicheamicin after internalization into CD33+ tumor cells. However, the 
linker technology used in GO yields conjugates of rather poor thermostability, which can 
result in the inadvertently release of calicheamicin in the circulation and subsequent 
systemic toxicity due to CD33-independent uptake of calicheamicin in normal cells and 
tissues [12]. Therefore, we compared the thermostability and associated untargeted 
toxicity of scFvCD33:sTRAIL and GO by storing them for up to 72h at 37ºC. This revealed 
that CD33- MOLT-16 cells were fully resistant to scFvCD33:sTRAIL from all storage time 
points evaluated, whereas treatment with identically stored GO resulted in a steep time-
dependent apoptosis induction. In addition, we analyzed the activity of scFvCD33:sTRAIL 
towards patient-derived AML samples which indicated a potent apoptosis induction 
apoptosis in 3 out of 3 samples. This activity of scFvCD33:sTRAIL could be further 
enhanced by combination with experimental and conventional AML therapeutics. Together 
this indicates that the further pre-clinical testing of scFvCD33:sTRAIL for the treatment 
of CD33+ AML is warranted.
Despite recent advances, treatment of leukemia is often not curative. New insights 
indicate that this may be attributable to a small population of therapy-resistant 
malignant cells with self-renewal capacity and the ability to generate large numbers of 
more differentiated leukemia cells [13]. These leukemia-initiating cells are commonly 




relapses observed in patients. The chemo-resistance of LSCs is thought to arise from 
their relative quiescent cellular activity, their array of self-protecting mechanisms and the 
highly protective microenvironment in which they reside. However, for curative treatment 
it appears to be essential to also specifically target and eliminate LSCs [14]. In chapter 
7 we reviewed current progress and perspectives for the elimination of these LSCs. A 
possible therapeutic approach for the elimination of LSCs includes targeting cell surface 
molecules which are selectively over-expressed on LSCs. Thus far, several of those cell 
surface antigens are identified on these LSCs, including CD33 and C-type Lectin-Like 
Molecule-1 (CLL-1) [15-20]. Importantly, it has been demonstrated that LSCs have a 
high cell surface expression of death receptors [21;22]. Therefore, it seems feasible 
to target and eliminate LSCs with scFv:death ligand fusion proteins. In this respect, in 
chapter 8 we describe the activity of two CLL-1-targeted fusion proteins towards AML-
LSCs, designated scFvCLL-1:sTRAIL and scFvCLL-1:sFasL Recently, the expression of the 
cell surface molecule C-type Lectin-Like Molecule-1 (CLL-1) was identified in 92% of 
the AML patients. Importantly, CLL-1 is also expressed on CD34+/CD38- AML stem cells 
and not expressed on normal hematopoietic stem cells and non-hematopoietic tissue 
[17;23]. Moreover, this expression profile is retained under all conditions of treatment 
and disease [17]. Both fusion proteins potently induced CLL-1-restricted apoptosis in AML 
cell lines and primary AML cells. Moreover, CD34+/CD38- AML stem cells were sensitive 
to treatment with scFvCLL-1:sTRAIL and scFvCLL-1:sFasL. In conclusion, treatment with 
scFvCLL-1:sTRAIL and scFvCLL-1:sFasL results in AML-restricted apoptosis including the 
CD34+/CD38- AML LSCs. 
CONCLUDING REMARKS AND PERSPECTIVES
Targeted approaches using antibody-based therapeutics have the potential to eliminate 
leukemia cells both efficiently and safely. The activity of antibody-based therapeutics is 
exemplified by the improved clinical responses observed upon treatment with targeted 
therapeutics such as Rituximab and GO. This promise of antibody-based therapeutics 
for novel therapies has been the driving force for the identification of several leukemia-
associated target antigens and tumoricidal moieties. In this respect, the studies 
described in this thesis clearly demonstrate the feasibility of scFv:death ligand fusion for 
the targeted elimination of leukemia cells. 
The discovery of chemo-resistant LSCs being the root of different forms of leukemia has 
generated new insights for leukemia therapy [24-26]. However due to the typical low 
abundance of LSCs, high throughput screening of potential LSCs therapeutics is particular 
difficult. Therefore, sensitive and robust techniques for the assessment of therapeutics 
using only a few cells are necessary. In this respect advances in fluorescence microscopy 
allow for live tracking of apoptosis in a single cell [27]. A disadvantage of this technique 
is that the cells have to remain in the focal plane of the microscope, which hampers 
its utility for the tracking of non-adherent cells. However, developments in lithographic 
techniques have resulted in the generation of microfluidic devices which can trap single 
cells [28]. By this means the apoptosis induction in a single LSC can be assessed using 
fluorescence microscopy [29;30]. In addition, novel mass spectrometry applications can 
be used for immunoassay-based analysis of single cells. An advantage of this type of 
mass spectrometry over fluorescence microcopy is that more antigens can be labeled 
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and assessed simultaneously, since mass spectrometry is not limited by spectral overlap 
of fluorescence substrates as is the case in fluorescence microscopy [31]. 
Another challenge for the targeted elimination LSCs is the highly protective and 
difficult to access micro-environment in which LSCs reside. In this respect, it has been 
demonstrated that the interaction of leukemia cells with their niche results in a reduced 
sensitive to therapeutics, a process known as cell adhesion-mediated drug resistance 
[32]. Interference in these interactions between leukemia cells and their niche has 
been shown to sensitize leukemia cells to therapeutics [33;34]. Therefore, elucidation 
of the interactions of LSCs with their niche might offer valuable new insights. Recently, 
techniques have been developed which allow for the real-time visualization of LSCs in 
their microenvironment [35-37]. Using these techniques new approaches for the targeted 
elimination of LSCs in their niche can be assessed. 
Finally, due to the increased expression of death receptors on LSCs as compared with 
normal HSCs [21;22], the targeted activation of these death receptors appears to be a 
promising approach. In chapter 8 we demonstrate proof-of-concept that AML-LSCs can 
indeed be eliminated by targeted activation of the death receptors using scFv:sTRAIL 
and scFv:sFasL fusion proteins. Since, LSCs have an array of self-protecting mechanisms 
it is likely that multifaceted therapy combining several strategies will appear to be the 
most effective approach. Therefore, high throughput screening and real-time in vivo 
analysis of scFv:death ligands fusion proteins combined with other therapeutics for 
multi-modality targeting of LSCs is warranted.
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In een gezond beenmerg worden continu nieuwe bloedcellen aangemaakt. Dit proces 
wordt hematopoiese genoemd en zorgt ervoor dat er voortdurend voldoende van alle 
verschillende soorten bloedcellen aanwezig zijn. Hematopoiese verloopt via meerdere 
opeenvolgende stappen. Aan het begin van hematopoiese staan de hematopoietische 
stamcellen (HSCs). Deze cellen hebben onder andere de unieke capaciteit om te 
differentiëren in alle verschillende bloedcellen. Hiertoe delen HSCs asymetrisch waarbij 
enerzijds een nieuwe HSC wordt gevormd en anderzijds een iets meer gedifferentieerde 
dochtercel, de hematopoietische progenitor cel (HPC). Door deze asymetrische celdeling 
blijft de populatie van HSCs bestaan en worden nieuwe cellen gevormd. De HPCs delen op 
hun beurt via symetrische celdeling verder waarbij twee identieke dochtercellen gevormd 
worden. Deze dochtercellen delen vervolgens ook weer via een symetrische deling en 
doordat deze cyclus meerdere keren wordt herhaald worden grote aantallen nieuwe 
cellen gevormd. Een belangrijke eigenschap is dat de nieuw gevormde dochtercellen 
steeds verder gedifferentieerd zijn richting een specifiek bloedceltype. 
De ontwikkeling van niet uitgerijpte bloedcellen tot een volledig gedifferentieerde en 
volwassen bloedceltype gebeurt in de twee verschillende hoofdlijnen van hematopoietische 
ontwikkeling. In de lymphatische lijn worden bepaalde witte bloedcellen zoals de T cellen, 
B cellen en NK cellen gevormd. In de myeloïde lijn van de ontwikkeling worden de vele 
andere soorten witte bloedcellen gevorm zoals de granulocyten en de monocyten, maar 
ook de rode bloedcellen en de bloedplaatjes.  Normaal verloopt de hematopoiese zonder 
problemen en is er altijd voldoende van elke celtype aanwezig. Echter, als gevolg van 
bijvoorbeeld genetische mutaties kan de hematopoiese ernstig verstoord raken, zoals 
het geval is bij leukemie.
Deze genetische mutaties kunnen in verschillende stadia van de hematopoiese optreden, 
hetgeen zich lijkt te weerspiegelen in de grote verscheidenheid aan verschillende soorten 
leukemie. De acute leukemieën worden gekenmerkt door een hele snelle aanmaak van 
niet of weinig uitgerijpte bloedcellen. Een heersend denkbeeld is dat hierbij zoveel maligne 
cellen gevormd worden dat er nauwelijks nog gezonde bloedcellen worden aangemaakt. 
Het verloop van chronische leukemie is een stuk langzamer en wordt gekenmerkt door 
de ongecontroleerde aanmaak van meer gedifferentieerde cellen. Echter, na verloop van 
tijd zijn in chronische leukemie zoveel leukemische cellen aangemaakt dat ook hier een 
groot deel van de bloedcellen bestaat uit maligne cellen. Doordat acute en chronische 
leukemie zowel in de lymphatische lijn als in de myeloïde lijn kunnen ontstaan zijn er 
vier hoofdcategorieën leukemie te onderscheiden, Acute Lymphatische Leukemie (ALL), 
Chronische Lymphatische Leukemie (CLL), Acute Myeloïde Leukemie (AML) en Chronische 
Myeloïde Leukemie (CML). Een verdere categorisatie van leukemie kan o.a. worden 
gemaakt op basis van het specifieke celtype dat betrokken is in de leukemie, bijvoorbeeld 
T-cel Acute Lymphatische Leukemie (T-ALL) of B-cel Chronische Lymphatische Leukemie 
(B-CLL).
De meeste therapieën voor leukemie zijn erop gericht om de sneldelende leukemische cellen 
te elimineren. Dit gebeurt meestal met behulp van chemotherapie en/of radiotherapie. 
Helaas hebben deze therapieën veel schadelijke en soms zelfs dodelijke bijwerkingen 
doordat ook vele gezonde cellen beschadigd of geëlimineerd worden. Daarom wordt er 
veel onderzoek gedaan naar nieuwe behandelmethodes die specifiek de leukemiecellen 
kunnen uitschakelen. Een veelbelovende methode is het gebruik van antilichamen die 




kunnen binden. Als een antilichaam gebonden is aan een leukemische cel kan dit er toe 
leiden dat deze cel wordt geëlimineerd en opgeruimd door het eigen immuunsysteem. 
Het immuunsyteem gebruikt hiervoor twee methodes die antilichaam-afhankelijke cel-
gemedieerde cytotoxiciteit (ADCC) en complement-afhankelijke cytotoxiciteit (CDC) 
worden genoemd. Het eerste antilichaam die voor deze vorm van gerichte therapie werd 
toegepast is Rituximab. Inmiddels worden vele verschillende anti-kanker antilichamen 
met succes in de kliniek toegepast. Echter, het therapeutische effect van antilichamen 
kan zeker nog verbeterd worden. Dit kan door bijvoorbeeld celdodende eiwitten te 
koppelen aan antilichamen of antilichaamfragementen. Op deze manier is het mogelijk 
om celdodende eiwitten specifiek af te leveren bij leukemiecellen. Er zijn verschillende 
manieren waarop een cel gedood kan worden. Echter de meest veelbelovende methode 
voor therapeutische doeleinden is de inductie van geprogrammeerde celdood. Deze vorm 
van celdood wordt ook wel apoptose genoemd. Een groot voordeel van apoptose is dat 
de cel op een gecontroleerde manier wordt opgeruimd met weinig of geen negatieve 
gevolgen voor het lichaam. De optimalisatie van bestaande en de ontwikkeling van 
nieuwe eiwitten voor de gerichte inductie van apoptose in leukemiecellen is het doel van 
de studies beschreven in dit proefschrift. 
Apoptose inductie wordt door cellen van het immuunsysteem gebruikt voor het opruimen 
van cellen die niet meer gewenst zijn. Dit kunnen cellen zijn die te oud zijn en plaats moeten 
maken voor nieuwe cellen. Echter, ook cellen die geïnfecteerd zijn met virussen of cellen 
die (pre-)maligne veranderingen laten zien worden op dezelfde manier geëlimineerd. Om 
apoptose te induceren hebben de cellen van het immuunsysteem enkele gespecialiseerde 
eiwitten op hun celoppervlak, zoals TRAIL en FasL. Deze eiwitten zijn normaal gesproken 
gebonden aan het oppervlakte van de immuuncellen. Echter, TRAIL en FasL kunnen 
ook losgeknipt worden en komen dan vrij als oplosbare (soluble) moleculen, en worden 
aangeduid met sTRAIL en sFasL. Met behulp van moleculair biologische technieken is 
het mogelijk om sTRAIL, sFasL en andere apoptose inducerende eiwitten na te bouwen 
en vervolgens genetisch te koppelen aan antilichamen en antilichaamfragmenten die 
eiwitten op leukemische cellen kunnen herkennen. Zodoende ontstaan fusie-eiwitten die 
geschikt kunnen zijn voor de gerichte apoptose inductie in leukemiecellen. Hieronder 
volgt een samenvatting van de resultaten behaald in de studies uitgevoerd in het kader 
van de gerichte apoptose inductie in verschillende vormen van leukemie.
In hoofdstuk 2 beschrijven we een nieuw fusie-eiwit dat ontworpen werd om sFasL 
selectief af te leveren aan cellen die het oppervlakte molecuul CD7 tot expressie 
brengen. CD7 is een eiwit waarvan de expressie normaal gelimiteerd is tot enkele 
bloedcellen, zoals NK cellen en geactiveerde T cellen. Echter, in veel gevallen van T-cel 
Acute Lymphatische Leukemia komt CD7 erg hoog tot expressie op het oppervlakte van 
de leukemiecellen. Door een anti-CD7 antilichaamfragment (scFvCD7) te koppelen aan 
sFasL werd een CD7-gerichte pro-apoptotische eiwit scFvCD7:sFasL. Uit de experimenten 
blijkt dat scFvCD7:sFasL in staat is om specifiek en zeer potent apoptose te induceren 
in T-ALL cellijnen en cellen geïsoleerd uit T-ALL patiënten. Verder bleken de meeste 
normale celtypen ongevoelig te zijn voor scFvCD7:sFasL. De enige normale celtype die 
wel gevoelig bleek voor scFvCD7:sFasL waren geactiveerde T cellen. Dit is te verklaren 
doordat geactiveerde T cellen CD7 tot expressie brengen en dat ze normaliter worden 
opgeruimd door middel van FasL-geïnduceerde apoptose op het moment dat ze niet 
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meer nodig zijn. Omdat geactiveerde T cellen ook een pathologische rol spelen in enkele 
auto-immuun ziekten zoals Rheumatoïde Arthritis zou scFvCD7:sFasL wellicht een 
therapeutisch effect kunnen hebben in dergelijke ziekten. 
In hoofdstuk 3 beschrijven we een studie uitgevoerd aan het antilichaam Rituximab, die 
het oppervlakte eiwit CD20 herkent. In zowel Non-Hodgkin Lymphoma en B-cel leukemieën 
komt CD20 erg hoog tot expressie en daarom wordt in deze ziekten Rituxmab frequent 
toegepast als therapie. Binding van Rituximab resulteert in de eliminatie van de CD20-
positieve maligne cellen via antilichaam-afhankelijke cel-gemedieerde cytotoxiciteit 
(ADCC) en complement-afhankelijke cytotoxiciteit (CDC). Echter, Rituximab kan ook na 
binding aan CD20 apoptose induceren in leukemische cellen. Het mechanimse achter 
deze apoptose signalering van Rituximab via CD20 is nog niet volledige begrepen. Tot 
dusver is het al wel bekend dat binding van Rituximab aan CD20 ervoor zorgt dat CD20 
zich verplaatst in het celmembraan naar gebieden die rafts worden genoemd. In deze 
rafts worden verscheidene eiwitten dicht bij elkaar in de buurt gebracht, hetgeen leidt tot 
een gespecialiseerd en efficiënt signaleringsplatform in het celmembraan. De resultaten 
van onze studie laten zien dat deze translocatie van CD20 als gevolg van de binding 
van Rituximab gepaard gaat met de translocatie van Fas, de receptor van sFasL, naar 
de rafts. De resulterende clustering van Fas in deze rafts leidt er vervolgens toe dat 
apoptose wordt geïnitieerd. 
In hoofdstuk 4 hebben we de gepaard gaande activiteit van CD20 en Fas na behandeling 
met Rituximab getracht te optimaliseren met behulp van een nieuw fusie-eiwit. Dit 
fusie-eiwit bestaat uit een antlichaam fragment van Rituximab (scFvRit) dat genetisch 
gekoppeld is aan sFasL. In deze studie laten wij zien dat dit eiwit, scFvRit:sFasL, inderdaad 
de CD20-gemedieerde en de FasL-gemedieerde apoptose route kan induceren. Een 
belangrijke bevinding was dat het combineren van de CD20 en FasL apoptose routes 
in een enkel eiwit zorgt voor een zeer potente anti-tumor activiteit. Deze anti-tumor 
activiteit van scFvRit:sFasL bleek zelfs vele malen hoger dan wanneer leukemische cellen 
tegelijkertijd werden behandeld met Rituximab en sFasL. Als gevolg van de potente anti-
tumor activiteit bleek scFvRit:sFasL ook zeer succesvol in het elimineren van maligne 
cellen geïsoleerd uit patiënten met B cel leukemieën. In een analyse van de mogelijke 
bijwerkingen van scFvRit:sFasL bleek dat gezonde B cellen ongevoelig waren voor 
scFvRit:sFasL. Tevens waren er ook geen indicaties van enige toxische effecten in muizen 
na intraveneuze toediening van scFvRit:sFasL.
In de volgende hoofdstukken van dit proefschrift worden enkele studies beschreven die 
wij hebben uitgevoerd in het kader van gerichte therapie voor Acute Myeloïde Leukemie 
(AML).  
De vijfjaars-overleving van patiënten met AML is slechts 20-30%; dit is mede het gevolg 
van ernstige bijwerkingen van de therapieën en het frequent terug komen van therapie-
resistente vormen nadat de behandeling is gestopt. Een deel van de patiënten voor 
wie de standaard therapieën een te zware belasting vormt komen in aanmerking voor 
een gerichte therapie. Deze gerichte therapie bestaat uit de immunotoxine gemtuzumab 
ozogamicine (GO). Door een antilichaam wordt GO gericht naar het oppervlakte eitwit 




CD33 herkent en bindt is een zeer giftige molecuul, calicheamicine, gekoppeld. Als GO 
bindt aan CD33 wordt het in de cel opgenomen en wordt het calicheamicine gesplitst van 
het antilichaam. Het vrije calicheamicine dat zich in de cel bevindt nestelt zich in het DNA 
en zorgt daar voor onherstelbare schade. Deze DNA schade zorgt er uiteindelijk voor dat 
de cel afsterft. Ondanks dat deze gerichte vorm van therapie minder schadelijk is dan de 
standaard therapieën heeft ook de behandeling met GO ernstige bijwerkingen. Daarom 
zou een verhoging van de anti-AML activiteit van GO en tegelijkertijd een verlaging van 
de bijwerkingen een grote verbetering zijn.  
In hoofdstuk 5 beschrijven we de synergistische anti-AML activiteit van een combinatie 
van GO met de histon deacetylase inhibitor, valproïnezuur (VPA). Behandeling van cellen 
met VPA zorgt ervoor dat het DNA een meer open structuur krijgt. Door deze verandering 
van het DNA kunnen eiwitten zich gemakkelijker in het DNA nestelen. Dit leidde ons tot 
de hypothese dat VPA de werking van GO zou kunnen verbeteren door de innesteling 
van calicheamicine in het DNA te verhogen. De experimenten uitgevoerd in onze studie 
laten zien dat het DNA van cellen door de behandelding met VPA inderdaad een hogere 
innesteling van calicheamicine hebben gekregen. Deze verhoogde innesteling ging ook 
gepaard met een toename in DNA afbraak door calicheamicine, wat tevens de verklaring 
is voor de synergistische anti-AML activiteit van GO en VPA. Door de synergistische 
activiteit van VPA en GO is het mogelijk om met een lagere dosis van GO hetzelfde effect 
te verkrijgen. Deze lagere dosis van GO zal ook gepaard gaan met een verlaging van de 
bijwerkingen van GO.
In hoofdstuk 6 beschrijven we een fusie-eiwit gericht tegen CD33. Dit fusie-eiwit, 
scFvCD33:sTRAIL, bestaat uit een anti-CD33 antilichaamfragment (scFvCD33) genetisch 
gekoppeld aan het pro-apoptotische eiwit sTRAIL. In deze studie hebben we de activiteit, 
stabiliteit en toxiciteit van scFvCD33:sTRAIL in vitro vergeleken met GO. De vergelijking 
van de apoptotische activiteit gaf aan dat het fusie-eiwit  scFvCD33:sTRAIL meer dan 30 
keer potenter AML cellen kan elimineren in vergelijking met GO. 
Zoals reeds beschreven is het essentieel voor de werking van GO om na opname in 
de cel uiteen te vallen, zodat het calicheamicine kan innestelen in het DNA. Om dit te 
bewerkstelligen wordt er in GO gebruik gemaakt van een chemische linker tussen het 
antilichaam en calicheamicine die gemakkelijk uiteen kan vallen. Als gevolg van deze 
instabiele linker kan het gebeuren dat het calicheamicine losraakt van het antilichaam 
voordat het in een CD33-positieve cel is. Dit vrije calicheamicine kan dan toxiciteit 
veroorzaken door gezonde cellen te elimineren. In het fusie-eiwit scFvCD33:sTRAIL 
hebben wij gebruik gemaakt van een veel stabielere genetische linker om sTRAIL aan het 
antilichaamfragment te koppelen. In onze experimenten hebben we daarom vergeleken 
of dit verschil in stabiliteit van de linker ook van invloed is op eventuele ongewenste 
apoptotische activiteit tegen CD33-negatieve cellen. Daartoe hebben we thermo-
stabiliteit van GO en scFvCD33:sTRAIL geanalyseerd door beide eiwitten tot 72 uur op 
te slaan bij 37°C. Vervolgens hebben we de apoptotische activiteit van de opgeslagen 
eiwitten tegen CD33-negatieve cellen bestudeerd. Het bleek dat activiteit van GO tegen 
CD33-negatieve cellen toenam in de tijd als gevolg van opslag bij 37°C. Deze thermo-
instabiliteit en de ongewenste apoptotische activiteit tegen CD33-negatieve cellen werd 
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niet waargenomen bij scFvCD33:sTRAIL na opslag bij 37°C. 
Voor de vergelijking van de toxiciteit van GO en scFvCD33:TRAIL werden CD33-positieve 
gezonde monocyten behandeld met beide eiwitten. Dit experiment liet duidelijk zien dat 
GO wel toxisch was voor deze gezonde monocyten, terwijl ze ongevoelig waren voor 
scFvCD33:sTRAIL. Door dit experiment werd het duidelijk dat GO het potentieel heeft 
om alle, gezonde en ongezonde, CD33-positieve cellen te elimineren en dat de activiteit 
van scFvCD33:sTRAIL beperkt is tot maligne cellen. De grondslag voor deze specificiteit 
van sTRAIL tegen maligne cellen is nog een enigma. Echter, juist door deze specificiteit 
wordt sTRAIL door vele kankeronderzoekers bestempeld als een zeer veelbelovend anti-
kanker therapeuticum. 
Ondanks dat de laatste jaren veel vooruitgang geboekt is, is de behandeling van leukemie 
vaak nog steeds niet genezend. Dit kan mede verklaard worden door een kleine populatie 
van leukemische cellen die resistent blijken te zijn tegen conventionele therapieën 
en bovendien de capaciteit hebben om nieuwe leukemische cellen aan te maken. De 
leukemische cellen met deze eigenschappen worden leukemische stamcellen (LSCs) 
genoemd en worden verantwoordelijk gehouden voor het ontstaan van leukemie en het 
terugkomen van leukemie na een schijnbaar succesvolle behandeling. De resistentie van 
de LSCs tegen de gebruikte therapieën is onder andere het gevolg van de beschermende 
niche in het beenmerg waarin zij verblijven. Verder blijkt het dat LSCs maar zeer beperkt 
delen en daardoor niet gevoelig zijn voor de meeste therapieën omdat die erop gericht 
zijn om sneldelende cellen te elimineren. Ten slotte blijken deze cellen ook te beschikken 
over allerlei speciale mechanismen waardoor zij zichzelf kunnen beschermen tegen de 
gebruikte therapieën. Echter, voor een genezende therapie is het wel noodzakelijk om deze 
cellen te elimineren. In hoofdstuk 7 beschrijven we ontwikkelingen in, en perspectieven 
voor het elimineren van deze LSCs. Een mogelijke benadering is door oppervlakte eiwitten 
die hoog tot expressie komen op deze LSCs te gebruiken voor gerichte therapieën met 
behulp van antilichamen en antilichaamfragmenten. Tot dusver zijn enkele mogelijk 
geschikte oppervlakte eiwitten op LSCs geïdentificeerd, zoals CD33 en CLL-1. Verder 
blijken LSCs ook een hoge expressie te hebben van apoptose inducerende oppervlakte 
eiwitten zoals de TRAIL en FasL receptoren. Door dit gegeven lijkt het daarom mogelijk 
om LSCs te elimineren met scFv:sTRAIL en scFv:sFasL fusie-eiwitten. In hoofdstuk 8 
beschrijven we de anti-AML activiteit van twee nieuwe fusie-eiwtten die gericht zijn 
tegen CLL-1, genaamd scFvCLL-1:sTRAIL en scFvCLL-1:sFasL. Recentelijk is de expressie 
van CLL-1 aangetoond op AML cellen van 92% van de patiënten, inclusief de LSCs. Uit 
onze experimenten blijkt dat beide fusie-eiwitten specifiek apoptose induceren in CLL-1-
positieve AML cellen inclusief AML cellen geïsoleerd uit AML patiënten. Een belangrijke 
bevinding is dat beide fusie-eiwitten ook apoptose kunnen induceren in fenotypisch 
geïdentificeerde LSCs geïsoleerd uit AML patiënten. 
CONCLUSIES EN PERSPECTIEVEN
Gerichte therapiën gebaseerd op antilichamen en antilichaamfragmenten hebben het 
potentieel om op een veilige en efficiënte manier leukemie cellen te elimineren. Dat deze 




Rituximab en GO. Deze positieve resultaten zijn de aanleiding geweest om additionele 
oppervlakte en apoptose inducerende eiwitten te identificeren die gebruikt kunnen worden 
voor de gerichte apoptose inductie in leukemische cellen. De experimenten beschreven 
in dit proefschrift laten zien dat scFv:sFasL en scFv:sTRAIL fusie-eiwitten wellicht ook 
gebruikt kunnen worden voor de gerichte eliminatie van leukemische cellen in patiënten. 
Daarom is de aanbeveling dan ook om scFv:sFasL en scFv:sTRAIL fusie-eiwitten verder 
te ontwikkelen en uitvoerig te testen in additionele pre-klinische modellen. Indien de 
resultaten van scFv:sFasL en scFv:sTRAIL ook in deze additionele pre-klinische studies 
veelbelovend blijven, dan zou dit opvolgende klinische studies justificeren. 
De ontdekking van therapie-resistente LSCs in leukemie heeft tot nieuwe inzichten geleid 
voor de ontwikkeling van leukemie therapieën. Echter, een fundamenteel probleem 
voor een grootschalige screening van therapeutica wordt gevormd door de zeer lage 
aantallen waarin LSCs voorkomen. Daarom is het noodzakelijk om zeer gevoelige en 
robuste methoden te ontwikkelingen die de analyse van apoptose inductie in slechts 
een enkele LSC mogelijk maakt. Een methode die hiervoor geschikt lijkt te zijn is 
fluorescente microscopie gecombineerd met moderne litografische technieken. Door de 
recente ontwikkelingen in litografische technieken is het mogelijk om een enkele LSC te 
immobilizeren op een chip. Met behulp van geavanceerde microscopen is het vervolgens 
mogelijk om apoptose inductie in deze ene cel in real-time te volgen. Verder is het 
mogelijk om met behulp van de nieuwste massa spectrometrie technieken om tot wel 
20 verschillende parameters van een enkele cel gelijktijdig te bestuderen. Dergelijke 
technieken kunnen een belangrijke bijdrage leveren aan het ontdekken van moleculen 
die in staat zijn om efficiënt LSCs te elimineren.   
Voor de applicatie van LSCs specifieke therapeutica moet ook de moeilijke bereikbaareid 
van LSCs in het beenmerg overwonnen worden. Recente ontwikkelingen maken het 
mogelijk om de interactie van de LSCs met het beenmerg in real-time in proefdieren 
te bestuderen. Studies die gebruik maken van dergelijke technieken zouden inzicht 
kunnen geven in hoe de LSCs in de niche het beste te elimineren zijn. In dit opzicht 
zijn er recentelijk moleculen gesynthetiseerd die de LSCs stimuleren om het beenmerg 
verlaten en zodoende veel beter bereikbaar maken voor therapeutica. Echter, deze 
moleculen zorgen er ook voor dat de normale hematopoietische stamcellen hun niche 
in het beenmerg verlaten. Desalniettemin tonen dergelijke studies aan dat het mogelijk 
is om LSCs uit hun beschermende omgeving te verwijderen en wellicht is het mogelijk 
om varianten van deze moleculen te generen die specifiek de LSCs stimuleren om het 
beenmerg te verlaten.  
Verder, als gevolg van een verhoogde expressie van apoptose inducerende receptoren 
op LSCs, lijkt de gerichte activatie van deze receptoren een veelbelovende benadering. 
In hoofdstuk 8 beschrijven we experimenten die laten zien dat het mogelijk is om LSCs 
te elimineren met scFv:sTRAIL en scFv:sFasL fusie-eiwitten. Echter omdat de LSCs vele 
beschermings mechanimsen hebben tegen therapeutica is het waarschijnlijk dat een 
therapie die verschillende strategiën combineert het meest effectief zal blijken te zijn. 
Daarom is de screening en real-time analyse van scFv:sTRAIL en scFv:sFasL fusie-eiwitten 
in combinatie met andere therapeutica voor de eliminatie van LSCs een veelbelovende 
strategie voor de ontwikkeling van nieuwe therapieën.
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Heerlijk, het laatste hoofdstuk! Hierin kan ik dan eindelijk een poging doen om de vele 
mensen die betrokken zijn geweest bij de totstandkoming van mijn proefschrift te 
bedanken. 
Allereerst wil ik beginnen met het bedanken van Wijnand Helfrich, want zonder hem was 
dit boekje er niet gekomen. Gedurende de afgelopen vier jaar hebben we voortdurend 
zitten discussiëren over de experimenten, de resultaten van experimenten en over 
vervolgexperimenten. Regelmatig, als ik teleurgesteld was in de resultaten, wist jij mij 
steeds weer te motiveren door er met je frisse blik toch allerlei onvermoede positieve 
elementen uit te halen. Van jouw kritische manier van redigeren van mijn manuscripten 
en dus het vele rood in de teksten die ik terug kreeg, raakte ik af en toe lichtelijk 
gefrustreerd. Echter, het resulteerde wel in een aantal mooie publicaties. Verder heb 
ik goede herinneringen aan ons congresbezoek in Washington en ook zeker aan de 
anderhalve dag na het congres. Als een stel professionele toeristen, compleet gewapend 
met diverse fotocamera’s, hebben we toen in no-time alle highlights van de stad gezien. 
Daarnaast wil ik graag mijn promoter Lou de Leij bedanken. Ondanks dat je mijn dagelijkse 
begeleiding vol vertrouwen aan Wijnand overliet, stond jouw deur altijd voor mij open. 
De besprekingen die wij gehad hebben waren altijd erg prettig en hierin werden een 
aantal hele goede keuzes gemaakt. 
  
Verder wil ik graag de leescommissie bestaande uit: Prof. dr. E. Vellenga, Prof. dr. W.J. 
Quax en Prof. dr. G.J. Ossenkoppele hartelijk bedanken voor het beoordelen van mijn 
proefschrift.
Verreweg het grootste deel van mijn promotieonderzoek heb ik uitgevoerd in het U-lab 
van de Medische Biologie. In dit lab heb ik een leerzame, maar zeker ook een heel 
erg leuke tijd gehad. Enkele van de collega’s van het U-lab wil ik hier nog even extra 
bedanken. Anita, ik zou niet weten hoe het lab zou kunnen functioneren zonder jou. 
Behalve dat je zorgde voor een hoop gezelligheid, zorgde jij er ook voor dat alles op 
rolletjes liep in het lab. Helemaal top was het als ik na de bestel-deadline toch nog een 
ingeving kreeg en een last-minute spoedbestelling wilde plaatsen dat jij dit altijd toch 
nog wist te regelen. Jelleke, jij hebt mij de fijne kneepjes van het celkweken bijgebracht 
en ook al was daarna niet erg vaak in het celkweeklab, het was er altijd erg gezellig. 
Even de laatste nieuwtjes uitwisselen en elkaar updaten over goede restaurants die we 
hadden ontdekt, dit allemaal terwijl de cellen werden doorgezet. Als jij mij niet zo vaak 
had gematst was het iedereen veel vaker opgevallen dat ik wéér eens mijn corvee had 
vergeten. Ook was het U-lab zeker minder gezellig geweest als mijn koffiemaatje Harold, 
Henk, Pytrick, Maaike en Bart er niet waren geweest. 
Ook in het naastgelegen Cytometrielab kwam ik dagelijks, maar niet alleen om mijn 
cellen te analyseren of te sorteren, maar ook gewoon om even te buurten bij de operators 
Geert en Henk, bedankt voor al deze gezellige momenten.
Heel veel heb ik ook te danken aan de rest van de ‘Helfrich-research groep’. Edwin, toen 
ik begon met mijn onderzoek had jij er al 2 jaar op zitten als AIO-er. Je hebt mij meteen 
op sleeptouw genomen en al jouw kennis en ervaring met mij gedeeld. Ik weet nog erg 
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goed hoe wij in het begin achter de FACS zaten; toen de eerste cellen nog maar net op 
het beeldscherm verschenen had jij al de goede conclusies getrokken en ook al een 
vervolgexperiment bedacht. Ik heb erg veel geleerd van jou als onderzoeker en daar 
ben ik je erg dankbaar voor. Douwe, ook jij was er bij toen ik begon en ik kon mij geen 
betere start wensen dan met met zo’n goede analist in de buurt. Je hebt me alle ins-and-
outs bijgebracht van allerlei essentiële assay’s. Ook heeft jouw heldere inzicht menig 
experiment gered, bedankt voor alles. Theo, bijna tegelijkertijd zijn wij begonnen op ons 
project. Vier jaar lang was jij mijn steun en toeverlaat. Zonder jouw magische vingers 
zou het zeker veel langer geduurd hebben voordat alle constructen goed in elkaar zaten 
en zouden er bovendien ook nooit cellen beschikbaar geweest zijn voor de experimenten. 
Maar behalve dat je onmisbaar was in mijn promotieondezoek, zorgde jij ervoor dat er ook 
altijd een topsfeer op het lab was. Ik vind het dan ook super dat jij mijn paranimf wilde 
worden, bedankt voor alles. Marco, je begon als student bij ons, maar het duurde niet lang 
voordat je een volwaardig lid was van de ‘Helfrich-research groep’. Het was dan ook niet 
meer dan logisch dat jij bij ons bleef voor jouw promotieonderzoek ik heb erg genoten 
van de twee jaren dat wij samen hebben gewerkt, bedankt hiervoor. Ik weet zeker dat jij 
een prachtig boekje gaat afleveren en wens je alvast heel veel succes hiermee. Dennis, 
we hebben niet veel proeven samen gedaan, maar toch heb jij mij meerdere keren uit de 
brand geholpen en daarmee mijn proeven gered, ook jij bedankt. 
Go, ook jij was intensief betrokken bij ons clubje en jouw aanwezigheid zorgde altijd voor 
een hoop gezelligheid. Ik kan me haast niet voorstellen dat iemand mij beter had kunnen 
helpen en begeleiden bij mijn eerste proefdierexperiment op het Bio-Optical Imaging 
Center dan jij, bedankt hiervoor. Manon, meestal zat jij op het dierenlab, maar ik ben blij 
dat we toch enkele proeven samen hebben kunnen doen. Ik vond het erg leuk om met je 
samen te werken, bedankt.
Furthermore, I would like to thank Georg Fey (University of Erlangen-Nuremberg), 
Gerwin Huls (UMCG) and Gerrit Jan Schuurhuis (VUMC) for the collaborations in several 
projects. 
   
Als AIO-er besteed je ook vele uren achter de computer om de data uit te werken, 
artikelen te lezen en te schrijven. Dankzij de dames: Betty, Marieke, Ineke en Sabine was 
er altijd een topsfeer op de AIO-kamer. Ondanks dat er hard gewerkt werd, was er altijd 
wel even tijd voor lolletje of een praatje. Dames, bedankt en veel succes toegewenst met 
jullie boekjes. 
 
Bart-Jan Kroesen bedankt voor alle waardevolle discussies die wij hebben gehad over 
het onderzoek, maar ook over de vele andere interessante onderwerpen. Alja Stel, ook 
al was het maar van een korte duur ik vond het erg fijn om met jou samen te werken, 
bedankt. 
 
Henriëtte en Annet, door jullie vrolijke aanwezigheid was het ophalen van de post en het 
versturen van pakjes iets wat altijd erg leuk (en gemakkelijk) was om te doen, bedankt.
In het laatste half jaar van mijn promotieonderzoek is de ’Helfrich-research groep’ 
overgegaan van de Medische Biologie naar het Chirurgische Onderzoekslaboratorium 
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van de afdeling Chirurgie. Dat ik mijzelf al vrij snel thuis voelde op deze nieuwe plek 
kwam onder andere door Ton, Jacco, Jeffrey en alle andere nieuwe collega’s die ons op 
een fantastische manier ontvingen, bedankt daarvoor.
Maar niet alleen de collega’s zijn van belang geweest voor het afronden van mijn 
promotieonderzoek, ook mijn vrienden en familie hebben een heel belangrijke rol 
gespeeld. Bij deze mensen kon ik altijd terecht, ook als ik even wilde klagen of het er 
gewoon niet over wilde hebben. Ik ben gezegend met een hele hoop goede vrienden met 
wie ik een hele goede tijd heb gehad voor, tijdens en straks ook weer na mijn promotie. 
Sommige vrienden zie ik gelukkig vaak en anderen zou ik graag vaker willen zien. Ik wil 
graag bedanken: Johnny, Niels, Maarten en Esther, Marc en Irma, Frank en Marieke, Paul 
en Christine, Tjalling, Luuk en Lobke, Huygen, Wouter en Sachi, Sebastiaan, Laura en 
Steijn, Raphaël en Margriet, Jeroen en Heleen, Tobias, Michael, Robert, Sjoerd, Susanne 
en Hilmar, Guido en Karin, Sarah, Sander de Haas, Maarten de Jong, Jurgen Batsleer, 
Marcel Buter, Maarten van Benthem, Frank Stegeman en Mark Hoogendoorn voor alle 
mooie momenten die wij tot dusver al hebben gehad en alvast voor alle mooie momenten 
die nog komen gaan. 
Wing Ho, ook al werkte jij gedurende mijn hele promotieonderzoek in Peking en Hong 
Kong, altijd als jij even over was, was het een groot feest! Ik ben heel erg blij dat je sinds 
kort, samen met Marieke, weer terug bent in Nederland en dat jij mijn paranimf wilt zijn, 
bedankt.
Jasmin en Nefisa, al direct vanaf het begin voelde ik mij thuis bij jullie. Altijd staat jullie 
deur open en is er tijd voor een goed gesprek, bedankt. Emina, Jasmin en sinds kort 
Damir bedankt voor alle gezellige momenten en jullie nooit aflatende interesse.
Er zijn maar weinig mensen die je beter kennen dan je eigen familie en ik heb het geluk 
dat het allemaal fantastische mensen zijn, bedankt voor alle mooie momenten.
  
Lieve Agnes omdat je mijn enige zus bent is het natuurlijk een beetje flauw om te zeggen 
dat je de liefste bent, maar eerlijk gezegd zou ik mijzelf geen betere zus kunnen wensen. 
Jij en Jochem staan altijd voor mij klaar en zijn altijd super geïnteresseerd in alles wat 
ik doe. Het is altijd weer een feestje om samen met jullie te zijn. Ik ben heel erg blij dat 
alle donkere wolken inmiddels zijn weggetrokken en dat de zon weer volop schijnt, ik ben 
supertrots op jullie.    
Lieve Pap en Mam, in slechts een paar zinnen kan ik jullie nooit genoeg bedanken voor 
alles. Altijd hebben jullie alleen maar het beste voor mij gedaan. Dankzij jullie heb ik 
de mogelijkheid gehad om keuzes te kunnen maken en in deze keuzes werd ik altijd 
onvoorwaardelijk gesteund. Door jullie ben ik wie ik ben.
Lieve Sabina, gelukkig heb ik met jou alles mogen delen de afgelopen jaren. Een promotie 
verloopt namelijk via ups en downs, maar door jou zorg en liefde werd altijd alles weer 
relatief. Nog maar heel even en dan zijn we allebei gepromoveerd en kunnen we beginnen 
aan ons volgende avontuur. 
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